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Profiling the kinome in oncogenic Ras mutant cells 
Leah Jane Wilson  
 
RAS Proteins (KRAS4A, KRAS4B, NRAS and HRAS) are small GTPases 
involved in normal cellular proliferation, differentiation and apoptosis. 
Mutations in RAS, rendering it in the active GTP-bound state, are present in 
around 20% of human cancers, making it the subject of many years intensive 
research. Despite this, there has been limited success in targeting the RAS 
pathway due to the complex nature of RAS biology. Studies have shown that 
although highly homologous, the RAS isoforms are not functionally redundant. 
Furthermore, different activating RAS codon mutations illicit different signalling 
responses.  
 
Our work aimed at understanding the differential signalling outputs within the 
RAS pathway and the wider signalling network. 
 
Most understanding of RAS isoform biology has derived from ectopic 
expression experiments; however, there is a general consensus that studying 
endogenous RAS signalling is desirable. We have used a panel of isogenic 
SW48 colorectal cancer cells harbouring different RAS codon mutations to 
profile kinome-wide responses. The human protein kinome comprises 535 
kinases and these key signalling components are frequently dysregulated in 
human cancers. We propose that each RAS mutant activates distinct kinase 
driven tumourigenic pathways.  
 
Using NanoString technology, we characterised the transcript-level expressed 
kinome in each RAS mutant isogenic cell line. We identified a subset of 401 
kinases expressed in SW48 cells that show differential expression. In order to 
build a more comprehensive kinome profile, we next measured protein kinase 
expression in the RAS mutant cells. Using beads conjugated to a broad 
specificity kinase inhibitor, we enriched the kinome fraction from cell lysates 
and quantified 177 protein kinases by mass spectrometry. Integrating this data 
with the NanoString and pre-existing proteomic datasets has enabled us to 
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infer likely protein expression and/or activation differences within the kinomes 
of Ras mutant SW48 cells. 
 
The combination of methodologies that have been optimised allow large scale 
profiling of kinome expression and in some cases differential kinase activation. 
The data generated from these global kinase assays identify kinase nodes 
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Chapter 1 : Introduction 
The Ras superfamily of small guanosine triphosphatases (GTPases) comprise 
over 150 human members. The family is subdivided into five groups based on 
sequence homology: Ras, Rho, Ran, Rab and Arf (Wennerberg, Rossman and 
Der, 2005). The RAS family were the founding members of small GTPases 
and have been the subject of intense research due to their crucial role in 
oncogenesis. These small GTPases are involved in the acquisition of all the 
hallmarks of cancer as defined by Hanahan and Weinberg (Hanahan and 
Weinberg, 2011). Although similar to the α subunit of	heterotrimeric G proteins 
in biochemistry and function, Ras GTPases function as monomeric G proteins 
(Hurley et al., 1984). RAS proteins act as binary molecular switches that cycle 
between a GDP-bound inactive form and a GTP-bound active form (Gibbs et 
al., 1984; McGrath et al., 1984; Sweet et al., 1984) (section 1.2.1). Once in the 
active GTP-bound form, RAS can illicit many downstream signalling responses 
that control multiple cellular processes that drive tumorigenesis. These 
processes include all of the hallmarks of cancer: sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis (Hanahan and Weinberg, 2011).  
1.1. The discovery of RAS  
1.1.1. RAS Retroviruses 
The discovery of RAS genes originally stemmed from studies of potently 
transforming retroviruses that were conducted throughout the 1960s 
(Malumbres and Barbacid, 2003). The studies of retroviruses that induced the 
formation of sarcomas in animals and transformed cells in culture, provided 
the first evidence of RAS involvement in cancer. In 1964, Jennifer Harvey 
isolated the Harvey murine sarcoma virus (HA-MuSV) by passage of a murine 
leukaemia virus in rats (HARVEY, 1964). A few years later in 1967, Werner H. 
Kirsten isolated the Kirsten murine sarcoma virus (Ki-MSV) by passage of 
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murine leukaemia viruses in rats (Kirsten and Mayer, 1967). These initial 
discoveries provide the basis for their current gene names; the RAS gene 
family name is derived from the fact they were found to induce rat sarcomas, 
whilst their individual gene names hail from their discoverers’ (Karnoub and 
Weinberg, 2008).  
 
Scolnick and colleagues conducted an array of pioneering studies throughout 
the 1970s that underpins much of our understanding of the fundamental 
properties of cellular RAS proteins (see section 1.2) (Scolnick et al., 1973; 
Scolnick and Parks, 1974; Scolnick, Papageorge and Shih, 1979; Shih et al., 
1979b; Willingham et al., 1980). Although, initially identified as a viral 
component that induced transformation in rats, a study in 1974 revealed that 
the transforming properties of these viruses were in fact, a normal component 
of the rat genome (Scolnick and Parks, 1974). Despite this, it wasn’t until 
sometime later that experiments linked RAS directly to human cancer.  
1.1.2. RAS human oncogenes  
In the early 1970s, scientists were able to transfer DNA into mammalian cells 
by transfection, following the precipitation of DNA using calcium phosphate 
(Hill and Hillova, 1971). The focus on these initial studies was to determine the 
effect of DNA transfection and as a result, deduce gene function. By 1978, 
Wigler et al. had adapted the method so that a single copy of eukaryotic DNA 
could be transferred into mammalian cells. Focus then shifted to determine 
whether the transfected DNA had the ability to transform cells (Wigler et al., 
1978). In 1979, Weinberg and colleagues first applied the method in NIH3T3 
mouse fibroblast cells; DNA isolated from chemically transformed mouse cells 
caused morphological transformation (foci) when transfected into the NIH3T3 
cells in culture (Shih et al., 1979a). The ability of NIH3T3 cells to become 
morphologically transformed by a single gene enabled researchers to measure 
the oncogenic potential of a gene of interest, an assay that is still widely used 
today (Jainchill, Aaronson and Todaro, 1969). However, there was a lack of 
confidence in these first reports. Although NIH3T3 cells were immortalized, 
they had been shown to become spontaneously transformed when 
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continuously cultured at high confluency (Malumbres and Barbacid, 2003). 
Furthermore, no evidence was presented in the report that indicated that the 
DNA was efficiently transfected into the cells. 
 
Any scepticism was resolved over the following years after the assay was used 
to identify the transforming activity of DNA isolated from human cancer cell 
lines. The focus formation assay was used firstly to clone a human 
transforming gene isolated from human bladder carcinoma cells (Krontiris and 
Cooper, 1981) and later studies that identified transforming activity in lung, 
colon and leukaemia cell lines also provided further evidence of the presence 
of transforming genes in human cancer (Perucho et al., 1981; Murray et al., 
1981; Shih et al., 1981).   
 
Whilst efforts were made to identify and isolate the human oncogenes that 
were responsible for NIH3T3 cell transformation, a surprising discovery was 
made (Cox and Der, 2010). In 1982, three independent groups discovered that 
the transforming genes isolated from human bladder cancer cells were 
homologous to the Harvey and Kirsten sarcoma viruses identified in the 1960s 
(Santos et al., 1982; Der, Krontiris and Cooper, 1982; Parada et al., 1982). 
Furthermore, studies later that year revealed that HRAS was activated in 
human bladder carcinomas by a single amino acid substitution at codon 12 
(Taparowsky et al., 1982; Reddy et al., 1982; Tabin et al., 1982) and similar 
observations were made for activated KRAS in lung and colon tumour cells 
(Capon et al., 1983). Moreover, the same single missense mutation at codon 
12 was found in the viral RAS genes (Cox and Der, 2010).  
 
However, the notion that a single point mutation could induce transformation 
in cells was scrutinised by the scientific community (Malumbres and Barbacid, 
2003) and this presumption was later revised when it was discovered that 
activated HRAS alone could not transform primary fibroblast cells (Land, 
Parada and Weinberg, 1983). Instead, it was shown that concurrent activation 
of an oncogene or suppression of tumour suppressor gene is required to 
promote transformation, a concept that is critical to our current understanding 
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of the multistep pathway to carcinogenesis (Vogelstein et al., 1988; Hruban et 
al., 2000).   
 
In 1983, a third RAS gene was discovered in a human neuroblastoma cell line 
(Hall et al., 1983; Shimizu et al., 1983). Considering, it had not been previously 
identified in retrovirus studies and it was first described as a neuroblastoma 
transforming gene, it was designated the name NRAS (Cox and Der, 2010).  
 
Over the next few years, RAS mutations were detected in several human 
tumour cell lines (Pulciani et al., 1982). Furthermore, mutant RAS genes were 
identified in patient tumours and not in normal tissue, thus providing evidence 
that this phenomenon was not an artefact of the NIH3T3 cell model (Feig et 
al., 1984; Santos et al., 1984). It is now widely accepted that RAS is one of the 
most prevalently mutated oncogenes in human cancers, mutated in 
approximately 20% of all cancer patients (section 1.3) (Prior, Hood and 


















1.2. RAS regulation 
1.2.1. The RAS GDP/GTP cycle  
Early biochemical studies focusing on the RAS retroviral genes provided the 
first indication that RAS may function as a GTPase (Scolnick et al., 1973; 
Scolnick and Parks, 1974). The discovery by Scolnick and colleagues that the 
viral RAS genes encode a 21kDa protein subsequently led to studies to 
characterise the function of RAS proteins (Shih et al., 1979b). One of the many 
key discoveries, was that RAS proteins bind to guanine-containing nucleotides 
with high affinity (Scolnick, Papageorge and Shih, 1979). This finding, along 
with the fact that RAS has a similar amino acid homology to the alpha subunit 
of G proteins sparked speculation that like other G proteins, RAS functions as 
a GDP/GTP regulated binary switch (Hurley et al., 1984).  
 
In 1984, three groups confirmed that RAS proteins were in fact GTPases, 
cycling between an inactive GDP-bound state and an active GTP-bound state 
(Gibbs et al., 1984; McGrath et al., 1984; Sweet et al., 1984). Moreover, 
authors revealed that intrinsic GTP hydrolysis was significantly reduced in 
mutant proteins vs. wild-type proteins. These studies provided the first 
indication that impaired GTPase activity leading to preferential binding of GTP 
may be responsible for the transformation of cancer cells.  
 
The studies that followed provided an explanation as to why point mutations at 
codon 12 and 61 of RAS resulted in constitutively activated proteins; 
McCormick et al. reported that an antibody that specifically recognised the 
region of codon 12 on HRAS blocked the binding of GTP (Clark et al., 1985), 
whilst another study revealed that several mutations in HRAS at position 61 
impaired GTP hydrolysis (Der, Finkel and Cooper, 1986). Collectively, these 
studies showed that mutations in RAS impair GTP hydrolysis rendering 
proteins in the active GTP-bound state.  
 
However, the impaired GTPase activity of mutant vs. wild-type proteins 
observed in vitro was not enough to justify RAS activity in vivo, and therefore 
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researchers endeavoured to understand how the RAS GDP/GTP cycle was 
being regulated (Malumbres and Barbacid, 2003; Cox and Der, 2010).  
 
A breakthrough came in 1987 when the first GTPase activating protein 
(RasGAP) was identified (Trahey and McCormick, 1987). In a study using 
xenopus oocytes, Trahey and McCormick discovered a protein that stimulated 
the GTPase activity of wild-type proteins but not mutant proteins; The cytosolic 
protein stimulated the hydrolysis of GTP-bound wild-type proteins more than 
200-fold, however there was little effect on the NRAS codon 12 mutants 
(Trahey and McCormick, 1987). The following year the group purified the 
protein and described it as p120RasGAP (Trahey et al., 1988). Shortly after 
the discovery of the first RasGAP, a second RAS inactivating protein, 
Neurofibromin (NF1), was identified in a study of patients with 
neurofibromatosis (Wallace et al., 1990). When the NF1 gene, which is 
mutated in Neurofibromatosis disease was cloned, scientists discovered that 
there was a region of significant sequence homology to p120RasGAP 
(Ballester et al., 1990; Xu et al., 1990). Moreover, this region was shown to 
interact with and inactivate RAS (Martin et al., 1990).   
 
In parallel to the discovery of RasGAPs, research efforts focused on identifying 
activating regulators of RAS that induce GTP binding. The first evidence of 
proteins that facilitated the exchange of GDP to GTP on RAS was provided in 
genetic studies of yeast and Drosophila. Firstly, the guanine nucleotide 
exchange factor (GEF), CDC25, was shown to regulate RAS activity in 
Saccharomyces cerevisiae (Robinson et al., 1987; Broek et al., 1987) whilst, 
the RasGEF, Son of Sevenless (SOS) was identified in a genetic study of 
Drosophila and was later found to be related to the yeast CDC25 gene (Rogge, 
Karlovich and Banerjee, 1991; Bonfini et al., 1992). Soon thereafter, the first 
mammalian RasGEFs, were identified (Downward et al., 1990; Wolfman and 
Macara, 1990). Structural and functional analyses of the Drosophila SOS gene 
and the yeast CDC25 gene revealed homologous mammalian proteins that 
included Son of Sevenless 1 (SOS1) and RAS nucleotide releasing factor 1 
(RASGRF1) (Bowtell et al., 1992; Wei et al., 1992).  
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In the years following, several more RasGEFs and RasGAPs were identified, 
some of which are highlighted in Figure 1.1 (Bos, Rehmann and Wittinghofer, 
2007). It is now widely accepted that RAS functions as a GDP/GTP regulated 
binary switch which is controlled by RasGAPs and RasGEFs (Figure 1.1). 
RasGAPs stimulate intrinsic GTPase hydrolysis to promote the formation of 
(inactive) RAS-GDP, whilst RasGEFs promote the dissociation of GDP to 
facilitate the formation of (active) RAS-GTP (Mitin, Rossman and Der, 2005). 
Mutations in RAS render it in its active GTP-bound state and is typically a result 
of GAP insensitivity, whereby GAP mediated GTP hydrolysis is disrupted 
causing an accumulation of active RAS (Moore et al., 2020). However, 
mutations that increase the rate of GEF mediated GDP/GTP exchange have 
also been described (Hunter et al., 2015). See section 1.3.2 for more details 
of the individual RAS mutants.  
 
The determination of the crystal structures of RAS provided a better 
understanding of the structural dynamics of RAS proteins cycling between the 
inactive and active conformations (de Vos et al., 1988). Comparison of the 
GDP-bound and GTP-bound structures of RAS revealed two key regions of 
conformational change referred to as switch 1 (residues 30-40) and switch 2 
(residues 60-76) (Milburn et al., 1990; Schlichting et al., 1990). In the active 
conformation, hydrogen bonds form between the γ-phosphate of GTP and the 
threonine and glycine residues (T35, G60) of the switch 1 and switch 2 regions 
respectively. Upon GTP hydrolysis, the γ-phosphate is released and the switch 
regions return to the relaxed inactive conformation (Vetter and Wittinghofer, 
2001). The conformational change in these regions is critical for the interaction 
between RAS and its upstream regulators or downstream effectors (Karnoub 






 Gene name Protein name 
GEFs SOS1/2 SOS1/2 
RASGRP 1-4 RASGRP 1-4 
RASGRF 1/2 RASGRF 1/2 
GAPs RASA1 p120 RasGAP 
RASA2 GAP1 M/RASA2 




NF1 Neurofibromin 1 
GAPVD1 GAPVD1 
DAB2IP DAB2IP 
Figure 1.1. Regulation of RAS activity.  
RAS GEFs stimulate the exchange GDP to GTP thus, resulting in the formation of a pool of 
active GTP-bound RAS. In contrast, RAS GAPs accelerate the intrinsic GTPase activity of 
RAS thus promoting in the formation of inactive GDP-bound protein. Known regulators of the 
RAS GDP/GTP cycle are highlighted in table above. 
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1.2.2. Upstream regulation of RAS 
Another important advance in our understanding of how RAS is regulated 
came from studies linking mitogenic signalling and RAS activation. Initial 
evidence indicating that mitogenic signalling may control RAS GTPase activity 
came from an early study conducted in NIH3T3 cells. Scientists revealed that 
Epidermal Growth Factor (EGF) treatment stimulated guanine nucleotide 
binding of cellular HRAS (Kamata and Feramisco, 1984). The following year, 
further evidence was provided in studies conducted by Stacey et al. that 
utilised a monoclonal antibody targeting RAS. The microinjection of the 
antibody into NIH3T3 cells prevented serum induced DNA synthesis thus 
indicating that RAS was essential for signalling downstream of extracellular 
mitogens (Mulcahy, Smith and Stacey, 1985).  
 
The first direct link between upstream mitogenic signalling and RAS regulation 
came from a study linking the cell surface platelet derived growth factor 
receptor (PDGF) and RasGAP p120. The study revealed that stimulation of 
the PDGF receptor induced the tyrosine phosphorylation of RasGAP p120, 
resulting in its translocation to the cell membrane where it can regulate RAS 
(Molloy et al., 1989). 
 
Further evidence came from seminal studies linking the cell surface epidermal 
growth factor receptor (EGFR) and RAS activation. In Caenorhabditis elegans, 
a novel protein was identified named sem-5, that consisted of one SH2 domain 
and two SH3 domains (Clark, Stern and Horvitz, 1992). Authors reported that 
Sem-5, along with let-23 (EGFR like) and let-60 (RAS like) proteins were 
essential for vulval development in Caenorhabditis elegans. Concurrent with 
this discovery, a mammalian protein, GRB2, that exhibited notable structural 
and functional homology to sem-5 was identified in a study searching for 
proteins that bind to the intracellular tail of EGFR (Lowenstein et al., 1992). 
Several studies later discovered that the SH2 and SH3 domain containing 
protein, GRB2 (sem-5) was the missing link between EGFR and the RASGEF, 
SOS1; Eight studies revealed that GRB2 was an adaptor protein, that could 
bind to EGFR via its SH2 domain at one end, and SOS via its two SH3 domains 
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at the other end (Olivier et al., 1993; Rozakis-Adcock et al., 1993; Simon, 
Dodson and Rubin, 1993; Egan et al., 1993; Chardin et al., 1993; Buday and 
Downward, 1993; Gale et al., 1993; Li et al., 1993). It was later shown that the 
formation of the EGFR: GRB2:SOS1 complex at the plasma membrane was 
crucial for RAS activation; When EGFR is activated, Grb2:SOS1 is recruited 
from the cytosol to the membrane where it can then activate RAS (Quilliam et 
al., 1994; Aronheim et al., 1994). Moreover, GRB2 can bind to other adaptor 
proteins (such as SHC and IRS-1) permitting the interaction of SOS1:RAS with 
several different receptor tyrosine kinases (RTKs) (Margolis and Skolnik, 
1994).  
 
These studies were crucial to our understanding of the signal transduction from 
extracellular stimuli to RAS. Moreover, these observations also emphasised 
the importance of subcellular localisation of RAS regulating proteins (see 
section 1.2.4). It is now widely accepted that several RTKs can activate 
downstream RAS. Upon activation, RTKs become auto phosphorylated on 
multiple tyrosine residues that in turn, recruit adaptor proteins containing SH2 
domains to the cell membrane, where associated RASGEFs can activate RAS 
(Margolis and Skolnik, 1994).  
1.2.3. RAS downstream effector signalling 
In 1993, the first RAS effector, Raf, was discovered thus providing the final link 
in the RAS canonical signalling pathway. Several groups revealed that Raf 
preferentially binds to RAS in its active GTP-bound state rather than its inactive 
GDP-bound state (Wigler et al., 1978; Zhang et al., 1993; Warne, Viciana and 
Downward, 1993; Moodie et al., 1993). Furthermore, it was reported that Raf 
is a potent competitive inhibitor of RasGAP proteins, such as p120 RasGAP 
and NF1 (Warne, Viciana and Downward, 1993). The role of Raf downstream 
of RAS was also verified in independent genetic studies of Caenorhabditis 
elegans and drosophila (Han et al., 1993; Dickson et al., 1992). Raf had been 
discovered as a retrovirus oncogene many years prior, thus the protein had 
already been well characterised (Rapp et al., 1983). It was known that Raf 
activates downstream MEK and ERK thus, the RAS-RAF-MEK-ERK (MAPK) 
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signalling cascade was delineated (Gallego et al., 1992) (Kyriakis et al., 1992; 
Wood et al., 1992; Howe et al., 1992; Dent et al., 1992). 
 
RAS promotes cellular transformation through activating the downstream 
cascade and in turn, a number of different families of transcription factors. 
These include c-MYC, c-FOS, c-JUN and ETS1 that promote a wide variety of 
cellular processes including cell cycle entry, angiogenesis, and cell survival 
(Deng and Karin, 1994; Westwick et al., 1994; Brunner et al., 1994; Gimple 
and Wang, 2019). Furthermore, cytoplasmic ERK can also regulate a number 
of different downstream kinases, including ribosomal s6 kinases (RSKs) that 
regulate diverse cellular processes (Takács et al., 2020). Recently, Nils 
Bluthgen and colleagues compiled a comprehensive ERK target phosphosite 
archive taken from various research studies; A list of 2507 phosphosites were 
compiled from various sources, including 659 direct and 1848 indirect ERK 
targets thus, highlighting the complexity of downstream signalling (Ünal, Uhlitz 
and Blüthgen, 2017). It is also important to note that activated ERK can also 
downregulate RAS activity by phosphorylating upstream components. For 
example, a negative feedback loop has been described whereby activated 
ERK phosphorylates SOS1 and as a result, the SOS1:GRB2 complex is 
uncoupled from the tyrosine residues of RTKs (Buday, Warne and Downward, 
1995).  
 
A short time after the discovery of Raf, a second RAS effector, 
Phosphatidylinositol 3-kinase (PI3K), was described. Although the association 
of PI3K and RAS had first been reported in 1991 (Sjölander et al., 1991), it 
wasn’t until 1994 that the kinase was accepted as a direct RAS effector when 
Julian Downward and colleagues revealed that RAS interacts with the catalytic 
p110 subunit of PI3K (Rodriguez-Viciana et al., 1994). Like Raf, PI3K binds 
active RAS-GTP through its Ras Binding domain (RBD) (Rajalingam et al., 
2007). Upon activation by RAS, P13K phosphorylates Phosphatidylinositol 
4,5-bisphosphate (PIP2) leading to the production of Phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) at the plasma membrane. Subsequently, AKT is 
recruited to the membrane and associates with PIP3 through its PH domain. At 
the membrane, AKT can be activated through phosphorylation of tyrosine and 
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serine residues (T308 and S473) by PDK1 and mTORC2 respectively 
(Castellano and Downward, 2011). AKT has been shown to activate over 200 
substrates including GSK3, mTOR, and FOXO family members that promote 
cell cycle progression, cell survival and metabolism (Manning and Toker, 
2017).  
 
In the meantime, a third RAS effector, Ral guanine nucleotide dissociation 
stimulator (RALGDS) was described (Cox and Der, 2010; Spaargaren and 
Bischoff, 1994). RALGDS associates with RAS through its RAS association 
(RA) domain and also acts as a GEF for RAL (RAS like protein) thus providing 
a bridge between RAS and RAL proteins (Rajalingam et al., 2007; Hofer et al., 
1994) . Initial studies in mouse fibroblast NIH3T3 cells suggested a minimal 
role for RALGDS in RAS transformation (White et al., 1996; Urano, Emkey and 
Feig, 1996). However later studies in human kidney cells revealed that the 
effector has a significant role in oncogenic RAS signalling (Hamad et al., 2002). 
Furthermore, it was revealed that RalGDS is essential for transformation of 
HRAS mutant skin carcinoma cells (González-García et al., 2005). Loss of 
function analyses provided further evidence of the importance of both RAL 
isoforms (RALA and RALB) as key modulators of oncogenic cell proliferation 
and survival (Chien and White, 2003). The study used RNAi to define the roles 
of each isoform in transformation. It was revealed that RALA is required for 
anchorage independent proliferation of cancer cells, whilst RALB prevents 
transformed cells from programmed cell death via sec5/TBK1 (Chien and 
White, 2003; Chien et al., 2006).    
 
The growing family of RAS effectors now comprise more than nine different 
classes of effectors (Raf, PI3K, RALGDS, Tiam, RASSF, Rin1, Af6, PLCε and 
PKCζ) (Rajalingam et al., 2007). Some are highlighted in Figure 1.2. In broad 
terms Ras effectors can be described as GEFs/GAPs regulating other 
GTPases and kinases. Most attention has focussed on RAF-MEK-ERK and 
the PI3K due to their significant contributions to oncogenesis. Ral has also 
been relatively well studied although it is still unclear if it supports oncogenic 
Ras function in all contexts. Of the remaining effectors, two of the most 




Figure 1.2. RAS signalling network  
Several RTKs have been shown to activate RAS. Upon activation, RAS binds to its 
downstream effectors. RAS-GTP preferentially binds to Ras binding domain (RBD) or Ras 
association (RA) domain containing effectors. There are over nine different families, some of 
the best characterised effector- signalling cascades are highlighted above. Many upstream 
and downstream nodes within the Ras network are kinases (highlighted in blue). 
T lymphoma invasion and metastasis protein (Tiam1) is a RAC specific GEF 
that mediates the activation of RAC through RAS (Rajalingam et al., 2007). 
Channing Der and colleagues first described Tiam1 as a RAS effector that 
preferentially binds to RAS-GTP through a RAS binding domain (Lambert et 
al., 2002). Concurrent with this discovery, it was reported that Tiam1 is 
essential for HRAS induced skin tumour formation in mice indicating the 
importance of RAS-Tiam1 interaction in human cancer (Malliri et al., 2002). 
Upon activation by RAS, Tiam1 promotes the formation of RAC-GTP leading 
to the phosphorylation of the p21 activated kinases (PAK) (Manser et al., 
1994). TIAM1-PAK signalling predominantly controls proteins regulating 
cytoskeleton rearrangement and migration, but has also been implicated in cell 
growth and survival (Takács et al., 2020).  
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RAS association domain family (RASSF) possess a RA domain, but no 
catalytic function (Rajalingam et al., 2007). The most characterised RASSF, 
Nore1 (RASSF5), acts as a scaffold between active RAS and the proapoptotic 
proteins mammalian sterile-20-like protein kinases (MST1/2) (Khokhlatchev et 
al., 2002). Thus, RASSF proteins act as a tumour suppressors through MST 
induced cell cycle arrest and apoptosis (Vos and Clark, 2006) and may act as 
a homeostatic mechanism to prolonged RAS signalling.  
 
Many RAS effector signalling pathways have been established that control 
diverse cellular functions. However, it is important to note that RAS induced 
oncogenesis occurs through a complex network of signalling nodes, rather 
than just the simple linear pathways highlighted above. Feed forward 
signalling, cross talk between multiple downstream effector pathways and 
negative feedback loops all contribute to RAS induced oncogenesis. Another 
layer of complexity is added by the fact that the convergence of downstream 
pathways will also be dependent on signalling intensity and duration (Hornberg 
et al., 2005). Understanding the context dependence of downstream effector 
signalling will be key for our understanding of RAS biology. 
1.2.4. Post-translational mechanisms of RAS regulation  
As previously mentioned, most of our understanding of how RAS is regulated 
was derived from early studies of RAS retroviruses. It was appreciated in the 
early stages of RAS research that RAS was not solely controlled by its 
GDP/GTP cycle, but that recruitment of cytosolic RAS to the membrane was 
essential for its activation. Evidence first emerged in 1980 when Ha-MuSV p21 
protein was detected on the inner leaflet of the plasma membrane by electron 
microscopy (Willingham et al., 1980). Scolnick and colleagues also reported 
that viral HRAS contained tightly bound lipids which facilitated its interaction 
with the membrane (Sefton et al., 1982). Moreover, in 1984 Lowy et al. 
revealed that lipid binding and membrane association through a cysteine 
residue (C186) at the C-terminus of RAS is essential for the transforming 
activity of RAS (Willumsen et al., 1984a). Based on the critical importance of 
the cysteine residue, authors correctly hypothesised that no more than 3 amino 
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acids are cleaved during lipid processing (Willumsen et al., 1984b). Others 
also speculated that cysteine 186 was the site of palmitoylation due to the fact 
that viral HRAS could incorporate palmitate acid (Buss and Sefton, 1986).  
 
These initial findings prompted a series of experiments that fully defined the 
molecular mechanisms of RAS lipid processing (Karnoub and Weinberg, 
2008). It was revealed that actually, several steps of post-translational 
modifications (PTMs) are required for the stable association of RAS proteins 







Figure 1.3. RAS structure  
The three RAS genes encode four RAS isoforms. The isoforms share almost complete 
sequence homology in the G domain. The G domain consists of the effector lobe, which is 
essential for effector interactions, and the allosteric lobe which connects the effector lobe to 
membrane associated residues. The hypervariable region (HVR) is the only region of 
significant sequence divergence. A series of post-translational modifications of the HVR 
promote recruitment to the membrane where they can become activated. Once activated, 
conformational changes occur in the switch 1 (residues 30-40) and switch 2 (residues 60-76) 
regions that allow for effector engagement and downstream signalling. 
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Although highly homologous, each RAS isoform has a region of significant 
sequence divergence in the C-terminal hypervariable region (HVR) (Figure 
1.3) (Mo, Coulson and Prior, 2018). The HVR encompasses 23/24 amino acids 
which undergo a series of PTMs that promote recruitment and binding to the 
membrane where they can function (Prior and Hancock, 2012). Each isoform 
shares a CAAX box motif at the extreme C-termini that is sequentially 
processed; Firstly, the cysteine residue is prenylated by farnesyl protein 
transferase (Casey et al., 1989). This initial step promotes the affinity of 
cytosolic RAS to the endoplasmic reticulum (ER) where additional enzymes 
required for CAAX processing are localised (Prior and Hancock, 2012). At the 
ER, the AAX motif is cleaved off by Ras-converting enzyme (Rce1) and the 
cysteine residue is carboxymethylated by isoprenyl cysteine transferase 
(ICMT) (Hancock and Parton, 2005).  
 
Although the latter step produces hydrophobic proteins that weakly associate 
with membranes, it was shown that a second signal, upstream of the CAAX 
motif, is required for stable association with the membrane (Hancock et al., 
1991). For KRAS4B, the second signal is a region of 6 polybasic lysine 
residues that provide an electrostatic interaction with the hydrophilic heads in 
the plasma membrane (Hancock, Paterson and Marshall, 1990). The second 
signal for the other three RAS isoforms is palmitoylation. HRAS is 
palmitoylated on cysteine residues 181 and 184 whilst NRAS and KRAS4A are 
mono palmitoylated on cysteine residues 181 and 180 respectively (Hancock 
et al., 1989). It is important to note that the second signal determines how each 
RAS isoform is trafficked and where in the membrane they are localised (Mo, 
Coulson and Prior, 2018). Palmitoylated RAS proteins traffic through the Golgi 
to the membrane, whereas unpalmitoylated KRAS4B bypasses the Golgi and 
traffics through the cytosol to the membrane (Choy et al., 1999; Apolloni et al., 
2000). Once at the plasma membrane, the HVR motifs regulate the 
interactions of each isoform with different microdomains that contain different 
RAS regulators and effectors (Prior et al., 2003) (Casar et al., 2009). Thus, 
differential compartmentalisation of the RAS isoforms is thought to contribute 
to the isoform-specific differences in signalling (Abankwa et al., 2010; 
Omerovic, Laude and Prior, 2007).  
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1.3. RAS contribution to cancer 
1.3.1. Isoform-specific RAS signalling 
In vivo studies have shown that although highly homologous, the four RAS 
isoforms (HRAS, NRAS, KRAS4A and KRAS4B) are not functionally 
redundant (Mo, Coulson and Prior, 2018). It was originally shown that, only the 
KRAS4B isoform was essential for normal mouse embryogenesis. Whilst 
NRAS and HRAS double knockout mice were healthy, KRAS ablation was 
embryonic lethal (Koera et al., 1997; Esteban et al., 2001). However, a later 
study showed that there was no specific requirement for KRAS in mouse 
development. When HRAS was expressed in the KRAS locus, mice were 
viable, despite the mice later displaying cardiomyopathy (Potenza et al., 2005). 
Furthermore, mice heterozygous for KRAS that lack NRAS function are 
embryonic lethal suggesting partial overlap between the RAS gene family 
(Johnson et al., 1997). This suggests that isoform specific differences in 
development arise from RAS gene expression patterns, rather than the 
specific function of the RAS protein itself. However, it is important to note that 
KRAS may still have a role in healthy development (Mo, Coulson and Prior, 
2018).  
 
Other evidence of isoform specific differences comes from the fact that the 
isoforms have different mutation frequencies; KRAS is most frequently 
mutated in cancer, mutated in 69% of all cancers, compared with 22% for 
NRAS and 9% for HRAS (Mo, Coulson and Prior, 2018). Moreover, each 
isoform is differentially associated with specific cancers: KRAS is strongly 
associated with pancreatic, colorectal and lung tumours, NRAS is frequently 
mutated in melanomas and HRAS is predominantly mutated in Head and Neck 








Figure 1.4. Ras mutations in cancer 
A) Despite being highly homologous, each isoform is not functionally redundant. Each 
individual RAS isoform exhibits differential and preferential coupling to specific cancers. Pie 
charts display RAS mutational frequencies per cancer type. Pie chart colours: green, KRAS; 
blue, NRAS; yellow, HRAS. B) Ras-isoform–specific codon mutation bias. K-Ras is typically 
mutated at codon 12, whereas N-Ras favours codon 61. H-Ras displays intermediate 
behaviour. Bar chart colours: grey, codon 12; purple, codon 13; orange, codon 61. Data taken 
from previous studies using TCGA and COSMIC datasets (Prior, Lewis and Mattos, 2012; Mo, 
Coulson and Prior, 2018) . 
The mechanistic basis for isoform specific frequencies remains poorly 
understood. Most understanding of RAS isoform biology has derived from 
ectopic expression experiments. The studies describe preferential coupling of 
each isoform with key Ras effector pathways. KRAS was shown to be a more 
potent activator of the MAPK pathway whereas HRAS and NRAS were shown 
to more potently activate the PI3K pathway (Yan et al., 1998; Voice et al., 
1999). This is in contrast to findings from studies using cell lines or mouse 
models with endogenously expressed mutant RAS; Very little evidence of 
preferential coupling to Ras effectors was presented. Instead, significant 
heterogeneity for effector requirements was displayed for each isoform 
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suggesting that RAS signalling is more context dependent (Tuveson et al., 
2004; Omerovic et al., 2008). 
 
Despite this, functional differences between the RAS isoforms have been 
described. A study using genetically engineered mice with inducible 
expression of different oncogenic RAS isoforms in the endogenous loci, 
revealed unique functions of KRAS and NRAS in human colon cancer. Only 
mutationally activated KRAS, not NRAS, can promote colonic epithelium 
proliferation thus, providing an insight into KRAS mutation bias in colorectal 
cancer (Haigis et al., 2008). Moreover, the study revealed activated KRAS 
mediates oncogenesis through a non-canonical pathway that includes RAF, 
but not MEK or ERK and authors suggest that the isoforms display distinct 
phenotypic differences due to their ability to interact with the downstream 
effector.  
 
Indeed, there is plenty of evidence that isoform specific signalling arises from 
structural differences that result in differential localisation and effector 
engagement. As previously discussed, differential post-translational 
modifications of the HVR of each isoform has a significant influence on where 
each RAS isoform is localised in the cell membrane (Prior et al., 2003; 
Hancock and Parton, 2005) (section 1.2.4). Each RAS isoform occupies 
distinct non-overlapping nanoclusters in the membranes that are thought to 
influence which RAS regulators and effectors each isoform is able to interact 
with, and mediate oncogenesis through (Prior et al., 2003; Prior and Hancock, 
2012; Abankwa et al., 2010). Further evidence of isoform specific signalling 
arises from structural differences in the allosteric lobe (Mo, Coulson and Prior, 
2018). Although there is almost 90% isoform sequence homology in the 
allosteric lobe, there is sequence divergence in residues that are thought to 
mediate nucleotide binding and conformational changes (Parker and Mattos, 
2018). It has been reported that KRAS occupies the ‘closed’ GTP-bound state 
more readily than HRAS and NRAS (Johnson et al., 2017). Considering the 
closed GTP-bound state promotes effector binding, the ability of each isoform 
to adopt the active conformation state could provide another reason for KRAS 
isoform mutation bias in human cancer.  
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1.3.2. RAS mutation specific signalling  
Emerging evidence for the different functional outcomes of RAS codon 
mutations at amino acid positions G12, G13 and Q61, adds another layer of 
complexity to RAS biology (Hobbs, Der and Rossman, 2016). Although 
missense mutations at these three codon hotspots are activating, they are not 
all equally transforming (Hobbs and Der, 2019). In a study using site-directed 
mutagenesis to introduce 17 different amino acid substitutions in position Q61 
of HRAS, authors reported that mutants varied over 100-fold in transforming 
potency (Der, Finkel and Cooper, 1986). Similar observations were also made 
in another in vitro mutagenesis study analysing the transforming potential of 
20 different amino acid substitutions in HRAS at position 12 (Seeburg et al., 
1984).  
 
Recent findings from biochemical studies may provide an explanation as to 
why RAS mutations aren’t created equal. Studies revealed that mutation 
specific differences in intrinsic or GAP mediated GTP hydrolysis, GDP/GTP 
binding kinetics and effector interactions all contribute to distinct biologic 
behaviours (Smith, Neel and Ikura, 2013; Hunter et al., 2015).  
 
Hunter and colleagues created a model based on the biochemical and 
biophysical properties of individual KRAS mutants to predict biological 
readouts that ultimately may enable the rational selection of therapies targeting 
different RAS mutations (Hunter et al., 2015). Most oncogenic mutants 
displayed marked GAP insensitivity indicating that inactivation is largely 
dependent on intrinsic GTP hydrolysis. Thus, authors concluded that mutation 
specific signalling may arise from differential intrinsic GTP hydrolysis rates that 
predominantly control the duration of RAS activation. Moreover, since 
RasGAPs are unable to compete with the nano affinity of RAS and RAF 
(Moodie et al., 1995), authors used intrinsic hydrolysis rates alongside RBD-
RAF affinities to predict the dependence of each mutant on the Raf-MAPK 
signalling cascade.    
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For example, authors predicted that the Q61L mutant mutants preferentially 
signal through the RAF kinase pathway, since the mutant Q61L has a high 
affinity to RAF and a low intrinsic GTP hydrolysis rate that promotes a longer 
duration of activation (Hunter et al., 2015). The model also predicted that the 
G12V and G12R mutants are moderate activators of Raf due to the fact they 
have low affinity to RAF but a slow GTP hydrolysis rate that extends the 
duration of time RAS is in the active conformation and therefore bound to RAF. 
On the other end of the spectrum, the G12D mutant with its low affinity to RAF 
and high intrinsic hydrolysis rate is less likely to be dependent on RAF kinase 
pathway activation, however it is unknown whether this leads to the 
preferential binding of other signalling pathways such as PI3K and RalGDS.  
 
Authors predicted that the G13D and G12C mutants would be moderate 
activators of RAF; whilst both mutants have a high affinity to RAF, both retain 
intrinsic levels of GTP hydrolysis that would attenuate prolonged effector 
interactions. Notably, unlike the other mutants, the KRAS G13D mutant 
displayed rapid nucleotide exchange kinetics (Hunter et al., 2015). The rate of 
SOS independent exchange of GDP to GTP was one order of magnitude faster 
than KRAS wild type indicating that this mutant becomes spontaneously active 
rather than relying on GEF mediated regulation. Moreover, it has been 
reported that the fast-cycling K13D mutant may be more vulnerable to direct 
inhibition. Kevan Shokat and colleagues published a pioneering study showing 
that the KRAS G12C mutant can be directly targeted by covalent inhibition via 
the cysteine residue that locks it in its inactive GDP-bound state (Ostrem et al., 
2013). This was the first indication that RAS can be directly targeted (see 
section 1.4.1). It has been noted that rapid nucleotide cycling of mutant G13D 
may make the active site more assessable to a small molecule inhibitor (Hunter 
et al., 2015).  
 
There is independent evidence that supports the aforementioned classification 
scheme of KRAS mutations. Carla Mattos and colleagues also reported that 
the Q61L mutant more potently activates RAF compared to the G12V mutant 
due to differences in intrinsic GTP hydrolysis rates (Buhrman et al., 2011). 
Cespedes et al. revealed that the G12D mutant preferentially associates with 
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PI3K, rather than RAF, thus supporting evidence that the G12D mutant is a 
poor activator of RAF (Céspedes et al., 2006). Furthermore, authors also 
showed that the G12V mutant, which was classed as a moderate RAF 
activator, binds to both RAF and PI3K. However, it is important to note, the 
role of GEF stimulated nucleotide exchange remains unclear and the affinity 
of each mutant to other effector pathways needs to be elucidated in order to 
extend our understanding of how differences in the biochemical properties of 
RAS mutants result in distinct biological readouts.  
 
Indeed, there is evidence supporting the notion that each activating RAS 
mutation elicits a distinct network response. Several studies have shown that 
KRAS codon 12 and 13 mutants harbour unique downstream responses that 
result in differential phenotypic outputs (Guerrero et al., 2000; Vizan et al., 
2005; Hammond et al., 2015). Furthermore, these differential responses can 
inform patient outcome and treatment responses in the clinic, further 
emphasizing that mutation specific signalling is biologically relevant (De Roock 
et al., 2010). Patient data taken from the TCGA (The Cancer Genome Atlas) 
programme also suggests that mutation specific biology is relevant (Mo, 
Coulson and Prior, 2018). Each isoform is preferentially mutated at different 
codon hotspots, with KRAS predominantly mutated at codon 12, NRAS at 
codon 61 and HRAS at codon 12 and 61 (Figure 1.4) (Prior, Lewis and Mattos, 
2012). Furthermore, the frequency of an amino acid missense substitution in 
a given RAS isoform is dependent on the cancer cell type. For example, in 
PDAC the most common mutation is KRAS G12D, whereas in NSCLC, KRAS 
G12C mutations are the most frequently seen (Hobbs, Der and Rossman, 
2016).  
 
Why RAS isoforms differentially and preferentially couple to specific cancers, 
codons and amino acid substitutions remains unclear. Whilst some studies 
suggest isoform specific mutagen exposure in different tissues may contribute 
to differences in cancer frequencies (Riely et al., 2008), there is increasing 
amounts of evidence indicating that mutation specific oncogenicity is 
responsible (Mo, Coulson and Prior, 2018). For example, melanomas are 
predominantly associated with NRAS Q61 mutations and a study revealed that 
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NRAS Q61R efficiently promoted melanoma in mice, whilst NRAS K12D did 
not (Burd et al., 2014). Moreover, Winters et al. used AAV/Cas-9 mediated 
gene editing to introduce 12 different KRAS mutations into mice (Winters et 
al., 2017). Authors identified significant differences in the oncogenicity of each 
KRAS variant in each tissue type, in concordance with the frequencies 
observed in human cancers.  
 
Finally, a recent study by Kevin Haigis and colleagues brings together several 
aspects of RAS isoform and mutation specific biology that help us to 
understand why RAS mutations aren’t created equal (Poulin et al., 2019; 
Hobbs and Der, 2019). The group used a multifaceted approach to profile the 
biological differences between two KRAS mutants, KRAS G12D and A146T. 
Whilst K12D mutations are commonly found in a variety of human cancers, 
A146T mutations are nearly exclusive to colorectal cancer. The aim of the 
study was to understand what is driving RAS mutational selection in specific 
tissues. Authors concluded that oncogenic potencies are the major 
contributing factor to the RAS mutational spectrums seen in different human 
cancers. Each mutant has distinct biochemical properties; KRAS G12D 
impairs GTP hydrolysis, whilst nucleotide exchange activities remain similar to 
wild type. Whereas the A126T mutant retained GTP hydrolysis activity but 
showed enhanced nucleotide exchange kinetics. Authors demonstrated the 
contrasting mechanisms of biochemical activation, that are likely to result in 
differences in the steady state level of KRAS-GTP, translate into distinct 
signalling properties. Furthermore, the authors showed that differential 
downstream signalling responses result in mutation specific phenotypic 
outputs. Moreover, the ability of each mutant to disrupt homeostasis in 
colorectal vs. pancreatic tumours was dependent on the intensity of 
downstream (MAPK) signalling. Thus, this study provides the first indication 
that variations in signalling downstream of different RAS mutations may drive 
the RAS mutational pattern seen in human cancers.  
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1.4. RAS targeting  
1.4.1. Efforts to target RAS directly 
Until recently, there has been limited success in targeting RAS. Early efforts to 
target RAS were confounded by the fact that RAS has picomolar affinity to 
GTP, together with a relatively flat surface that lacks a deep binding pocket for 
the binding of a small molecule inhibitor (Cox and Der, 2010). However, recent 
studies have emerged that have reinvigorated interest in RAS targeting and 
challenged the widely held perception that RAS is ‘undruggable’ (Stalnecker 
and Der, 2020).  
 
Kevan Shokat and colleagues have led pioneering work in the development of 
direct RAS inhibitors (Ostrem et al., 2013). Importantly, the inhibitors are 
expected to overcome toxicity concerns associated with the pan-inhibition of 
all RAS isoforms; KRAS is essential in mouse development, therefore there 
are concerns that targeting both wild-type and mutant proteins wouldn’t be well 
tolerated (Koera et al., 1997). The group developed a covalent inhibitor that 
specifically targets the glycine to cysteine mutation in KRAS at position 12 
(KRAS G12C), a mutation often associated with smoking (Ostrem et al., 2013) 
(Stalnecker and Der, 2020). The reactive cysteine residue in the active site of 
the protein can be covalently targeted by a small molecule inhibitor. As 
compounds rely on the reactive cysteine for binding, there is no effect on wild-
type proteins (Moore et al., 2020).  
 
Crystallographic studies revealed a novel allosteric binding pocket beneath the 
switch II region of RAS-GDP (Ostrem et al., 2013). The Shokat group used a 
tethering based approach to identify small molecule fragments that bound to 
the region, now termed the switch II pocket. The compounds irreversibly bind 
to the pocket and lock the K12C mutant in the GDP-bound state, thus leading 
to an accumulation of inactive protein. This in turn, attenuates effector 




Most RAS mutations are GAP insensitive and have diminished intrinsic 
GTPase activity (Scheffzek et al., 1997)(section 1.3.2). In contrast, it was 
reported that the G12C mutant has similar levels of intrinsic GTP hydrolysis to 
wild-type proteins (Hunter et al., 2015). As a result, the mutant more frequently 
occupies the inactive GDP-bound state compared to other mutants, meaning 
the switch II pocket can be more readily accessed. This aspect, along with the 
cysteine reactive residue creates a unique therapeutic vulnerability to inhibition 
(Stalnecker and Der, 2020). 
 
Several companies are currently developing KRAS G12C inhibitors, some of 
which have now entered phase 1/2 clinical trials (Stalnecker and Der, 2020). 
Initial observations have been promising, more so in NSCLC than CRC (Moore 
et al., 2020). The first G12C molecule to enter clinical trials was AMG510; out 
of 13 NSCLC patients, 7 had partial response and 6 had stable disease. 
Results in CRC were less remarkable as only 1 out of 12 has a partial response 
(Moore et al., 2020).   
 
Although several more potent inhibitors are in the pipeline, it seems inevitable 
that acquired resistance to KRAS G12C inhibitors will arise. Considering that 
the compounds only bind to GDP-bound RAS, mechanisms of resistance are 
likely to include activation or mutation of proteins that either, promote the 
exchange of GDP to GTP, or diminish GTP hydrolysis (Moore et al., 2020). 
Fortunately, it has been shown that AMG510 has synergistic growth inhibitory 
effects when combined with other inhibitors of the MAPK pathway, thus 
compensatory mechanisms may potentially be overcome by combinational 
therapies (Canon et al., 2019).  
 
KRAS G12C mutations only account for 12% of all KRAS mutations and are 
most commonly found in smoking associated NSCLC (Stalnecker and Der, 
2020). Going forward, it will be important to find new strategies to target other 
more common RAS mutations (G12D and G12V) that lack the reactive 
cysteine substitution. Although, all RAS proteins possess the switch II binding 
pocket, it remains unclear whether targeting this region will be successful for 
other mutants that frequent the active GTP-bound state (Moore et al., 2020). 
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A recent tethering screen has identified a ligand that can bind RAS in its GTP-
bound state via a novel switch II groove adjacent to the switch II pocket 
(Gentile et al., 2017). This discovery has prompted hope within the field that if 
RAS mutants can be targeted in either the active or inactive conformation, 
other individual RAS mutations may be ‘druggable’ (Moore et al., 2020). 
Understanding the differences in the biochemical properties of each mutant 
will be critical for the evolution and development of more direct RAS inhibitors.  
1.4.2. Targeting RAS localisation 
Early efforts to target RAS focused on disrupting RAS processing to the 
membrane where it becomes activated (Cox and Der, 2010) (see section 
1.2.4). As mentioned previously, the first step in RAS processing is catalysed 
by Farnesyl Transferase (Hancock et al., 1991). Farnesyl Transferase 
Inhibitors (FTIs) were developed to prevent the prenylation of the cysteine 
residue of the CAAX motif, ultimately preventing membrane association and 
downstream RAS signalling (Moore et al., 2020). These inhibitors were initially 
proved unsuccessful (Macdonald et al., 2005). It was revealed that KRAS and 
NRAS proteins are resistant to FTIs as they can be alternatively prenylated by 
geranylgeranyl transferase (Whyte et al., 1997; Fiordalisi et al., 2003). 
However, recent work has indicated that this approach may be successful for 
treating HRAS mutant cancers (Moore et al., 2020). HRAS proteins are 
exclusively prenylated by farnesyl transferase and therefore inhibition of this 
first critical modification may be successful in this subset of patient (Whyte et 
al., 1997). Indeed, the FTI, Tipifarnib has showed promising results in a recent 
phase II clinical trial of HRAS mutant HNSCC and thyroid cancer (Moore et al., 
2020).  
 
Other efforts to target RAS processing have focused on inhibiting downstream 
enzymes such as RCE1 and ICMT that control post-prenylation CAAX 
processing (Cox and Der, 2010). Efforts to target RCE1 have been confounded 
by toxicity issues, whilst ICMT inhibitors display limited potency in vivo (Cox, 
Der and Philips, 2015). Nevertheless, both RCE1 and ICMT were identified in 
a screen for essential genes in RAS driven Acute Myeloid leukaemia (AML) 
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(Wang et al., 2017). Furthermore, a recent study has been published that 
identified a potent ICMT inhibitor that targets all four RAS isoforms in RAS 
driven AML and may lead the way to the development of more efficacious 
inhibitors (Marín-Ramos et al., 2019).   
1.4.3. Targeting the RAS pathway  
Before the recent discovery of KRAS G12C inhibitors, anti-RAS drug discovery 
mainly focused on blocking RAS signalling by inhibiting the activity of upstream 
or downstream kinases (Cox and Der, 2010).  
 
Targeting upstream of RAS has proven difficult. Cancers expressing mutant 
RAS are generally resistant to therapies targeting upstream RTKs (Moore et 
al., 2020). Whilst, the use of monoclonal antibodies targeting EGFR have 
proved successful for the treatment of metastatic colorectal cancer (mCRC), 
they are limited to patients with wild type RAS alleles (Stalnecker and Der, 
2020). Two examples are cetuximab and panitumumab that significantly 
improve overall and progression free survival in patients with RAS wild type 
cancer, but not patients with KRAS mutations. (Amado et al., 2008; Karapetis 
et al., 2008). As a result, the FDA recommend that patients with RAS mutations 
should not be candidates for treatment with anti-EGFR monoclonal antibodies 
(Stalnecker and Der, 2020). However, retrospective analysis of the mCRC 
clinical trials revealed that patients with KRAS G13D mutations may benefit 
from treatment with cetuximab (De Roock et al., 2010). Again, this exemplifies 
the fact that RAS mutations should not be treated as one homologous group.  
 
EGFR tyrosine kinase inhibitors (TKIs) have also proved ineffective in RAS 
mutant cancers. Erlotinib and gefitinib are used for the treatment of EGFR 
mutant NSCLC patients, yet patients with KRAS mutations are resistant to 
treatment (Mao et al., 2010). It was revealed that mechanisms of resistance to 
EGFR inhibition converge on MEK activation, and therefore it has been 
suggested that targeting EGFR and MEK in combination may overcome any 
compensatory mechanisms (Troiani et al., 2014). Indeed, there has been 
promising observations in lung and colorectal cancers; suppression of ERBB3 
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by afatinib sensitizes KRAS mutant NSCLC and CRC cells to MEK inhibition 
(Sun et al., 2014). Furthermore, similar observations were made in NSCLC 
mouse models, where the combination of afatinib with trametinib improved 
survival of mice with KRAS G12D mutant tumours (Kruspig et al., 2018).  
 
Another promising combinational approach is the use of EGFR inhibitors with 
KRAS G12C inhibitors (Moore et al., 2020). As previously discussed, KRAS 
G12C inhibitors only bind to RAS in the inactive GDP-bound state (Ostrem et 
al., 2013). It has been reported that EGFR inhibition prevents GEF stimulated 
nucleotide exchange, which in turn, reduces the pool of GTP-bound RAS. Thus 
improving the efficacy of G12C inhibitors (Moore et al., 2020).  
 
There has been some success targeting downstream RAS signalling however, 
the development of inhibitors for downstream nodes has been met with similar 
problems concerning mechanisms of resistance (Stalnecker and Der, 2020). 
The majority of signalling nodes downstream of RAS are kinases (Wilson et 
al., 2018). Although, kinases are readily druggable, the success of 
monotherapies for RAS mutant cancers is limited due to inhibitor driven 
induction of compensatory mechanisms (Moore et al., 2020).  
 
The development of resistance following therapy can occur through adaptive 
or acquired mechanisms of resistance (Wilson et al., 2018). Adaptive 
resistance involves the rewiring of signalling pathways in response to 
inhibition, that ultimately results in the reactivation of the pathway. Whereas, 
acquired resistance develops over time and typically involves the mutation or 
gene amplification of a node within the pathway that confers a selective 
advantage over the effects of kinase inhibition. 
 
For example, in RAS mutant cells, resistance to the BRAF inhibitor, 
vemurafenib, emerges via an adaptive mechanism of resistance involving the 
paradoxical activation of wild-type RAF (Hatzivassiliou et al., 2010). 
Unexpectedly, the inhibitor promotes the formation and transactivation of RAF 
dimers, which in turn results in elevated downstream MEK and ERK signalling 
(Poulikakos et al., 2010). Vemurafenib is approved for the treatment of BRAF 
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V600E mutant melanoma where RAF signals as a monomer; however, in 
some cases resistance can be acquired over time (Wilson et al., 2018). 
Following vemurafenib treatment, an ERK dependent negative feedback loop 
is inactivated and results in the restoration of upstream RTK signalling (Lito et 
al., 2012). Similar mechanisms of resistance to MEK inhibition have been 
described through which loss of activated ERK induces the reactivation of 
upstream RTKs or CRAF (Duncan et al., 2012a) (Lito et al., 2014).  
 
Since monotherapies targeting RAF, MEK or ERK are considered clinically 
ineffective in RAS mutant cancers, the efficacy of combinational therapies is 
currently being evaluated in the clinic (Moore et al., 2020). Indeed, clinical trials 
are currently in progress that aim to investigate the effect of combining RAF 
and MEK inhibitors, something which showed promising results in preclinical 
studies (Yen et al., 2018).  
 
In summary, whilst the recent discovery of KRAS G12C inhibitors have 
renewed optimism that RAS may be ‘druggable’, finding direct inhibitors that 
target the other common RAS mutants will remain challenging. What’s more, 
even supposing the development of allele-specific inhibitors is achieved, 
mechanisms of resistance are likely to arise. Finding combinational strategies 
that negate emerging mechanisms of resistance, whilst improving the efficacy 
of new or existing treatments, will be critical to the success of targeting RAS. 
Firstly, it is imperative that we understand the requirements of specific RAS 
codon mutations and the context dependency of downstream kinase 
signalling. This may assist in the development of other allele specific RAS 
inhibitors, or more likely, inform effective drug combinations that will achieve 
maximal pathway suppression in a variety of RAS mutant cancers. Moreover, 
understanding what kinome rewiring occurs in response to RAS pathway 




1.5. The Human Kinome  
1.5.1. Kinome overview  
Protein kinases mediate protein function by catalysing the transfer of the ¡-
phosphate of ATP onto protein substrates, a process termed phosphorylation 
(Manning et al., 2002). Phosphorylation occurs on the alcoholic amino acid 
side chains, Serine (S), Threonine (T) or Tyrosine (Y) of protein substrates and 
underpins much of biological signalling in eukaryotic cells (Wilson et al., 2018). 
Recent evidence suggests that over 90% of proteins expressed in human cells 
are phosphorylated (Sharma et al., 2014). Other regulators of phosphorylation 
include protein phosphatases that catalyse the removal of phosphate groups 
from proteins (Chen, Dixon and Manning, 2017). Together, protein kinases and 
phosphatases mediate most of cellular signalling in eukaryotic cells so it’s not 
surprising that they have been described as the master regulators of signalling 
(Wilson et al., 2018). Moreover, kinase dysregulation is commonly associated 
human disease and for this reason, they have been the subject of intensive 
pharmacological inhibition. (Fabbro, 2015)  
 
The human kinome consists of 535 kinases (Wilson et al., 2018). Most kinases 
belong to a superfamily that contain a eukaryotic protein kinase (ePK) catalytic 
domain. These 479 kinases can be subdivided into seven kinase families 
based on their primary structure. The ePK families include: AGC, CAMK, CK1, 
CMGC, STE, TK and TKL (Figure 1.5). A subgroup of ePK kinases that don’t 
fall into these categories are described as the ‘other’ family. It is important to 
note that more recently, the AGC family has been reclassified and now belongs 
within the ‘other’ subgroup. The 56 remaining non ePK kinases are classed as 
‘atypical’ kinases. This family possess an atypical kinase domain and display 






Figure 1.5. The human kinome 
Kinases are visualized on the kinase dendrogram previously defined by Manning et al 
(Manning et al., 2002). The human kinome consists of 535 kinases. A total of 479 ePKs are 
displayed on the kinase dendrogram and can be further subclassified on the basis of primary 
sequence into seven major ePK families: TK, TKL, STE, CK1, AGC, CAMK, and CMGC. The 
remaining 56 atypical non-ePK kinases share little sequence homology with the major 
superfamily and are not included on the classical kinase dendrogram. Kinase nodes within the 
immediate RAS signalling network are highlighted in blue.  
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1.5.2. Kinase regulation  
Protein kinases consist of two lobes: a small N terminal lobe comprised of a 
five-stranded β-sheet with an α-helix called the C-helix, and a large C-terminal 
lobe comprising six α-helices (Modi and Dunbrack, 2019). Generally, the N-
lobe co-ordinates ATP binding, whilst the C-lobe binds protein substrates and 
catalyses phosphorylation (Wilson et al., 2018). The two regions are 
connected by a flexible hinge region that forms a cleft for ATP binding (Kornev 
et al., 2006). Kinases oscillate between an inactive conformation and an active 
catalytically competent conformation (Endicott, Noble and Johnson, 2012).  
 
Although kinases are mainly regulated by phosphorylation, they can also be 
regulated by several other post-translational modifications, autoinhibition or 
binding to a regulatory partner (Johnson, Noble and Owen, 1996). Kinases 
adopt one or more of these mechanisms to promote or stabilize an active 
conformation (Wilson et al., 2018). Several key interactions between 
conserved residues, ATP and the protein substrate are critical for kinase 
activation. In the N-lobe, one of the most important features is the conserved 
Lys-Glu pair (K72, E91). In the active conformation state, the C-helix is 
orientated in towards the active site and positions a glutamic acid residue in 
the helix so that it is able to form a salt bridge with a lysine residue in the β-
sheet strand. 
 
This interaction allows for hydrogen bonds to form between the lysine and the 
α and β phosphates of ATP, anchoring ATP in place (Kornev et al., 2006). 
Another key feature in this region, is the glycine rich loop. More specifically, 
the three conserved glycine residues in the tip of the loop position the 
phosphates and poise ¡-phosphate for transfer (Aimes, Hemmer and Taylor, 
2000).  
 
The C-lobe includes an activation loop. The activation segment consists of 20-
35 residues beginning with the DFG motif (Asp–Phe–Gly). In the active 
conformation, the conserved aspartate residue in the DFG motif binds a 
magnesium ion that interacts with the β-phosphate of ATP (Modi and 
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Dunbrack, 2019). The phenylalanine residue of the DFG motif forms contacts 
with the HRD motif (usually His-Arg-Asp) of the catalytic loop facilitating the 
transfer of the ¡-phosphate of ATP to the substrate (Fabbro, Cowan-Jacob 
and Moebitz, 2015). Importantly, the phenylalanine residue also makes contact 
with the C-helix and orientates the helix so that the Glu residue is in the correct 
position to form the salt bridge interaction that is essential for the ATP binding 
and therefore kinase activity (Endicott, Noble and Johnson, 2012).  
 
It is important to note, that 52 non-enzymatic kinase members of the human 
kinome have been identified (Wilson et al., 2018). These kinases belong to the 
pseudokinase group which represent approximately 10% of the human kinome 
and are distributed across all kinase families  (Wilson et al., 2018). Although 
pseudokinases lack the catalytic machinery required for phosphorylation, they 
are able to control the activity of proteins via alternative mechanisms (Eyers 
and Murphy, 2013). Pseudokinases can control enzymatic activity by acting as 
allosteric modulators, substrate competitors, scaffolding proteins or spatial 
anchors (Reiterer, Eyers and Farhan, 2014). Prominent examples include 
KSR1 and KSR2 that act as scaffolds to coordinate the assembly of RAF-MEK-
ERK signalling pathway (Nguyen et al., 2002). Thus, pseudokinases are still 
biologically relevant in human disease. In fact, mutation or overexpression of 
this group of kinases has been implicated in many human diseases including 
cancer, emphasizing that this non enzymatic group should not be overlooked 
(Bailey et al., 2015).  
1.5.3. The RAS regulated kinome  
Deep proteomic analysis of 23 human cell lines revealed that cells typically 
express between 300-400 kinases (Wilson et al., 2018). Yet, most kinase 
research has focused on a select number of kinases. The principle kinase 
nodes found upstream and downstream of RAS are highlighted on the kinase 
dendrogram in figure 1.5. These nodes alone, account for almost 35% of the 
approximately 120,000 kinome research publications (Wilson et al., 2018). 
Therefore, unsurprisingly the nodes within the immediate RAS network are 
particularly well served by the 75 kinase chemical inhibitors currently approved 
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in the clinic (MRC) https://www.ppu.mrc.ac.uk/list-clinically-approved-kinase-
inhibitors. In contrast, over 50% of kinome members account for less than 5% 
of kinome research publications and consequently, approximately 300 kinases 
still do not have an inhibitor that has ever reached clinical evaluation (Wilson 
et al., 2018). Moreover, there is no structural information for over 200 of these 
kinases and therefore drug design would be challenging. This highlights an 
area of unmet need. The development of inhibitors will be vital to our 
understanding of kinase function, however counterintuitively, a lack of 
knowledge of kinase biology stifles any drug discovery efforts (Wilson et al., 
2018).  
 
It is clear that global approaches to study the kinome are required to increase 
our understanding of the understudied members of the kinome. In a typical 
phosphoproteomic analysis, >10,000 phospho-sites can routinely be identified 
from low milligram quantities of starting material (Wilson et al., 2018). The most 
commonly used enrichment strategies use metal oxides such as TiO2, which 
are highly specific for most phosphopeptides (Leitner, 2016). However, this 
method provides poor enrichment of the phospho-tyrosine (pTyr) pool and 
therefore, anti-pTyr antibody-based enrichment is typically employed to 
evaluate this less abundant modification (Leitner, 2016). Effective sampling of 
this subset is particularly important given the dominant role of tyrosine kinases 
in controlling early events in signalling that are frequently dysregulated in 
diseases such as cancer (Wilson et al., 2018). However, fewer than 2% (5330 
phospho-sites) have known regulatory consequences for their target proteins 
thus, illustrating the scale of the challenge for generating broad mechanistic 
insight from phospho-proteomic datasets (Wilson et al., 2018).  
 
The integration of global kinase profiling approaches with transcriptomic 
datasets will be essential for the systems-level understanding of kinome 
networks and their contributions in diseases such as cancer. However, whilst 
kinase profiling is used to determine drug specificity and sensitivity in vitro, 
profiling dynamic kinome adaptations in a cellular context remains challenging 
(Wilson et al., 2018).  
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A method (MIB/MS) has recently been developed that claims to allow the 
simultaneous measurement of the relative expression and activities of 
hundreds of kinases within cells (Duncan et al., 2012a). The method utilises 
broad specificity kinase inhibitors which are immobilised onto Sepharose 
beads to make up the Multiplexed Inhibitor Bead (MIB) slurry. Type I kinase 
inhibitors, which are thought to only bind to the ATP binding pocket of kinases 
in their active DFG-in conformation, are used to make the MIBs (Roskoski, 
2016). The rationale is that binding of kinases to the column reflects kinase 
activity; increased binding of the kinase to the column indicates increased 
kinase activity. Quantitative mass spectrometry is used to identify and quantify 
the kinases in each sample. Incorporating a quantitative proteomic labelling 
technique, such as SILAC makes it possible to simultaneously measure and 
compare global kinome adaptions between multiple samples (Ong and Mann, 
2005).  
 
Considering that the RAS signalling network is enriched in kinases, I propose 
to use the method to profile RAS isoform and mutation specific signalling. Most 
of our understanding of RAS isoform biology has been based on studies with 
experimental systems using ectopic expression of activated RAS, rather than 
mutation of the endogenous RAS gene (Hood et al., 2019). Whilst ectopic 
expression studies have reported that each isoform is preferentially coupled to 
a key RAS effector pathway (Yan et al., 1998; Voice et al., 1999), more recent 
endogenous expression studies revealed that there is significant heterogeneity 
for effector requirements of each RAS isoform (Tuveson et al., 2004; Omerovic 
et al., 2008; Hammond et al., 2015; Hood et al., 2019)(see section 1.3.1). Thus, 
there is now a general consensus that studying endogenous RAS signalling is 
more desirable. Moreover, there is an appreciation that RAS signalling is more 
context dependent than originally thought, and therefore profiling global 
kinome responses may reveal ‘dark’ kinases that are essential for RAS 
signalling.  
 
For this reason, we have decided to use an isogenic cell system that has been  
engineered, using rAAV technology, to harbour different activating RAS 
mutations in the endogenous loci. We will use MIB/MS to profile kinome-wide 
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responses and thus characterise the context dependence of endogenous 
isoform-specific Ras-signalling responses. We propose that each RAS mutant 
activates distinct kinase driven tumourigenic pathways. If such patterns could 
be identified, it could provide a rationale for selecting novel kinase targets for 
drug discovery, inform treatment selection of existing therapies, or inform new 













1.6.  Aims and objectives  
Aim 
 
To understand the differential network responses downstream of common 






































Chapter 2 : Materials and methods 
2.1. Cell biology  
2.1.1. Cell culture  
Unless otherwise stated, all cell culture reagents and Foetal bovine serum 
(FBS) were purchased from Gibco (Invitrogen, Paisley, UK). For all 
experiments, FBS was dialysed and heat-inactivated at 55oC prior to use. All 
cell culture plasticware was purchased from Corning (NY, USA).  
2.1.1.1. Cell lines  
SW48  
The SW48 cell line is an epithelial-like colorectal adenocarcinoma cell line 
established in 1973 from an 82-year-old female Caucasian patient (Leibovitz 
et al., 1976). A panel of isogenic SW48 cells were obtained from Horizon 
Discovery (Cambridge, UK). The SW48 cells have been engineered, using 
rAAV technology, to harbour different activating RAS mutations in the 
endogenous loci (Mageean et al., 2015). The panel have heterozygous knock-
in of different activating RAS mutations (table 2.1); these are all derived from 
the same matched parental cell line that are homozygous wild-type RAS 
expressing cells. All Horizon's cell Lines are authenticated and validated by 
PCR amplification and Sanger Sequencing to confirm the mutation at the 
genomic level. 
 
SW48 Parental and KRAS G12D cells containing doxycycline inducible shRNA 
targeting KRAS were used for knockdown studies (section 2.1.3.1). 
 54 
            Table 2.1: Panel of isogenic SW48 cell lines 
Cell line Clone 
no. 
Shorthand 
cell line ID 
Horizon 
Catalogue no. 
Parental RASwt MK2/238 PAR HD PAR-006 
KRAS G12D C22 K12D HD 103-011 
KRAS G13D C3D3 K13D HD 103-002 
KRAS G12V c16 K12V HD 103-007 
HRAS G12V 878 H12V HD 103-034 
NRAS G12V G9-1 N12V * 
 
*N. B: The NRAS mutant cell lines were made in-house by Simon Oliver. 
 
MDA-MB-231 
The MDA-MB-231 cell line is an epithelial, human breast adenocarcinoma cell 
line established in 1978 from a 51-year-old female Caucasian patient 
(Cailleau, Olivé and Cruciger, 1978). These cells are a metastatic triple 
negative breast cancer cell line derived from plural effusion and harbour a 
KRAS G13D mutation (Eckert et al., 2004). The cells were purchased from the 
American Type Culture Collection (ATCC, Middlesex, UK) (cat no. ATCC® 
CRM-HTB-26™). All ATCC’s cell lines are authenticated and validated by 
Short Tandem Repeat (STR) Profiling, Karyotyping and Cytochrome C 
Oxidase I (COI) Assay Testing. 
2.1.1.2. Routine cell culture  
Cells were cultured in 5% CO2 at 37oC and typically passaged at 70-80% 
confluency, every 2-3 days. For maintenance, growth medium was aspirated, 
cells were washed with pre-warmed Phosphate-buffered saline (PBS) and 
then dissociated from flasks or dishes with 0.05% trypsin/EDTA (Gibco). Cells 
were resuspended in fresh medium and reseeded into new flasks or dishes at 
the ratios described in table 2.2. Cells were grown in culture for no longer than 
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30 passages and were routinely tested for mycoplasma using the EZ-PCR 
Mycoplasma Testing Kit (Geneflow, UK).  
 
Table 2.2: Cell culture medium and split ratio used for each cell line 
Cell line  Medium  Supplementation Split ratio 
SW48  McCoys 5A (modified) 
medium, with 
GlutaMAXTM supplement  
10% (v/v) foetal 
bovine serum 
1:3-1:4 
MDA-MB-231 DMEM, high glucose, 
with GlutaMAXTM 
supplement, pyruvate  




2.1.1.3. Cell line storage  
Cells grown in a T175cm2 flask were cultured as above, resuspended into fresh 
medium and pelleted by centrifugation (200g, 5mins). Pelleted cells were 
resuspended into 9mL of freezing medium (50% FBS, 45% serum-free 
medium, 5% DMSO). The cell suspension was aliquoted into cryovials 
(1mL/vial) and frozen to -80oC in a ‘Mr Frosty’ freezing box. The cryovials were 
frozen slowly to -80oC at a rate of 1oC/min and subsequently transferred to 
liquid nitrogen for long term storage.  
 
As required, cells were thawed rapidly at 37oC and resuspended into a T25cm2 
flask containing pre-warmed medium. After 16-24h, the medium was replaced 
to remove any residual DMSO. 
2.1.2. Cell treatments  
2.1.2.1. Cell stimulation and inhibition  
Growth factor stock solutions were prepared in filtered PBS and stored at -
80OC. Pervanadate was prepared from an equimolar solution containing 
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sodium orthovanadate (NaVO4) and hydrogen peroxide (H2O2) (Sigma-
Aldrich, Poole, UK).  
 
Stock solutions of FBS, EGF, HGF or pervanadate were diluted in cell culture 
medium without FBS supplementation to the achieve the final concentrations 
listed in table 2.3. Cells were serum starved for 16h before each treatment was 
added. Treated cells were incubated in 5% CO2 at 37oC for the length of time 
indicated in table 2.3 and subsequently harvested for immunoblotting or Mass 
spectrometry (see sections 2.2.1 and 2.4.2 for cell lysis). 
 
Table 2.3: Cell treatments 
Treatment  Type Target Conc. Duration Supplier 
Foetal bovine 
serum (FBS) 



























2.1.2.2. Drug treatments 
Drug stocks were prepared in DMSO (Sigma-Aldrich, Pool, UK) and stored in 
1 mL aliquots at -20oC. Prior to use, drug stocks were thawed and diluted in 
cell culture medium to yield the final drug concentration (5 𝜇𝑀). In every case, 
vehicle-only (DMSO) containing medium was used as a control. Cells were 
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serum starved for 16h and subsequently treated with Selumetinib for 4hr/ 
24hrs in 5% CO2 at 37oC. 
Table 2.4: Target and source of pharmacological inhibitor used 
Inhibitor Target Conc. Duration Supplier 
Selumetinib MEK1/2 5 𝜇M 4hr or 24hr Astra-Zeneca 
(Cambridge, UK) 
 
2.1.3. Transfections  
2.1.3.1. shRNA interference  
Table 2.5: shRNA sequences for KRAS knockdown 
Cell line shRNA Shorthand 
cell line ID. 
shRNA sequence 

















SW48 Parental and KRAS G12D cell lines containing doxycycline inducible 
shRNA targeting KRAS were provided by Horizon Discovery (Cambridge, 
UK), details of which can be found in table 2.5. 
 
Cells were maintained in medium containing 10% dialysed, tetracycline-free 
FBS. For knockdown of KRAS, cells were grown media containing 100 ng/𝑢l 
doxycycline for 1 week. After one week, cells were harvested for 
immunoblotting, MIB/MS and NanoString studies (see sections 2.2, 2,3, 2,4).  
2.1.3.2. DNA transfection 
For transient DNA transfections, cells were seeded in 6cm dishes one day prior 
to transfection. The following day, two solutions were prepared for DNA 
transfection, the volumes for each are listed in table 2.6. Solution A contained  
1𝜇g transfected plasmid DNA encoding the different RAS G12V isoforms, n-
terminally tagged with eGFP, diluted in optiMEM, to a total volume of 500𝜇l. 
Solution B contained Lipofectamine 2000, diluted in optiMEM to a total volume 
of 500𝜇l. Both mixtures were left at RT for 5 minutes before combining in a 1:1 
ratio. The DNA-lipid complex was incubated for a further 20 minutes at room 
temperature (RT) before being added dropwise to the cells. Fresh medium was 
added to bring the total volume to 5mL.  
Table 2.6: Reaction mixes for transient DNA transfection 
Sol. A Sol. B 






After 24hrs transfection efficiency was evaluated by visualising GFP 
expressing cells under a NIKON TiE microscope. A separate dish of cells was 
grown in parallel and harvested for analysis by immunoblotting.  
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2.2. Protein biochemistry 
2.2.1. Preparation of whole cell lysates  
For mass spectrometry, cells were lysed in MIB/MS buffer (section 2.4.2). 
Otherwise, cells were lysed in RIPA buffer supplemented with PhosSTOP 
phosphatase inhibitor tablets (Roche, Basel, Switzerland) and Mammalian 
Protease Inhibitors (MPI, Sigma Aldrich, Poole, UK).  
Table 2.7: Composition of RIPA Lysis buffer solution 
Solution Contents 







10mM Tris-Hcl pH7.5  
150mM NaCl  
1% (w/v) NP40 
0.1% (w/v) SDS  
1% sodium deoxycholate 
1:250 mammalian protease buffers  




Cells grown in a 6cm or 10cm dish were placed on a bed of ice before cell 
lysis. Firstly, cells were washed twice with ice-cold PBS with the PBS being 
aspirated after each wash. Next, cells were placed on a rocker, on ice and 
incubated with 250𝜇l of lysis buffer for ten minutes. The lysates were collected 
into a 1.5 mL microcentrifuge tube and then cleared of non-soluble material by 
centrifugation (14,000rpm, 10 minutes, 4oC). The supernatant was collected 
into a 1.5mL Eppendorf tube for protein determination. Lysates were stored at 
-80 oC for long term storage.  
2.2.2. Protein determination and sample preparation  
Protein concentration was assessed using the Bio-Rad bicinchoninic acid 
(BCA) assay kit (Pierce, UK) using IgG to generate a standard curve. The 
standards and lysates were arranged in duplicate on a clear 96-well plate. For 
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protein determination, 10𝜇l of diluted cell lysate was plated per well. 200𝜇l of 
BCA reagent (50:1 reagent A:B) was added to all wells containing the 
standards and samples and plates were incubated for 30 minutes at 37oC. A 
Glomax multi-detection system (Promega, WI, USA) was used to measure the 
colorimetric change observed after 30 minutes.  
 
Following protein quantification, lysates were adjusted accordingly and 
combined with a 1x final concentration sample buffer (3% w/v SDS, 62.5mM 
Tris-HCl pH 6.8, 10 % glycerol, 3.2% 𝛽-mercaptoethanol stained with 
bromophenol blue). Samples were boiled for 5 minutes at 98 oC then left on 
ice to cool for 5 minutes before separation by SDS-PAGE. Samples were 
stored at -20 oC for long term storage. 
2.2.3. SDS polyacrylamide electrophoresis (SDS-PAGE)  
Samples were loaded on 4-12% pre-cast Bis-Tris gels (NuPage, Invitrogen, 
Paisley, UK) and separated by SDS-PAGE. Gels were run in tanks containing 
1x MOPS or 1xMES running buffer (both NuPage, Invitrogen, Paisley, UK) 
depending on the molecular weight of the protein of interest. Separation 
typically took place at 100V for 15 minutes followed by 200V for 45 minutes. 
Samples were run alongside molecular weight markers: Rainbow Marker (GE 
healthcare, Amersham, UK) and Broad Range Marker (New England BioLabs, 
Herts, UK). 
2.2.4. Western blotting  
Following SDS-PAGE, separated proteins were transferred onto 0.45𝜇M 
Protran nitrocellulose membrane (Geneflow, Lichfield, UK) using the 
GenieBlotter system (Idea Scientific, Minneapolis, USA). The transfer was 
performed at a constant current of 0.9A for one hour. After the transfer, the 
membrane was stained with Ponceau S (Sigma-Aldrich, Poole, UK) to 
visualise proteins and assess the quality of the protein transfer. Subsequently, 
membranes were destained using distilled water and cut into multiple sections 
when there was more than one protein of interest to probe per blot.  
 61 
Membranes were incubated in a blocking buffer of either 5% milk/TBST 
(Marvel, Premier foods, UK) or 5% BSA/TBST (Bovine Serum Albumin, Sigma 
Aldrich, Poole, UK) for one hour at room temperature (see table 2.8). Primary 
antibodies were diluted in the same buffer used for the blocking step. See table 
2.9 for concentrations and conditions. Membranes were incubated with 
primary antibody and placed on a gentle rocker at 4 oC overnight. The following 
day, the membranes were washed three times with TBST for 15 minutes in 
total. The secondary antibodies were made up in the same blocking buffer 
used for the primary antibody. See table 2.10 for concentrations and 
conditions. The membranes were incubated with secondary antibody in the 
dark, for one hour at RT. The membrane was washed again twice with TBST 
and once with TBS for a total of 15 minutes. Protein bands were visualised 
using the LI-COR Odyssey 2.1 infrared imaging system (LI-COR, Nebraska, 
USA). Images were analysed and quantified using the Odyssey ImageStudio 
Lite Software (LI-COR, Nebraska, USA).  
Table 2.8: Composition of western blotting solutions 
Solution  Contents  
TBST  10mM Tris-HCl, pH 7.5  
100mM NaCl 
0.1% (v/v) Tween20  
Transfer buffer 3.03g Tris base 
14.4g Glycine  
200ml Methanol 
800ml dH20 
Blocking buffer- 5% milk/TBST 10mM Tris-HCl, pH 7.5  
100mM NaCl 
0.1% (v/v) Tween20  
5% (w/v) Marvel  
Blocking buffer- 5% BSA/TBST  10mM Tris-HCl, pH 7.5  
100mM NaCl 
0.1% (v/v) Tween20  
5% (w/v) BSA 
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Table 2.9: Primary antibodies used for Western blotting 




Company  Cat. no. 
AKT Rabbit Marvel  1:1000 Cell Signalling 9272 
pAKT (S473) Rabbit Marvel  1:2000 Cell Signalling 4060 
DCLK1 (short 
isoform) Rabbit Marvel  1:2000 Sigma 
SAB420018
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EGFR Goat BSA 1:200 Santa Cruz sc03-1005 
pEGFR 
(pY1068) Rabbit BSA 1:1000 Cell Signalling 2234 
ERK1/2 Rabbit Marvel  1:1000 Cell Signalling 4695 
pERK1/2 
(pT202,Y204) Rabbit Marvel  1:2000 Cell Signalling 4370 
KRAS Mouse Marvel  1:1000 Lifespan 3127 
MEK Rabbit BSA 1:1000 Cell Signalling 9122 
pMEK1/2 
(S217,221) Rabbit BSA 1:1000 Cell Signalling 9154 
MET Mouse BSA 1:1000 Cell Signalling 3127 
pMET 
(T1234/1235) Rabbit BSA 1:1000 Cell Signalling 3129 
MKK3 Rabbit BSA 1:1000 Cell Signalling 8535 
pMKK3 
(S189/S207) Rabbit BSA 1:1000 Cell Signalling 12280 
p21 Mouse Marvel  1:200 Santa Cruz sc-6246 
p38 Rabbit BSA 1:1000 Cell Signalling 8690 
p-p38 
(T180/Y182) Rabbit BSA 1:1000 Cell Signalling 4511 
p53 Mouse  BSA 1:1000 Santa Cruz sc-126 
p-p53 (S15) Mouse BSA 1:1000 Cell Signalling 9286 
p-p53 (S33) Rabbit BSA 1:1000 Cell Signalling 2526 
p90 RSK2 Rabbit BSA 1:1000 Cell Signalling 5528 
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p-p90 RSK2 
(S227) Rabbit BSA 1:1000 Cell Signalling 3556 
pan-RAS  Rabbit Marvel  1:1000 Abcam ab52939 
RAC1 Mouse  Marvel  1:500 Upstate  05-389 
 
 
Table 2.10: Secondary antibodies used for Western blotting 
Antibody IRDye Dilution (RT, 1h)  Company Catalogue no.  
Donkey α Mouse 680LT 
1:15000 Licor 
926-68022 
Donkey α Mouse 800CW 926-32212 
Donkey α Rabbit 680LT 926-68023 
Donkey α Rabbit 800CW 926-32213 
Donkey α Goat  680LT 326-32224 











2.3.1. NanoString nCounter Human Kinase kit  
N.B. All NanoString nCounter reagents and instruments were sourced from 
NanoString Technologies Inc., Seattle, USA. 
 
The NanoString nCounter GX human kinase kit (NanoString) is a hybridisation-
based profiling assay for detecting the expression of 522 kinase mRNAs in 
total RNA (Figure 2.1). The assay involves hybridising target sequences in the 
sample by complementary base pairing of two gene specific probes: the 
capture probe and the reporter probe. RNA is directly tagged with a capture 
probe and a reporter probe that are specific to the target of interest, creating a 
unique target-probe complex. Each reporter probe has a unique colour coded 
barcode made up from four possible colours placed in six possible 
configurations. After the hybridisation step, excess probes are removed on the 
nCounter prep station, leaving only purified target-probe complexes. These 
complexes are immobilised and aligned onto an imaging surface. The sample 
is scanned by the nCounter digital analyser (see section 2.3.5) where labelled 
barcodes are directly counted. After count normalisation with internal reference 
genes and controls, mRNA levels are quantified, and data is analysed using 
the nCounter advanced analysis software (see section 2.3.6).  
2.3.2. Experimental set up 
Figure 2.2 shows the experimental set up for each set of NanoString 
experiments (A and B).  Three 6cm dishes of each cell line/ cell condition were 
grown in parallel; one dish was taken for mRNA extraction (section 2.3.3), one 
dish was lysed for western blotting analysis (section 2.2) and one was kept for 








Figure 2.1. Overview of NanoString technology 
A) An overview of workflow used to profile kinase transcript expression in SW48 cells. B) Each 
nCounter GX human kinase kit consists of 522 kinase genes, 8 internal reference genes, 6 
positive controls and 8 negative controls. C) mRNA extracted from SW48 cells is mixed in 
solution with kinase reporter and capture probes. Each reporter probe has a unique colour 
coded barcode for each kinase of interest. mRNA is hybridised to 35-50 base target specific 
sequences and the complexes are orientated onto the codeset and analysed by the nCounter 
imaging software. The expression level of a kinase is measured by counting the number of 





































Figure 2.2. Experimental set up of cell lines used in NanoString experiments 
A) The first set of NanoString experiments, outlined in chapter four, involved profiling the 
kinase transcriptome of SW48 isogenic mutant cells, in which one allele has been edited to 
harbour a specific RAS mutation. The panel included three KRAS mutant cell lines (K12D, 
K13D, K12V) and a HRAS (H12V) and NRAS (N12V) mutant cell line. The parental wild-type 
cell line was used as a reference to create log2 ratios for kinase expression for every cell line 
(see table 2.1 for more details). B) The second set of NanoString experiments, outlined in 
chapter 5, involved mapping kinase transcriptome adaptations to KRAS knockdown in the 
K12D mutant cell line. For KRAS knockdown experiments, two independent SW48 K12D cell 
lines with inducible expression of shRNAs targeting KRAS (sh2 and sh3) were used, along 
with the parental and K12D cell lines as controls (see section 2.1.3.1 for more details). Four 
biological replicates were conducted for each set of NanoString experiments.  
2.3.3. mRNA extraction  
To avoid RNase contamination, only RNase-free tips and tubes were used for 
RNA extraction. All work took place in a designated area washed down with 
an RNase cleaning spray, RNaseZAP (Thermo Fisher Scientific, MA, USA).  
 
The RNeasy Mini kit (Qiagen, Germany) was used for the purification of total 
RNA from SW48 cells. Briefly, cells were washed with PBS, before a buffer 
containing guanidine thiocyanate (RLT buffer) was added to release RNA and 
inactivate RNases. For direct cell lysis, 350 𝜇l of RLT buffer was added to the 
6cm dish and the lysate was scrapped with a rubber policeman and collected 
into a 2mL microcentrifuge tube. The cell lysate was added to a QIA shredder 
spin column (Qiagen, Germany), placed into a collection tube and 
homogenised by centrifugation for 2 minutes at 15,000 rpm. One volume of 
70% ethanol was added to the homogenised lysate to promote the selective 
binding of the RNA to the column. The sample was transferred into a RNeasy 
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spin column, placed over a 2mL collection tube and centrifuged for 15 seconds 
at 8000 x g. Total RNA adhered to the membrane and the contaminants were 
washed away during a series of wash steps. Columns were washed with 350 
𝜇l of RW1 buffer, followed by two 500𝜇l washes with RPE buffer and the 
column was centrifuged for 15 seconds at 8,000g in between each wash step. 
The column was placed in a new collection tube, before 30 𝜇l of RNase-free 
water was added. The column was centrifuged for 1 minute at 8,000g and the 
RNA eluted into the collection tube. Concentrations of RNA were quantified on 
a NanoDrop 1000 Spectrometer (Thermo Fisher Scientific, UK) (section 2.3.3).   
2.3.4. Quality assessment of total RNA 
The concentration and quality of total RNA samples were firstly assessed in-
house, using a NanoDrop 1000 spectrometer (Thermo Fisher Scientific, UK). 
Nucleic acids were quantified using UV absorption at 260nM, and the 
A260/280 and A260/230 ratios were used to assess the quality of the sample. 
The A260/280 ratio was used to assess protein contamination, whilst the 
A260/230 ratio indicated the presence of organic contaminants. NanoString 
recommend a 260/280 ratio of >1.9 and a 260/230 ratio of >1.8 for optimal 
results. All samples met these criteria. 
 
The concentration and quality of total RNA was also reviewed at the Centre of 
Genomic Research (CGR) at The University of Liverpool, where the 
NanoString instruments are based.  The Qubit 2.0 fluorimeter (Thermo Fisher 
Scientific, UK) was used to quantify the total RNA, and an Agilent 2100 
bioanalyser (Agilent Technologies Inc, CA, USA) was used to assess the 
quality of total RNA. Each sample was given an RNA integrity number (RIN) 
between 1-10, with 1 being the most degraded and 10 being of the highest 
quality. For pure RNA, a RIN of >7 was deemed acceptable. All samples 
scored 10/10 and therefore were taken forward for NanoString analysis.  
 
Before NanoString analysis, all extracted RNA samples were adjusted to 100 
ng/𝜇l with RNase free water and the concentrations were confirmed on the 
Qubit 2.0 fluorimeter.   
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2.3.5. Solution phase hybridisation  
Initially, a mastermix for the reporter probe was made by adding 70	𝜇l of 
hybridisation buffer to the reporter codeset. Next, 8 𝜇l of the reporter probe 
mastermix and 5	𝜇l of sample (500 ng total RNA) was added to each of the 
individual strip tubes. Finally, 2	𝜇l of the capture probeset was added to each 
tube, before the strip was capped and contents mixed briefly by centrifugation. 
The samples were added to a Veriti Thermal Cycler (Fisher Scientific, 
Loughborough, UK) at 65 oC for 16- 20 hours overnight.  
2.3.6. Post hybridisation processing   
The following day, the samples were removed from the thermal cycler and 
transferred to the NanoString nCounter prep station. The nCounter prep 
station is a fully automated liquid handling system that uses affinity purification 
to wash excess probes away. Briefly, magnetic beads are used to bind the 
capture probe whilst excess reporter probe is washed away. The sample is 
then eluted from the beads and the process repeated to wash away any excess 
capture probe. Finally, the hybridised samples are eluted and immobilised onto 
the surface of the nCounter cartridge. 
 
The cartridge was transferred to the nCounter digital analyser for automated 
imaging and data collection. The samples were scanned by the automated 
fluorescence microscope and the images analysed at maximum FOV (555 
fields of view). The barcodes were counted and tabulated into a reporter code 
count file (RCC file). The expression level of a gene was determined by 
counting the number of times its specific barcode was detected. 
2.3.7. Data and statistical analysis  
Data analysis was conducted using the nSolver 4.0 advanced analysis 
software which utilises the statistical software programme R 3.3.2 to perform 
each advanced analysis.  
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Firstly, a reporter library file (RLF file) that is specific to the nCounter GX 
human kinase codeset was downloaded, providing the software with 
information of which probe was assigned to which gene. Next, the reporter 
code count file (RCC file) containing barcode counts for each gene and control 
was downloaded into the software.  
 
The nSolver software conducts a series of quality control (QC) and 
normalisation steps using the controls and internal reference genes. Firstly, 
the positive controls are used to assess the efficiency of the hybridisation 
reaction. The stepwise concentrations of the six positive controls are used to 
check the linearity performance of the assay; the R2 value needed to be >0.95 
to pass QC checks. Next, the negatives controls are used for background 
subtraction to account for any false discoveries produced by non-specific 
probe binding. For background correction, the geometric mean of the negative 
controls is subtracted from the raw counts of each kinase. Finally, in order to 
eliminate run to run and sample to sample variability, the internal reference 
genes are used for normalisation. The geNorm algorithm removes reference 
genes with the least stable expression relative to the other reference genes 
(Vandesompele et al., 2002). The geometric mean of the most stable reference 
genes is then used to calculate a normalisation factor for each sample.  
 
The normalised data was taken forward for advanced analysis. Gene 
expression data was analysed using the differential expression (DE) module.  
Table 2.11 Overview of Differential expression analyses 




K12D vs. PAR 
K13D vs. PAR 
K12V vs. PAR 
H12V vs. PAR 




K12D vs. PAR 
KRAS knockdown vs. no knockdown 
(2x shRNA K12D cell lines +/- doxycycline) 
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The average counts from four biological replicates were used to generate log2 
ratios for each kinase in respect to each covariate (table 2.11). Statistical t-
testing was performed on log2 transformed data comparing the chosen 
covariates. The p-value was adjusted using the Benjamini-Hochberg method 
to eliminate the false discovery rate (FDR), as previously described 
(p<0.001)(Benjamini et al., 2001). A volcano plot was generated for each DE 
analysis, displaying each kinase log2 fold change and -log10 (p-value) with 
respect to the chosen covariate.  
2.4. Mass Spectrometry (MIB/MS)  
Unless otherwise stated, all mass spectrometry grade (MS-grade) reagents 
were purchased from Sigma-Aldrich, Poole, UK. LoBind Eppendorf tubes 
(Fisher Scientific, Loughborough, UK) or glass vials were used throughout to 
maximise sample recovery,  
2.4.1. SILAC labelling and experimental set up  
SW48 cells were maintained in arginine and lysine free DMEM (Dundee cell 
products, cat no. LM010) and 10% dialyzed FBS (Life tech, cat no. 10270). To 
generate light, medium and heavy SILAC labelled cells the DMEM was 
supplemented with l-proline (Pro 0) and then either: 
• Light- l-lysine (Lys0), l-arginine (Arg0) 
• Medium- l-lysine-2H4(Lys4), l-arginine-U–13C6 (Arg6) 
• Heavy-  l-lysine- U–13C6-15N2 (Lys8), l-arginine-U–13C6–15N4 (Arg10) 
 
The final concentrations were 28 mg/L for the arginine, 146 mg/L for the lysine 
and 200mg/mL for the proline amino acids (Sigma-Aldrich, Poole, UK). Cells 
were passaged 6-7 times in Medium containing amino acids, before MS 
analysis was conducted to test for label incorporation. Test labelling was 
conducted by carrying out an in-gel digest prior to MS analysis (sections 2.4.6 
and 2.4.7 respectively). MaxQuant was used to assess the extent of label 
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incorporation (section 2.4.8) (>95% label incorporation was expected), as 






Figure 2.3. Experimental set up and SILAC configurations for SW48 MIB/MS 
experiments 
The mutant cell lines were labelled with medium and heavy amino acids. The light labelled 
parental wild-type cell line was used as a reference in every case so comparisons could be 
made across all cell lines. The lysates were mixed in a 1:1:1 ratio and poured onto each 
MIB/MS column. Three biological replicates were conducted for each set of MIB/MS 
experiments.  A) The first set of MIB/MS experiments, outlined in chapter four, involved 
profiling the kinome of SW48 isogenic mutant cells, in which one allele has been edited to 
harbour a specific RAS mutation. The mutant panel included three KRAS mutant cell lines 
(K12D, K13D, K12V) and a HRAS (H12V) and NRAS (N12V) mutant cell line. A total of 3 
columns (a,b,c) were used per biological replicate. B) The second set of MIB/MS experiments, 
outlined in chapter 5, involved mapping kinase adaptations to KRAS knockdown in the K12D 
mutant cell line. For KRAS knockdown experiments, two independent SW48 K12D cell lines 
with inducible expression of shRNAs targeting KRAS (sh2 and sh3) were used (see section 
2.1.3.1 for more details). A MIB column was run for each shRNA cell line.  
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2.4.2. Harvesting cells for MIB/MS 
SW48 cells grown in 24.5cm (500cm2) square dishes were placed on a bed of 
ice before cell lysis. Cells were washed twice with 75mLs of ice-cold PBS and 
the PBS discarded after each wash. Next, 10mL of ice-cold PBS was added to 
the dish and cells scraped using a window squeegee. The cells/PBS were 
placed into a 50mL centrifuge tube and pelleted by centrifugation (200g, 
5mins). Pelleted cells were resuspended into 1mL of MIB/MS buffer (table 
2.12) and placed on ice for ten minutes, inverting occasionally. Next, the 
lysates were sonicated (3 x 10 seconds), alternating to allow each sample to 
cool for at least 30 seconds on ice between pulses. The lysates were collected 
into a 2 mL microcentrifuge tube and then cleared of non-soluble material by 
centrifugation (14,000rpm, 10 minutes, 4oC). A small aliquot was taken for 
protein determination by BCA assay (section 2.2.2). Clarified lysates were 
taken forward for MIB/MS analysis or stored at -80 oC for long term storage. 
 
Table 2.12: Composition of MIB/MS lysis buffer 
Solution Contents 
MIB Lysis Buffer 50 mM HEPES, pH 7.5 
150 mM NaCl 
0.5% Triton X-100 
1 mM EDTA 
1 mM EGTA 
10 mM NaF 
2.5 mM NaVO4 
Protease Inhibitor Cocktail, 2 tablets/50 mL 
Phosphatase Inhibitor Cocktail 2, 500µL/50mL  
Phosphatase Inhibitor Cocktail 3, 500µL/50mL 
2.4.3. Production of Multiplexed Inhibitor Beads (MIBs) 
For coupling inhibitors to beads, the inhibitors were weighed out into a 15mL 
falcon tube (table 2.13). The inhibitors were dissolved in 1mL of NN-
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Dimethylformamide (DMF) (Sigma) and then diluted 1:1 with 50 mM sodium 
bicarbonate, pH 7.0. 
 
Meanwhile, 2mL of Sepharose 4B beads (GE healthcare, 17-0571-01) were 
added into a crucible and drained by vacuuming. The beads were washed 
twice with 10mLs of 0.5M NaCl, gently swirling and draining in between each 
wash. Using the same method, the beads were washed with 10mLs of MilliQ 
water and finally 10mLs of coupling buffer (50% DMF: 50% 50mM sodium 
bicarbonate). The beads were vacuumed dried on the crucible for 30 seconds 
and transferred into the falcon containing the inhibitor solution. In a separate 
50mL falcon, 0.3834g of EDC powder (Sigma) was weighed out to make a final 
concentration of 1M in 2mL solution. The EDC powder was added to the falcon 
containing the inhibitor and beads, inverting a few times to dissolve the 
powder. The tubes containing the reaction mixture were covered in foil and 
placed on a nutator overnight.  
 
The following day, the beads were washed twice with 5mL of coupling buffer. 
To cap the unreactive groups on the kinobeads, the beads were incubated with 
1M ethanolamine (Sigma) and 1M of EDC powder in 2mL of coupling buffer 
overnight.  
 
On the final day, the beads were washed three times with 10mLs of coupling 
buffer, followed by three times with 10mLs of MilliQ water and once with 10mLs 
of 20% aqueous ethanol. The beads were stored in 20% aqueous ethanol at 4 
oC until further use. See Figure 2.4 for more details.  
Table 2.13. Quantities of inhibitors used for MIB beads 
Inhibitor Weight Company  Catalogue no. 
Bisindolylmaleimide (Bis-X) 20mg SYNkinase SYN-1021 
CTx-0294885 (CTx) 14mg SYNkinase SYN-4001-100 
CZC8004 20mg SYNkinase SYN-1037 
Purvalanol B 20mg SYNkinase SYN-1070 
PP58 20mg MedChem Express HY-18622 




Figure 2.4. Structures of Multiplexed Inhibitor Beads (MIBs) used to profile the kinome 
Broad-spectrum kinase inhibitors were immobilised on Sepharose beads through covalent 
linkage of their primary amino groups or carboxyl group (Purvalanol B). A mixture of six beads 
were used to enrich the kinase fraction from whole cell lysates. 
2.4.4. MIB/MS experiments 
Lysates (2mg of total protein) were thawed on ice before being equalised with 
MIB lysis buffer to 4mLs total volume. The samples were bought to 1M NaCl 
(850	𝜇𝑙 per sample) using cold filtered 5M NaCl (Invitrogen, Paisley, UK). 
 
The chromatography columns (BioRad, UK) (Cat no, 731-1550) were set up 














































































































Figure 2.5. Overview of the workflow used to establish and compare the  kinome 
profiles of isogenic SW48 cells 
A panel of isogenic cell lines were labelled with SILAC allowing multiple samples to be 
compared in a single run. Total protein lysates were poured over a block column, containing 
un-conjugated Sepharose beads, to promote non-specific binding of any highly abundant non-
kinase proteins. The flow through passes onto an affinity column containing a mixture of MIBs. 
Kinases eluted from the column were trypsin digested in-solution. Peptides are separated by 
Liquid Chromatography (LC) and identified and quantitated by Tandem Mass Spectrometry 
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columns in the upper rack and the MIB columns on the lower rack. For the MIB 
column, 350𝜇𝑙 of total MIB bead slurry was pipetted into each column (section 
2.4.3). N.B. For most experiments, the MIB CTx was used alone, however a 
MIB slurry made up of all six MIBs in combination was tested (see section 3.2.1 
for more details).  
 
The MIB columns were washed with 2mL of high salt MIB wash buffer. For 
block columns, 200	𝜇𝑙 of Sepharose 4B (block beads) were pipetted into each 
column and washed with 2mLs of high salt MIB wash buffer. After the washes 
had flowed through, the block columns were brought directly over the MIB 
columns. All sample flow through and washes were discarded into a 
Tupperware. For details of all buffers used in the MIB/MS experiments see 
table 2.14. 
 
The lysates were gently poured into the block column and subsequently the 
block column was removed once the sample had flowed through. After the 
lysate had flowed through the MIB column below, several wash steps were 
conducted. The column was washed with 5mL of high salt MIB wash buffer, 
followed by 5mL of low salt MIB wash buffer and then 500	𝜇𝑙 of SDS MIB wash 
buffer. The base of the MIB columns were firmly secured with caps, before 
500	𝜇𝑙	of elution buffer was added and the column tops capped. The MIB 
columns were boiled in a heat block at 95 oC for 15 minutes before collecting 
the eluate in a 1.5mL Eppendorf LoBind tube. A further 500	𝜇𝑙	of elution buffer 
was added and the elution step was repeated bringing the total eluate volume 
to approximately 1mL.  
 
The samples were then processed for MS analysis. Mainly, proteins were 
digested using an in-solution digest method (section 2.4.5) but an in-gel 






Table 2.14: Composition of MIB/MS buffers 
Solution Contents 
Low Salt MIB Wash Buffer  50 mM HEPES, pH 7.5 
150 mM NaCl  
0.5% Triton X-100 
1 mM EDTA   
1 mM EGTA   
High Salt MIB Wash Buffer 50 mM HEPES, pH 7.5 
1 M NaCl  
0.5% Triton X-100 
1 mM EDTA   
1 mM EGTA   
SDS MIB Wash Buffer  50 mM HEPES, pH 7.5 
150 mM NaCl  
0.5% Triton X-100 
1 mM EDTA   
1 mM EGTA   
0.1% (w/v) SDS  
MIB Elution Buffer  0.5% (w/v) SDS 
1% (v/v) b-mercaptoethanol 
0.1M Tris-HCl, pH 6.8 
LC-MS grade water 
C18 equilibration buffer 5% ACN 
0.5% TFA  





2.4.5. In-solution digestion of proteins 
2.4.5.1. Dithiothreitol and Iodoacetamide treatment 
Dithiothreitol (DTT) (Sigma) is a reducing agent that is important for preventing 
intramolecular and intermolecular disulphide bonds from forming between 
cysteine residues of proteins by converting cystine disulphide bonds into 
cysteine free sulfhydryl groups (Gundry et al., 2009). Firstly, samples were 
incubated with 10	𝜇𝑙 of 500mM DTT in a heat block at 60 oC for 25 minutes. 
The samples were left to come to room temperature on ice, before being 
incubated in the dark with 100	𝜇𝑙 of 200mM iodoacetamide (IAA) (Sigma) for 
30 minutes. IAA is an alkylating agent that caps the free sulfhydryl groups of 
cysteine residues, preventing disulphide bonds forming prior to tryptic 
digestion (Gundry et al., 2009). Following incubation with IAA, 10	𝜇𝑙 of 500mM 
DTT was added to each sample to stop the alkylation step. Finally, samples 
were concentrated using Amicon Millipore Ultra-4 (10K cut off) spin columns 
(cat no. UFC801008). The samples were poured into the columns and 
centrifuged for 30 minutes (4 oC ,3000rpm). The concentrated samples (100	𝜇𝑙-
150	𝜇𝑙) were transferred into 2mL LoBind microcentrifuge tubes ready for 
protein precipitation.  
2.4.5.2. Methanol/ Chloroform precipitation of proteins   
Protein precipitation was performed by adding MS-grade methanol, water and 
chloroform to each sample in a 4:3:1 ratio. Samples were centrifuged at top 
speed at 4 oC for ten minutes to ensure an interphase layer of protein was 
formed. Using a pipette, the entire upper aqueous layer was removed, 
ensuring the white interphase layer of protein was still intact. Next, the samples 
were gently vortexed and centrifuged at 13,000rpm at 4 oC for 5-10 minutes, 
ensuring that the opaque protein pellet was visible at the bottom of the tube. 
After the supernatant was removed, the protein pellet was washed twice with 
500	𝜇𝑙 of MS-grade methanol. Finally, the samples were dried in a speed vac 
at 37 oC for approximately 5 minutes, ready for trypsin digestion.  
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2.4.5.3. Trypsin digestion 
The protein pellet was resuspended in 100	𝜇𝑙 of 50mM HEPES, pH8 buffer, 
using a pipette tip to dislodge the pellet from the side of the tube. The samples 
were incubated at 37 oC overnight with trypsin (4 ng/μL working concentration; 
Trypsin GOLD, sequencing grade, Promega, USA) to cleave C-terminal to 
arginine and lysine residues. 
2.4.5.4. Ethyl acetate extraction for the removal of triton 
Ethyl acetate was added to the samples for the removal of triton. Firstly, MS 
grade water was added to ethyl acetate in a 10:1 ratio in order to saturate ethyl 
acetate and prevent sample loss. 1mLs of saturated ethyl acetate was added 
to each sample. The samples were vortexed thoroughly before centrifugation 
at 13,000rpm for five minutes at RT. Next, the entire upper layer of ethyl 
acetate was removed in a fume hood. This extraction step was repeated twice 
more before residual ethyl acetate was evaporated by putting samples on a 
heat block for three minutes at 60 oC. Finally, samples were dried in a speed 
vac prior to desalting.  
2.4.5.5. C-18 pepclean 
The C-18 spin columns (Pierce, cat no, 89870) were placed in 2mL 
microcentrifuge tube to collect flow through from washes. The column resin 
was activated by adding 200	𝜇𝑙 of 50% Acetonitrile (ACN) in MS grade water 
and centrifugation at 4400rpm for one minute. Next, the column was 
equilibrated by the centrifugation of 200	𝜇𝑙 of C-18 buffer (5% ACN, 0.5% TFA, 
in MS water) at 4400rpm for one minute. The dried protein pellet was 
resuspended in 200	𝜇𝑙 of C-18 buffer and loaded onto the C-18 column. The 
column was centrifuged at 4400rpm for one minute and the flow through 
discarded. The column was washed by centrifugation with 200	𝜇𝑙 of C-18 
buffer at 4400rpm for a further minute. Finally, samples were eluted from the 
column into a new 1.5mL LoBind Eppendorf tube by adding 2x 25	𝜇𝑙 50% ACN 
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to the column and centrifuging at 4000rpm for one minute. Samples were dried 
down in a speed vac prior to MS analysis.  
2.4.6. In-gel digestion of proteins  
2.4.6.1. SDS-PAGE  
Samples were loaded on 4-12% pre-cast Bis-Tris gels (NuPage, Invitrogen, 
Paisley, UK) and separated by SDS-PAGE. Separation typically took place at 
100V for 15 minutes followed by 200V for 45 minutes. The gels were placed in 
a 15cm dish and stained with Colloidal Blue staining (Invitrogen, Paisley, UK). 
Each sample lane was cut into 1x1mm pieces using a sterile scalpel (approx. 
48 pieces). The gel pieces were transferred into 1.5mL LoBind Eppendorf 
tubes before being destained with 40	𝜇𝑙 of 50mM Ambic/50% ACN at 37 oC. 
for ten minutes. Next, the gel slices were dehydrated by adding 100	𝜇𝑙 of ACN 
and incubating for five minutes at RT. The supernatant was discarded, and 
samples dried for five minutes on a speed vac. 
2.4.6.2. Dithiothreitol and Iodoacetamide treatment  
The samples were reduced by adding 50	𝜇𝑙 of 10mM DTT in 100mM of ambic 
and incubated for one hour at 56 oC. The supernatant was discarded, and 
samples were left to cool on ice for five minutes. Next, the samples were 
alkylated by adding 50	𝜇𝑙 of 50mM IAA in 100mM ambic and incubated in the 
dark for 30 minutes at RT. The supernatant was discarded, before several 
wash steps were completed. Firstly, the gel pieces were washed with 300	𝜇𝑙 
of 100mM ambic for 15 minutes at RT. Again, the supernatant was discarded, 
before gel pieces were washed with 300	𝜇𝑙 of 20mM ambic /50% ACN for 15 
minutes at RT. Next, the gel slices were dehydrated by adding 100	𝜇𝑙 of ACN 
for five minutes at RT. The supernatant was discarded, and the samples were 
dried by a Speed vac.  
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2.4.6.3. Trypsin digestion  
The protein pellet was resuspended in 100	𝜇𝑙 of reaction buffer (40mM ambic, 
9%ACN) using the pipette tip to dislodge the pellet from the side of the tube. 
The samples were incubated at 37 oC overnight with trypsin (4 ng/μL working 
concentration; Trypsin GOLD, sequencing grade, Promega) to cleave C-
terminal to arginine and lysine residues.  
2.4.6.4. Peptide extraction 
The following day, 100	𝜇𝑙 of ACN was added to each digest and incubated for 
30 minutes at 30 oC. The supernatant containing the peptides for analysis were 
transferred into a new 1.5mL LoBind Eppendorf. The remaining gel pieces 
were incubated with 1% formic acid for 20 minutes at RT before, the 
supernatant was transferred to the tube containing peptides for analysis. 
Finally, 150	𝜇𝑙 of ACN was added to the gel pieces and incubated for ten 
minutes at RT before, the supernatant was again transferred to the tube 
containing peptides for analysis. The peptides were dried by a speed vac prior 
to MS analysis.  
2.4.7. MS/MS 
For label testing, samples were analysed in-house using our LTQ Orbitrap 
mass spectrometer. Dried protein pellets were resuspended in 1% formic acid 
and centrifuged at 13,000g for ten minutes before injection on the MS. A total 
of 5 μL of each sample was fractionated by nanoscale C18 high performance 
liquid chromatography (HPLC) on a Waters nanoACQUITY UPLC system 
coupled to an LTQ-OrbitrapXL (Thermo Fisher Scientific) fitted with a Proxeon 
nanoelectrospray source. Peptides were loaded onto a 5 cm × 180 μm trap 
column (BEH-C18 Symmetry; Waters Corporation) in 0.1% formic acid at a 
flow rate of 15 μL/min and then resolved using a 25 cm × 75 μm column using 
a 20 min linear gradient of 3 to 62.5% acetonitrile in 0.1% formic acid at a flow 
rate of 400 nL/min (column temperature of 65 °C). The mass spectrometer 
acquired full MS survey scans in the Orbitrap (R = 30 000; m/z range 300–
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2000) and performed MSMS on the top five multiple charged ions in the linear 
quadrupole ion trap (LTQ) after fragmentation using collision-induced 
dissociation (30 ms at 35% energy) (Hammond et al., 2015).  
 
For MIB/MS experiments, samples were sent for analysis at the proteomics 
facility at the University of Warwick. Reversed phase chromatography was 
used to separate tryptic peptides prior to mass spectrometric analysis. Cell 
proteomes were analysed with two columns, an Acclaim PepMap µ-precolumn 
cartridge 300 µm i.d. x 5 mm, 5 μm, 100 Å and an Acclaim PepMap RSLC 75 
µm i.d. x 25 cm, 2 µm, 100 Å (Thermo Fisher Scientific). The columns were 
installed on an Ultimate 3000 RSLCnano system (Thermo Fisher Scientific) at 
40°C. Mobile phase buffer A was composed of 0.1% formic acid and mobile 
phase B was composed of acetonitrile containing 0.1% formic acid. Samples 
were loaded onto the µ-precolumn equilibrated in 2% aqueous acetonitrile 
containing 0.1% trifluoroacetic acid for 8 min at 10 µL min-1 after which 
peptides were eluted onto the analytical column at 300 nL min-1 by increasing 
the mobile phase B concentration from 8% B to 25% over 37 min, then to 35% 
B over 10 min, followed by a 3 min wash at 90% B and a 10 min re-equilibration 
at 4% B. 
Eluting peptides were converted to gas-phase ions by means of electrospray 
ionization and analysed using an Orbitrap Fusion instrument (Thermo Fisher 
Scientific). Survey scans of peptide precursors from 375 to 1500 m/z were 
performed at 120K resolution (at 200 m/z) with a 2x105 ion count target. The 
maximum injection time was set to 150 ms. Tandem MS was performed by 
isolation at 1.2 Th using the quadrupole, HCD fragmentation with normalized 
collision energy of 33, and rapid scan MS analysis in the ion trap. The MS2 ion 
count target was set to 3x103 and maximum injection time was 200 ms. 
Precursors with charge state 2–6 were selected and sampled for MS2. The 
dynamic exclusion duration was set to 30 seconds with a 10-ppm tolerance 
around the selected precursor and its isotopes. Monoisotopic precursor 
selection was turned on and instrument was run in top speed mode. 
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2.4.8. MaxQuant data analysis 
Raw MS data files were processed using MaxQuant software, as described 
previously (Hammond et al., 2015). Data obtained from MaxQuant analyses 
were evaluated using Microsoft Excel and log2 ratios were generated for each 





Chapter 3 : Using MIB/MS to profile kinome 
activity on a global scale 
Traditional methods to measure kinase activity are relatively low throughput 
and limited to reagent availability, leaving much of the kinome understudied 
(Wilson et al., 2018). The traditional ‘gold’ standard kinase assay, measures 
the transfer of radiolabelled ATP onto a kinase substrate and this is directly 
proportional to kinase activity (Hastie, McLauchlan and Cohen, 2006). 
Although highly sensitive, this method only provides biochemical analysis of 
individual enzymes. (Cann et al., 2017). Western blotting is another traditional 
approach used to analyse the activity of select kinases via the presence of 
diagnostic phospho-sites (Stommel et al., 2007). Again, this approach is 
relatively low throughput and limited to phospho-specific antibody availability. 
In addition, the multi-step nature of activation of some kinases that involves 
accessory proteins and structural changes, the phospho-site may not faithfully 
measure activation state (Johnson, Noble and Owen, 1996). 
 
Advances in genomic technologies have allowed scientists to conduct high-
throughput whole-genome and whole-transcriptome sequencing (Fleuren et 
al., 2016). Scientists are therefore able measure the gene expression of 
kinases on a global scale and also map transcript changes in response to 
kinase inhibitors (Stuhlmiller, Earp and Johnson, 2014). This approach to 
studying the kinome however has some limitations. Firstly, the expression of a 
kinase at the transcript-level doesn’t always correlate to the expression at the 
protein-level (Schwanhäusser et al., 2011). Moreover, protein-level expression 
doesn’t necessarily correlate to the enzymatic activity of the kinase (Graves et 
al., 2013).  
 
It has become apparent that to improve our understanding of the information 
flow between kinases and the wider signalling network, we need to be able to 
globally measure kinase expression at both the genetic and proteomic level, 
but more importantly to determine whether a kinase is active. Furthermore, 
establishing what proportion of the kinase is active and whether it’s activation 
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status changes in response to activators or inhibitors will be critical to our 
understanding. 
 
A method has recently been developed that purports to allow simultaneous 
measurement of the relative expression/activities of hundreds of kinases within 
cells (Duncan et al., 2012a). The method utilises broad specificity kinase 
inhibitors which are immobilised onto Sepharose beads to make up the 
Multiplexed Inhibitor Bead (MIB) slurry. Type I kinase inhibitors, which are 
thought to only bind to the ATP binding pocket of kinases in their active DFG-
in conformation, are used to make the MIBs (Roskoski, 2016). The rationale is 
that binding of kinases to the column reflects kinase activity; increased binding 
of the kinase to the column indicates increased kinase activity. Quantitative 
mass spectrometry is used to identify and quantify the kinases in each sample. 
Incorporating quantitative proteomic labelling techniques, such as SILAC or 
iTRAQ, make it possible to simultaneously measure and compare global 
kinome adaptions between multiple samples (Ong and Mann, 2005).  
 
It is also important to note that the MIBs can also to bind pseudokinases; It 
was reported in a study by Murphy et al. that around 40% of pseudokinases 
still bind to ATP despite being catalytically inactive (Murphy et al., 2014).  
 
In the pioneering work by the Johnson lab, MIB/MS was used to profile kinome 
activity in response to MEK inhibition in TNBC cells (Duncan et al., 2012b). 
The assay was used to map kinome adaptations caused by MEK inhibition, 
and as a result, the group were able to define a mechanism of drug resistance: 
Acute loss of MEK/ERK signalling causes degradation of c-myc and relieves 
transcriptional repression of several RTKs (Johnson et al., 2013). An increase 
in RTK expression/activity thus causes an increase in downstream oncogenic 
MAPK signalling therefore providing the compensatory mechanism to MEK 
inhibition. The study provided the first example of how MIB/MS can be used to 
profile kinome activity, assess kinome rewiring in response to targeted 
inhibition, and therefore help rationally predict combinational therapy to 
overcome resistance in the clinic.  
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Many studies have since used MIB/MS to measure kinome reprogramming 
that occurs in response to targeted inhibition (Cox et al., 2011; Duncan et al., 
2012a; Cooper et al., 2013; Stuhlmiller et al., 2015; Johnson et al., 2014). 
MIB/MS has also been used to compare the differential signalling outputs of 
tumours or cells harbouring different mutations (Figure 2.5) (Gholami et al., 
2013). However, there seems to be some controversy as to what extent the 
MIB/MS assay reports activation-dependent binding and therefore what 
measuring kinome ‘responsiveness’ actually means. A recent paper was 
published opposing the notion that MIB/MS could be used to measure kinase 
activity; the authors state that binding to the MIBs is largely independent to 
kinase activation status (Ruprecht et al., 2015). Instead, the group argue that 
enrichment mainly depends on kinase expression levels, the affinity of a kinase 
to the immobilised compound and kinase conformation state. Nevertheless, it 
is undisputed that the method is a good enrichment tool for kinases that are 
lowly abundant in cells and therefore a difficult group of enzymes to study 
simultaneously in the cellular context.  
 
I propose to use MIB/MS to compare the differential signalling outputs of cells 
harbouring different Ras mutations. Since the Ras pathway is enriched in 
effectors that are kinases, MIB/MS would be useful for investigating the effect 
of Ras mutations on known downstream effectors but more importantly 
unknown Ras effectors that lie within the wider signalling networks. Before 
profiling differential kinome responses in Ras mutant cells, it will be imperative 
to elucidate to what extent the assay is able to report kinase activation status 
and therefore what type of ‘response’ we are measuring using the assay.  
3.1. Objective  
The objective of this chapter was to establish the MIB/MS kinome assay in the 
lab and determine to what extent the assay is able to report activation-




The aims of the initial stages of the project was to establish and optimise the 
MIB/MS assay in the lab (Figure 3.1). Several stages of optimisation were 
conducted in order to:  
i)  Produce Multiplexed Inhibitor Beads (MIBs) in our lab. 
ii) Validate the efficiency of six different MIBs in isolating kinases and 
potential binding partners. 
iii) Optimise the sample processing pipeline. 
3.2.1. CTx-0294885 is the most efficient MIB to isolate kinases 
Multiplexed inhibitor beads (MIBs) comprise broad-spectrum kinase inhibitors 
immobilised on Sepharose beads through covalent linkage of their primary 
amino or carboxyl group. Previous studies had used columns containing up to 
six different MIBs to enrich kinases from cells or tissues (Cooper et al., 2013; 
Cox et al., 2011; Duncan et al., 2012a; Stuhlmiller et al., 2015). These included 
Bisindolylmaleimide-X, CTx-0294885, CZC8004, Purvalanol B, PP58 and 
VI16832 (Figure 2.4). Using published protocols, each kinase inhibitor was 
conjugated to Sepharose beads (Zhang et al., 2013). I was able to observe a 
transfer of colour from the inhibitor solution to the beads which remained stable 
however, measuring conjugation efficiency by Mass Spectrometry should have 
been conducted to ensure that each inhibitor had linked with sepharose 
consistently, across all biological replicates.  
 
The efficiency of each MIB to isolate kinases and potential binding partners 
was evaluated. Each MIB was individually tested over the indicated number of 
replicates and experimental conditions (Figure 3.2). Figure 3.2A, shows the 
proportion of kinases and non-kinases isolated by each bead type. The total 
number of proteins captured by each bead ranged from 349 to 757 proteins. 
Kinases represented between 5-16% of total proteins pulled down by each 
bead, a significant enrichment against the background rate of kinase  
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Figure 3.1. Overview of MIB/MS method optimisation. 
When establishing the MIB/MS method in our lab, several aspects of the protocol were 
reviewed in order to achieve optimum kinome profiling in our cells (highlighted in orange). Prior 
to lysis, wild-type SW48 cells were treated with 100μM pervanadate for 15 mins at 37C. 
Different concentrations of cell lysate were loaded onto the column to determine if loading 
concentration correlated to the number of kinases detected by LC-MS/MS. Following passage 
through the block column, the lysate was passed through a column containing MIBs. Protein 
lysates were run over each bead type individually and also the six MIBs in combination to 
determine what combination provided the best coverage of the kinome (Bisindolylmaleimide, 
CTx-0294885, CZC8004, Purvalanol B, PP58, VI16832). To determine optimal tryptic 




















Figure 3.2. CTx-0294885 is the most efficient MIB in isolating kinases. 
Protein lysates were run over each bead type (Bisindolylmaleimide, CTx-0294885, CZC8004, 
Purvalanol B, PP58, VI16832). Data derived from MaxQuant analysis illustrating: A) The total 
number of all kinase (black) and non-kinase (white) proteins pulled down by each MIB over 
several experiments under various experimental conditions. B) The overlap between protein 
kinases enriched by the six different MIBs. C) The average intensity of each kinase detected 
across the kinome. These data indicate that CTx provides the greatest coverage of the kinome.   
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expression in the human genome (2.6%). All 6 beads therefore successfully 
enriched for a subset of kinases but to various extents. The most efficient MIB 
is CTx-0294885 capturing approximately 20% of the kinome (119/535); CTx 
isolated 748 proteins, of which 119 were kinases. Given that previous studies 
had typically used five or more beads in combination, I wanted to determine 
what unique contribution each MIB provided. The Venn diagram in Figure 3.2B 
shows there is significant overlap between the kinases enriched by the six 
MIBs. However, the majority of kinases isolated from the cells at this stage 
were isolated by CTx, with 45 kinases unique to CTx alone.  Furthermore, CTx 
clearly achieved the best coverage of the kinome, with kinases from all major 
kinase subfamilies captured by the MIB (Figure 3.2C). With this in mind, I 
decided to use the single bead CTx for further method optimisation. 
3.2.2. Method optimisation 
I wanted to ensure that the sample processing pipeline was as efficient as 
possible. Different concentrations of cell lysate were loaded onto a column 
containing MIBs and the number of kinases detected recorded. This series of 
experiments provided the opportunity to investigate whether loading 
concentration correlated to the number of kinases detected and also determine 
whether the method provides good kinase enrichment of SW48 cells. Figure 
3.3A shows that we detected a greater number of kinases after loading more 
cellular material. However, less than 10% of the kinome was isolated in initial 
experiments using in-gel digestion. This was far lower than expected, 
considering the method is thought to be capable of enriching 50%-60% of the 
expressed kinome (Duncan et al., 2012a). The only clear difference between 
the proteomic workflow that was adopted in our lab and that of the Johnson 
lab was that different types of proteolytic digest were utilised. Previous studies 
used an in-solution approach to digest proteins before peptides were 
separated by Liquid Chromatography (LC) and identified and quantified by 
Tandem Mass Spectrometry (MS-MS) (Duncan et al., 2012a; Cooper et al., 
2013).  I therefore wanted to see if kinase enrichment was improved after using 
an in-solution approach.  
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Optimum kinase enrichment was achieved using an in-solution digest. Nearly 
double the number of kinases were detected by LC/MS/MS after performing 
an in-solution digest vs. an in-gel digest (Figure 3.3A). For example, when 5mg 
of cell lysate was loaded, the in-solution digest yielded 88 kinases whilst the 
in-gel approach yielded 43. This trend was observed across all loading 
concentrations. Furthermore, it was found that to reach the maximal kinase 
enrichment, less loading material was needed using the in-solution digest vs. 
in-gel digest. For subsequent experiments, we decided to load 2mg of cell 
lysate as increasing the loading concentration in this context would not 
produce any greater benefit.  
 
A comparison was made between the average intensities of all proteins 
detected over the experiments utilising an in-gel digest vs. an in-solution 
digest, and this provided an explanation as to why the in-solution digest is more 
favourable (Figure 3.3B). It is clear that the majority of proteins (kinase or non-
kinase) are detected at a higher intensity after performing an in-solution digest. 
This suggests that the kinases are more abundant in a sample after this type 
of digestion and therefore are more likely to be detected.  
 
We were interested in what makes a kinase more likely to be detected by the 
LC/MS/MS. One might expect that proteins with a higher molecular weight are 
more likely to be detected by LC/MS/MS, as there would a greater number of 
peptides in solution after digestion than lower molecular weight proteins. The 
data suggests, however, that there is no correlation between the number of 
occasions each kinase was observed and its molecular weight (Figure 3.3C) 
Instead, a relationship between the number of times a kinase was detected 
and its average intensity is evident; a kinase is more likely to be seen if it has 
a higher average intensity (Figure 3.3D). If we assume the intensity of a kinase 
is a measure of abundance, then we can deduce that kinase enrichment is 




Figure 3.3. Improved enrichment of kinases observed using an in solution tryptic 
digest vs. in gel tryptic digest.  
Data generated from multiple experiments using a single MIB, CTx only. MaxQuant analysis 
illustrating: A) The number of kinases detected using different concentrations of cell lysate 
over several in-gel digest (black) or in-solution digest (red) experiments. B) The intensities 
of all kinase (red) and non-kinase proteins (grey) detected in experiments utilising an in-gel 
digest vs. in-solution digest. C) Representation of the number of occasions protein kinases 
were detected based on their molecular weight. D) Correlation between the average 
intensity of each protein kinase and the number of occasions each kinase was detected 
over several in-gel digest experiments. Kinase enrichment is based on protein abundance 
and is not influenced by molecular weight. 
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3.2.3. The MIB assay does not profile kinase activation state in SW48 
cells. 
In the original MIB/MS study (Duncan ref), activation-dependent binding to 
MIBs was demonstrated by:  
i) increased binding of MAPKs after cells were stimulated with 
EGF.  
ii) increased binding of Tyrosine Kinases (TK) after cells were 
treated with the tyrosine phosphatase inhibitor, Pervanadate, 
which renders kinases in their active state.   
 
I used the same approach to test activation-dependent binding in our SW48 
parental cell line. SW48 cells were serum starved for 16h before treatment with 
20% serum, 20ng/mL EGF or 100μM pervanadate. A simplified outline of the 
Ras signalling network is depicted in Figure 3.4A highlighting key nodes 
expected to be responsive after stimulation. The objective was to analyse the 
activation responses to each treatment and to see if this correlated to MIB 
binding.  
 
Firstly, western blotting was performed to generate independent evidence of 
kinase responses to treatment with serum, EGF or pervanadate. A phospho-
tyrosine (pY20) antibody was used to confirm pervanadate-induced TK 
activation.  A global increase in the phosphorylation of TKs in SW48 cells 
treated with pervanadate was observed (Figure 3.4B). Additionally, using 
phospho-specific antibodies I observed increased activity of individual nodes 
in the MAPK and PI3K pathways induced by three treatments. The data 
generated was used to inform whether an increase in binding to MIBs is 





Figure 3.4. Signalling responses of SW48 wild-type cells after treatment with serum, 
EGF or pervanadate. 
A) A simplified outline of the Ras signalling network. Ras proteins utilise various downstream 
effectors to illicit many signalling responses. Upon activation by RTKs, Ras can activate both 
the MAPK and PI3K pathways promoting cell differentiation and proliferation. B) SW48 wild-
type cells were serum starved for 16hrs before treatment with 20% serum for 5 mins, 20ng/mL 
EGF for 5 mins or 100μM pervanadate for 15 minutes. Cells were subsequently lysed with 
RIPA buffer. Lysates were separated by SDS-page and western blots were probed with the 
indicated antibody. 
Whilst evaluating whether the MIB/MS assay was capable of reporting 
changes in kinase activation in SW48 cells, several variations to the method 
were tested. These included comparing:  
i) SILAC and label-free configurations (figure 3.5) 
ii) CTx alone and a slurry of 6 MIBs in combination 
3.2.3.1. SILAC with CTx 
Firstly, the activity of serum starved SW48 cells were compared to cells that 
were treated with 20% serum. Lysates were combined and ran over a column 
containing CTx only. The heatmap in figure 3.6A clearly shows that there was 
no change in kinase enrichment after cells were stimulated with serum. Out of 
the 102 kinases that were captured, only one was ‘responsive’. Responsive is  
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Figure 3.5. Experimental strategy for the characterisation of activity dependent binding 
to Multiplexed inhibitor beads (MIBs). 
SW48 cells treated with serum, EGF or pervanadate were compared to serum starved cells to 
determine whether binding to the MIB column is dependent on kinase activation status. A) 
Cells were labelled with SILAC allowing two samples to be compared in a single run. Light 
labelled cells were serum starved and combined (1:1) with stimulated heavy labelled cells. B) 
Unlabelled cell lysates were ran over separate columns and label-free quantification was used 
to compare between the conditions.   
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defined by a 2-fold increase or decrease in activity after stimulation. 
Furthermore, there was no evidence of increased binding of key members of 
the MAPK pathway, whose activity we had previously shown to be induced by 
serum stimulation.  
3.2.3.2. SILAC with COMBINED MIBs 
Considering a slurry of six different MIBs (Bisindolylmaleimide-X, CTx-
0294885, CZC8004, Purvalanol B, PP58 and VI16832) was used in the original 
study, I decided to test whether I could achieve activation-dependent binding 
using all six beads in combination. In this series of experiments, a comparison 
was made between the activity profiles of serum-starved cells vs. cells treated 
with serum, EGF or pervanadate. The heatmaps in Figure 3.6B, show that 
kinase enrichment is comparable between rested and treated cells. In all three 
cases, there were very few, if any kinases that were responsive. Furthermore, 
it is clear that again there is a lack of differential binding to MIBs of kinases 
known to be active after treatment with EGF or pervanadate (Figure 3.6C). 
There was no increase in binding of the kinases that had previously been seen 
to be activated by EGF stimulation. Similarly, there was no increase in the 
retention of tyrosine kinases shown to be indirectly activated by pervanadate.  
 
At this stage, I started to consider why I couldn’t emulate previous findings and 
whether it may be due to labelling technique I had used. The cells that I used 
had been labelled using SILAC. SILAC is advantageous because the label is 
introduced at the amino acid level. Multiple samples can be combined after 
lysis and therefore sample-sample variability is limited giving more reliable 
quantification (Geiger et al., 2010). However, the original study employed 
iTRAQ to label samples (Duncan et al., 2012a). iTRAQ differs from SILAC in 
that peptides are labelled post elution and digestion. I was concerned that I 
was unable to emulate the results from the previous study because the 
samples were mixed before loading onto the column. It was hypothesised that 
this could be due to cross-activation between samples when mixing lysates. I 
decided, therefore, to test a label-free approach using the MaxQuant software. 
This method would adjust for sample variation caused by running samples on  
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Figure 3.6. Binding proteins in SW48 cell extracts using SILAC  
Data derived from MaxQuant illustrating there is no evidence of activation dependent binding 
following treatment of serum starved SW48 cells with serum, EGF or pervanadate. Heatmaps 
illustrating the kinase activation profile of SW48 cells employing A) CTx alone B) a combination 
of 6 MIBs (Bisindolylmaleimide, CTx-0294885, CZC8004, Purvalanol B, PP58, VI16832). The 
average intensities taken from 3 biological replicates were used to curate each heatmap. Pie 
charts show the ratio of kinases (grey) vs. non kinases (white) enriched under each 
experimental condition.  C) Graphs showing the intensities of kinases in serum starved (ss) 
vs. stimulated (st.) cells. Kinases were selected based on expected activation changes in 
response to EGF stimulation and pervanadate treatment. Each data point represents the 
intensity from a single biological replicate.  
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separate columns but also solve the potential problem with cross-activation 
(Figure 3.7).  
3.2.3.3. LABEL-FREE with CTx 
Similar experiments were conducted using a label-free approach to see if there 
was evidence of differential binding in this context. Lysates that had been 
starved or stimulated with serum were ran over separate columns containing 
CTx only (Figure 3.7). Figure 3.7A, shows that there was differential kinase 
enrichment after cells were stimulated with serum. 82 out of the 90 kinases 
detected were deemed responsive however after closer inspection it was 
apparent that all intensities decreased after serum stimulation. This suggested 
that there was a decrease in the number of kinases bound to the column and 
therefore all responsive kinases were less active after stimulation. In this case 
it seems there may have been a problem with quantification. Label-Free  
Quantification (LFQ) relies on a population of peptides that minimally change 
between conditions for normalisation (Cox et al., 2014). The software may be 
unable to carry out effective normalisation due to the relatively small number 
of proteins present within the enriched sample. 
3.2.3.4. LABEL FREE with COMBINED MIBs 
Subsequently, a label-free approach was tested using all six beads in 
combination. Similar to previous experiments, a comparison was made 
between the activity profiles of serum starved cells vs. cells treated with serum, 
EGF or pervanadate. In each case, there was a subset of responsive kinases 
that seemed to differentially bind to the column (Figure 3.7B).  Unfortunately, 
increased binding of kinases known to be activated by EGF for pervanadate 
was not observed and therefore the I concluded that the differential binding we 
observed could not be entirely dependent on activation status (Figure 3.7C).  
 
From this phase of experiments, I conclude that contrary to the previous 




Figure 3.7. Binding proteins in SW48 cell extracts using LFQ 
Data derived from MaxQuant illustrating there is no evidence of activation dependent following 
treatment of serum starved SW48 cells with serum, EGF or pervanadate. Heatmaps illustrating 
the kinase activation profile of SW48 cells employing A) CTx MIBs B) a combination of 6 MIBs 
(Bisindolylmaleimide, CTx-0294885, CZC8004, Purvalanol B, PP58, VI16832). The average 
intensities taken from 3 biological replicates were used to curate each heatmap. Pie charts 
show the ratio of kinases (grey) vs. non kinases (white) enriched under each experimental 
condition C) Graphs showing the intensities of kinases in serum starved (ss.) vs. stimulated 
(st.) cells. Kinases were selected based on expected activation changes in response to EGF 
stimulation and pervanadate treatment. Each data point represents the intensity from a single 
biological replicate.   
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individual kinases within the SW48 cell kinome regardless of bead type or 
labelling technique.  
3.2.4. The MIB assay does not directly profile kinase activity in MDA-MB-
231 cells.  
In the original MIB/MS study, kinome activity and drug responsiveness was 
profiled in the TNBC cell lines, MDA-MB-231 and SUM159.  (Duncan et al., 
2012a). SILAC labelled MDA-MB-231 cells were serum starved overnight and 
stimulated with 30ng/mL EGF for 15 minutes. Upon stimulation with EGF, there 
was a 10-fold increase in binding of EGFR to MIBs.  Furthermore, there was 
increased binding of tyrosine kinases to MIBs following pervanadate treatment, 
however this was observed in Chronic Myeloid leukaemia cells.  
 
 
Figure 3.8. Signalling responses of MDA-MB-231 cells after treatment with serum, EGF 
or pervanadate. 
A) A simplified outline of the Ras signalling network. Ras proteins utilise various downstream 
effectors to illicit many signalling responses. Upon activation by RTKs, Ras can activate both 
the MAPK and PI3K pathways promoting cell differentiation and proliferation. B) MDA-MB-231 
cells were serum starved for 16hrs before treatment with 20% serum for 5 mins, 20ng/mL EGF 
for 5 mins or 100μM pervanadate for 15 minutes. Cells were subsequently lysed with RIPA 
buffer. Lysates were separated by SDS-page and western blots were probed with the indicated 
antibody.    
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Although I had not been able to profile activity in SW48 cells using MIB/MS, I 
decided to try to reproduce previous results in MDA-MB-231 cells. As before, 
the activation status of tyrosine kinases was confirmed by immunoblotting with 
a phospho-tyrosine (pY20) antibody (Figure 3.8B) and then, similar to previous 
experiments, I investigated to what extent kinase activity translated into MIB 
binding. Unfortunately, activation-dependent binding was not observed in 
MDA-MB-231 cells. There were no significant differences in kinase intensity 
after activation suggesting no differential binding in these cells (Figure 3.9). 
Furthermore, there was no significant increase of EGFR binding to MIBs after 
stimulation with EGF, nor retention of Tyrosine kinases to MIBs after treatment 
with pervanadate. 
3.2.5. Pharmacological Kinase Inactivation does change affinity to MIBs 
In the same study, the Johnson lab go on to demonstrate how the MIB/MS 
assay can be used as a tool to detect kinome reprogramming in response to 
targeted MEK inhibition (Duncan et al., 2012a).  
 
Firstly, using western blotting Johnson et al. showed a loss of ERK1/2 
phosphorylation in TNBC cells treated with the MEK inhibitor, selumetinib for 
4 hours. Reactivation of ERK1/2 was observed after treatment with the MEK 
inhibitor for 24 hours indicating that both TNBC cell lines circumvented MEK 
inhibition. MIB/MS was subsequently used to measure global kinome 
responses that occur after MEK inhibition. The assay reported an increase in 
binding of a group of receptor tyrosine kinases (RTKs) and it was hypothesised 
that this reprogramming could be responsible for resistance to MEK inhibition.  
 
In SUM159 cells, the MIB/MS assay reported a clear increase in several RTKs 
such as: AXL, DDR1 and PDGFRb. However, there was a ‘less robust kinome 
response’ seen in the MDA-MB-231 cells, although a strong increase in 
PDGFRb binding was observed (Duncan et al., 2012b). Unfortunately, we 
didn’t detect PDGFRb when we conducted the same MIB/MS experiment in 
our lab. This may have been due to sensitivity issues caused by using a 
different MS/MS instrument. 
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Figure 3.9. Binding proteins in MDA-MB-231 cell extracts 
A) Data derived from MaxQuant illustrating there is no evidence of activation dependent 
following treatment of serum starved MDA-MB-231 cells with serum, EGF or pervanadate. 
Heatmaps illustrating the kinase activation profile of MDA-MB-231 cells using CTx alone. The 
average intensities taken from 3 biological replicates were used to curate each heatmap. Pie 
charts show the ratio of kinases (grey) vs. non kinases (white) enriched under each 
experimental condition.  B) Graphs showing the intensities of kinases in serum starved (ss) 
vs. stimulated (st.) cells. Kinases were selected based on expected activation changes in 
response to EGF stimulation and pervanadate treatment. Each data point represents the 
intensity from a single biological replicate.   
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Figure 3.10. Overview of the workflow used to establish what kinome re-programming 
occurs in response to targeted inhibition of the Ras pathway. 
The experimental strategy used to measure kinase activity of MDA-MB-231 cells following 
treatment with 5μM DMSO/Selumetinib (MEK inhibitor). SILAC labelling of MDA-MB-231 cells 
allows multiple samples to be ran in a single run. Total protein lysates were run over a block 
column, containing un-conjugated Sepharose beads, to promote non-specific binding of any 
highly abundant non-kinase proteins. The flow through passes onto an affinity column 
containing a mixture of MIBs. Kinases eluted from the column were trypsin digested in solution. 
Peptides are separated by Liquid-Chromatography (LC) and identified and quantitated by 
Tandem Mass Spectrometry (MS-MS). Analysis of the MS dataset is conducted using the 
MaxQuant software providing the possibility of predicting how cells circumvent inhibition of the 
Ras pathway.   
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Figure 3.11. Evidence of activation dependent binding following targeted MEK inhibition 
in MDA-MB-231 cells. 
MDA-MB-231 cells were serum starved for 16hrs before treatment with 5μM 
DMSO/Selumetinib for 4hrs or 24hrs. Graphs showing the quantitative changes in MIB binding 
as a log2 ratio of inhibitor treated cells/DMSO treated cells. Average intensities taken from 
three biological replicates were used to calculate a ratio for each kinase. 
Figure 3.11 shows data derived from in-house MIB/MS experiments assessing 
kinome responses after MDA-MB-231 cells were treated with Selumetinib for 
4h or 24h. Similar responses to the original study are observed for MEK1/2 at 
both time points. Furthermore, reactivation of ERK2 is seen after prolonged 
MEK inhibition. There is also a decrease of EPHA2 binding in our assay which 
was another significant response recorded in the original study.  
 
It important to note that Duncan et al. reported a significant increase in 
expression of the RTK, AXL, in SUM159 cells, however they were unable to 
detect AXL in MDA-MB-231 cells using MIB/MS (Duncan et al., 2012a). In our 
experiments, we were able to identify and detect an increase in AXL 
expression in MDA-MB-231 cells after 24h treatment. AXL was one of the 32 
kinases unique to our dataset and it is probable that we were able to detect 
























































































In conclusion, we were able to reproduce some of Johnson et al. findings in 
the lab but due to a lack of responsiveness of the MDA-MB-231 cells, it would 
have been useful to conduct the experiments using SUM159 cells to provide a 
clearer insight into reprogramming in response to MEK inhibition.  
3.3. Summary of results 
• The MIB/MS assay has been successfully established and optimised in 
our lab to enrich kinases from cell lysates. 
• Enrichment is a measure of protein abundance and/or activity  
• It is unclear as to whether responses are indicative of changes in protein 
abundance or activity therefore further validation is required to 
discriminate between each possibility. 
3.4. Discussion 
The aim of this chapter was to establish the MIB/MS assay in the lab and to 
determine whether the assay reports changes in kinase activity. The method 
was successfully established in the lab and several stages of optimisation were 
carried out to achieve optimal kinase enrichment.  
 
Whilst I was able to clearly enrich kinases from cell lysates (Figure 3.3), I 
struggled to obtain any evidence that MIB-binding was sensitive to the 
activation status of individual kinases. This included when I directly reproduced 
key elements of the experiments performed by the Johnson lab using the same 
cell line (Figure 3.9) and the same MIB bead composition (Figures 3.6 & 3.7). 
Although several early studies claimed that MIB beads capture kinases in their 
active conformation and therefore the assay has the ability to measure global 
kinome activation changes in response to stimuli or inhibitors (Johnson et al., 
2013; Stuhlmiller, Earp and Johnson, 2014; Cooper et al., 2013), this notion 
was challenged by the Kuster lab, who suggested that MIB binding was largely 
independent of kinase activation state (Ruprecht et al., 2015). Notably, the 
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Kuster lab found no evidence of increased binding of kinases known to be 
activated by pervanadate treatment and responsive kinases lay across all the 
kinase families (Ruprecht et al 2015. These findings are consistent with the 
data presented in this chapter.   
 
A feature of all of these early studies is that they perform a large-scale MIB 
screen followed by very selective follow-up of individual kinases. They then 
generalise the observations made with these select few kinases to make their 
wider point in support or opposition to the notion that MIBs report kinase 
activation status across the entire kinome. Given the timing of these 
publications close to the beginning of my project, we approached the 
interpretation of MIB data with caution and were not necessarily surprised by 
the negative data that was generated. 
 
Interestingly, in a more recent review discussing methods to study the kinome, 
Gary Johnson and co-authors address and support the contradictory findings 
presented in the Kuster publication and proceed to discuss the limitations of 
the assay (Cann et al., 2017). It seems that the capability of the MIB/MS assay 
to profile kinome activity was previously overstated. It is now generally 
accepted that activation-dependent binding to MIBs depends on three main 
factors: 
• the level of expression of a kinase in the cell  
• kinase affinity to MIBs 
• kinase conformation or activation status 
 
Authors agree that the assay mainly reports changes in kinase abundance and 
in limited cases changes in kinase activity (Cann et al., 2017; Ruprecht et al., 
2015). Evaluating the findings from this chapter also led me to the same 
conclusion; I found that a kinase was more likely to be detected by LC/MS/MS 
if it was more abundant in the cell lysate and that activation dependent binding 
was rare. It is also important to note that whether or not a true activation 
change can be detected depends on the proportion of active vs. inactive kinase 
in the cell lysate. In summary, the method is useful for looking at differential 
expression at the protein level; whilst evidence has been presented suggesting 
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that a fraction of the kinases captured on the column show activation 
dependent binding, this needs to be assessed on a case-by-case basis.  
 
The data presented in the Kuster publication, helps us to appreciate that, 
whether or not kinase activation status is reported depends on the bead type 
and conformation status of the kinase. The efficiency of nine different inhibitor 
beads to bind kinases known to be activated by pervanadate treatment were 
evaluated; These included some of the MIBs used in the original study 
(Ruprecht et al., 2015; Duncan et al., 2012a). Consistent with my findings, 
there was a large degree of overlap in kinase specificity between different bead 
types. However, surprisingly each kinase was differentially bound to each bead 
after pervanadate treatment. For example, pervanadate treatment caused an 
increase in binding of EGFR to one bead and loss of binding to another 
(Ruprecht et al., 2015). This indicates that MIBs can bind kinases in their active 
and inactive states and that there is bead conformation specificity. Gary 
Johnson presented data in a recent review supporting this premise (Cann et 
al., 2017). The data showed that the capture of EGFR after EGF stimulation is 
dependent on bead type. As expected, an increase in EGFR capture to some 
MIBs such as PP58 and Purvalanol was observed; however, there was no 
increase in EGFR binding to the MIB CTx. This suggests that CTx 
preferentially binds EGFR in the inactive conformation; again, this is consistent 
with my findings. In the same study, it was shown that when CTx was added 
into a mixture of beads, it was enough to mask any increase in EGFR binding 
that would have been reported by the other beads alone (Cann et al., 2017). 
Bead conformation specificity means that using a combination of beads in a 
single assay could obscure any potential activation dependent binding. The 
readout from a MIB correctly reporting a change in kinase activation state could 
be supressed by a MIB that preferentially binds kinases in their inactive state. 
I also found that there was no benefit in using several beads in combination 
and I decided to use the single MIB, CTx, going forward as it provided the best 
coverage of the kinome. 
 
Whilst I was writing this chapter, it seems that the viewpoint on how the 
MIB/MS assay can be used to study the kinome has shifted. Many people, 
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including Gary Johnson have revoked claims that MIB/MS can report ‘en 
masse’ kinome activation changes (Cann et al., 2017). A recent paper was 
published by the Duncan group, reporting kinome reprogramming in response 
to MEK inhibition in ovarian cancer (Kurimchak et al., 2019). Although the 
study is very similar to the original TNBC study, there is no mention of 
activation-dependent binding throughout the paper (Kurimchak et al., 2019; 
Duncan et al., 2012a). Instead, the group integrated RNAseq and MIB/MS 
datasets to build a ‘kinome signature’ and any interesting hits were 
investigated further. Kuster also contributed to a recent paper that used a MIB 
pulldown to study the kinome in NSCLC cells (Mulder et al., 2018). The paper 
combined proteome, kinome and phosphoproteome data to profile resistance 
to EGFR therapy.  
 
Considering what we know now, I propose to use the MIB/MS assay in 
combination with other approaches to profile the kinome in RAS mutant cells. 
The MIB assay reports expression and/or activity of kinases; therefore, to 
discriminate between these possibilities we will pair it with a kinome gene 
expression screen. By integrating the two datasets I may be able to infer likely 
activation changes. However, it is important to note that a negative correlation 
between the two datasets could be due to other post translational modifications 
therefore it will be imperative to validate any responses by western blot where 










Chapter 4 : Profiling the kinome in Ras 
mutant cells 
Most understanding of RAS isoform biology has derived from ectopic 
expression experiments. The studies describe preferential coupling of each 
isoform with key Ras effector pathways. KRAS was shown to be a more potent 
activator of the MAPK pathway whereas HRAS and NRAS were shown to more 
potently activate the PI3K pathway (Yan et al., 1998; Voice et al., 1999). This 
is in contrast to findings from studies using cell lines or mouse models with 
endogenously expressed mutant RAS; Very little evidence of preferential 
coupling to Ras effectors was presented suggesting that RAS signalling is 
more context dependent (Tuveson et al., 2004; Omerovic et al., 2008). It is 
now appreciated that ectopically expressed RAS proteins are often produced 
at supraphysiological levels and this can lead to mislocalisation or premature 
senescence (Serrano et al., 1997). Thus, there is a general consensus that 
studying endogenous signalling in cells where endogenous levels of RAS are 
expressed is more desirable.  
 
An isogenic panel of SW48 colorectal cancer cell lines have been developed 
to study endogenous RAS signalling. rAAV mediated homologous 
recombination was used to introduce different activating RAS mutations at the 
endogenous loci, in SW48 cells that otherwise have the same genetic 
background. Phosphoproteomic analysis of a panel of SW48 cell lines 
harbouring different activating mutations, at codons 12 or 13 of the KRAS 
gene, revealed that each mutant displays a unique signalling signature. 
Furthermore, codon 12 specific upregulation of kinases such as DCLK1 and 
MET was observed (Hammond et al., 2015). Moreover, a recent study using a 
panel of SW48 G12V wild-type and mutant cells revealed that despite 
displaying significant Ras activation, the outputs directly downstream of 
oncogenic Ras mutants were minimal in the absence of growth factor inputs 
(Hood et al., 2019). 
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Taking this into consideration and coupled with the fact that the RAS network 
is enriched in kinase effectors, I propose to conduct a kinome-wide analysis of 
RAS signalling using a panel of isogenic SW48 cell lines. We used a novel 
isogenic panel that includes SW48 cell lines harbouring different activating 
RAS mutations of the KRAS, HRAS and NRAS genes. By studying differential 
kinome responses of the individual mutants, we hope to gain a better 
understanding of the mechanisms underpinning both isoform and mutation 
specific RAS signalling.  
 
535 kinases are encoded by the human genome (Wilson et al., 2018). The 
NanoString nCounter platform allows gene expression analysis of 528 kinases 
therefore providing coverage of over 98% of the human kinome (Figure 2.1). 
Using the nCounter technology, I will be able to define the SW48 expressed 
kinome. Furthermore, analysis will reveal distinct kinome gene expression 
signatures of each mutant cell line. Subsequently, I will use MIB/MS to profile 
kinome responses at the protein level (Figure 2.5). The combination of 
methodologies allows large scale profiling of kinome expression and in some 
cases kinome activity; by integrating the two datasets, we may be able to infer 
likely protein expression versus activation changes within the kinomes of Ras 
mutant SW48 cells. The data generated from these global kinase assays will 
identify nodes sensitive to isoform and mutation specific Ras signalling.  
4.1. Objective  
The objective of this chapter is to understand the differential signalling 
occurring downstream of common RAS mutations. To achieve this, I aim to 
profile the kinome at both the transcript level and protein level in the isogenic 
SW48 panel. Finally, I will integrate the two datasets to reveal unique kinome 




4.2.1. NanoString analysis defines the expressed SW48 kinome and 
identifies differential kinome transcript signatures in SW48 isogenic cells 
Using the NanoString nCounter platform, we were able to define the expressed 
SW48 cell kinome. The analysis indicates that SW48 cells typically express 
362 kinases, representing 68% of the human kinome. Figure 4.1A displays the 
total expressed kinome and the proportion of kinases that are ‘responsive’ in 
SW48 mutant cells; Responsive can be defined as a 2-fold increase or 
decrease in gene expression in at least one mutant cell line compared to the 
Parental cell line. Of the 362 kinases expressed in the SW48 isogenic panel, 
40 were responsive. This indicates that approximately 11% of the expressed 
kinome is differentially expressed upon the introduction of an activating RAS 
mutation into the parental SW48 cell line.  
 
To examine the responsive subset in more detail, I considered the coverage 
of responsive kinases across the individual kinase families and the individual 
mutant cell lines (Figures 4.1B). The responsive subset is distributed across 
the majority of the kinome, although there is a notable enrichment of 
responsive kinases in the Tyrosine kinase (TK) family (Figure 4.1B). Figures 
4.2C and D, illustrate the distribution of responsive kinases across the 
individual mutant cell lines. There are kinases unique to each cell line 
harbouring a G12V mutation, thus providing evidence of isoform specific 
kinome responses. However, the N12V cell line has notably less responsive 
kinases than the other isoforms, suggesting that kinase signalling in the NRAS 
mutant is relatively unchanged in comparison to the parental cell line. 
Furthermore, there is evidence of mutation specific signalling; Responses 
unique to each KRAS mutant cell line harbouring a different codon mutation 
were observed. It is important to note, that there is a marked increase in unique 
responses in the K12D cell line compared to the other KRAS mutant cell lines 
and it is, in fact, the most responsive cell line across the panel. In addition to 
isoform and mutation specific responses, responses shared amongst the 




Figure 4.1. The kinase transcriptome of isogenic SW48 cells harbouring different RAS 
codon mutations 
A) NanoString analysis reveals 362 kinases are expressed in SW48 cell lines. A subset of 40 
kinases show differential expression in RAS mutant cells compared to Parental SW48 cells, 
based on a 2-fold change in expression. B) The bar chart displays the coverage of responsive 
and non-responsive kinases across the individual kinome families. C and D) Venn diagrams 
illustrate the overlap of responsive kinases between the different mutant RAS cell lines.   
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distinguish whether there was the same directional change in expression of 
these kinases across all mutant cell lines. 
 
Hierarchical clustering of the responsive subset was performed to analyse the 
pattern of expression across each cell line (Figure 4.2A). Cell lines and genes 
were clustered based on the ratio (log2) of kinase expression in the mutant cell 
line vs. parental cell line. Interestingly, the KRAS mutant cell lines cluster 
together, away from the HRAS and NRAS cell lines. This indicates that the 
shared responses observed between the KRAS mutant cell lines follow a 
similar pattern of expression. Furthermore, within the KRAS mutant cell lines, 
the codon 12 mutants cluster together, away from the codon 13 mutant. The 
HRAS and NRAS mutant cell lines cluster together but don’t appear to share 
the same degree of similarity that is observed in KRAS mutant cell lines. 
 
On the whole, there are very few pan-RAS responses; Very few kinases have 
the same pattern of expression across all mutant cell lines. The most striking 
pan-responsive kinase is TRIB3, a pseudokinase which is significantly 
downregulated in all five mutant cell lines. In line with the background rate of 
expression in the human kinome (Wilson et al., 2018), pseudokinases 
represent 10% of the expressed SW48 kinome. Five out of the 40 responsive 
kinases were pseudokinases. This suggests that despite lacking enzyme 
activity, this group of kinases may have a role in the regulation of oncogenic 
Ras signalling. Considering the lack of pan-RAS responses, I speculated 
whether or not the responsive kinases lay within the immediate RAS network. 
Taking into account the dogma derived from ectopic studies, I would have 
expected some common responses directly downstream of the oncogenic 
RAS mutants (Yan et al., 1998; Voice et al., 1999). For example, upregulation 
of nodes in the MAPK and PI3K pathways in the KRAS mutants and HRAS 
mutant respectively. However, only 1/10th of the responsive kinase subset lay 
within the direct RAS network (Figure 4.2B). Moreover, none of the responsive 
RAS related kinases show a pan-RAS response and are only defined as 
responsive in one or two mutant cell lines.  
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 Figure 4.2. The responsive kinase transcriptome 
A) Heatmap displaying responsive kinases; Responsive can be defined by a 2-fold change in 
gene expression in at least one mutant cell line vs. parental SW48 cell line. Responsive 
kinases are clustered by cell line and relative transcript changes. B) A simplified outline 
showing the responses within the immediate Ras network. Responsive kinases are highlighted 
in orange, unresponsive kinases are highlighted in blue and any kinases that are not 
expressed are left unshaded. C) The scatter plots show the raw counts of two kinases, DCLK1 
and MET, used as positive controls. The graphs display counts for each kinase taken from 
four biological replicates.  
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As previously reported, a codon 12 specific upregulation of MET was observed 
in the KRAS mutant cell lines (Figure 4.2C) (Hammond et al., 2015). Similarly, 
the kinase DCLK1 was significantly upregulated in the KRAS codon 12 mutant 
cell lines, again consistent with previous findings. MET and DCLK1 served as 
positive controls in our NanoString experiments and provided confidence in 
the other observed kinome responses.  
 
Deeper differential expression analysis was conducted using the NanoString 
advanced analysis software, providing an insight into which responses were 
statistically significant. The software used statistical t testing to calculate a p-
value for each kinase and the Benjamini-Hochberg method was applied to 
reduce the False Discovery Rate (FDR) (see section 2.3.7). The volcano plots 
in figure 4.3 the results of the differential expression analysis. The fold change 
(log2 ratio mutant/parental) and p value is displayed for each kinase. Highly 
statistically significant kinases fall above the p-value threshold (p<0.05) and 
differentially expressed kinases fall either side of the plot. The most statistically 
significant kinases are labelled for each mutant cell line. Any kinases that fell 
below the threshold, highlighted in grey, were removed from the responsive 
subset going forward. For example, initial analysis indicated that there were 
two differentially expressed kinases in the N12V line, however, this was 








Figure 4.3. Differential gene expression analysis of isogenic SW48 cells harbouring 
different RAS codon mutations 
The volcano plots display each kinase's log10 (p-value) and log2 fold change for mutant vs. 
parental SW48 cells. The most statistically significant kinase genes are labelled and 




4.2.2. MIB/MS analysis reveals a subset of kinases that show differential 
protein expression in SW48 isogenic cells 
Since transcript abundances only partially predict protein abundance 
(Schwanhäusser et al., 2011), it was also essential to understand whether 
differential kinome protein expression also occurs (de Sousa Abreu et al., 
2009). 
 
Using MIB/MS we were able to define and quantitate the expression of 
approximately 50% of the expressed SW48 kinome (Figure 4.4A). Of the 177 
kinases pulled down by MIBs, 56 were defined as responsive; Responsive can 
be defined as a 2-fold increase or decrease in protein expression in at least 
one mutant cell line compared to the Parental cell line.  
 
Similar observations can be made between the NanoString responsive dataset 
and the MIB responsive dataset: The MIB/MS responsive subset is distributed 
across every kinase family and again a notable enrichment of responsive 
kinases within the Tyrosine kinase family was observed (Figure 4.4B). 
Furthermore, there is evidence of isoform and mutation specific responses at 
the protein level. No shared responses were observed between the G12V 
mutant cell lines thus, providing evidence of isoform specific signalling (Figure 
4.4C). Mutation specific responses were also observed amongst the KRAS 
mutant cell lines. Coinciding with the transcriptome data, the K12D mutant cell 
line was the most responsive mutant cell line; The K12D mutant had the 
greatest number of unique responses within the KRAS mutant cell lines 
together with the greatest number of overall responses seen across the panel 
of mutant cell lines. It is also important to note, that despite displaying no 
differential expression of kinases at the transcript level, the N12V mutant cell 
line harboured several responsive kinases at the protein level (Figure 4.4C).  
 
Hierarchical clustering of the responsive subset was performed to analyse the 
pattern of expression across each cell line (Figure 4.5A). Cell lines and genes 
were clustered based on the ratio (log2) of kinase expression in the mutant cell 
line vs. parental cell line. Contrary to the NanoString responsive subset, the  
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Figure 4.4. The protein kinome of isogenic SW48 cells harbouring different RAS 
codon mutations 
A) MIB/MS enriched 177 kinases from SW48 cells. A subset of 56 kinases show differential 
expression in RAS mutant cells compared to Parental SW48 cells, based on a 2-fold change 
in expression. The bar chart displays the coverage of responsive and non-responsive 
kinases across the individual kinome families. B) Venn diagrams illustrate the overlap of 




Figure 4.5. The responsive protein kinome 
A) Heatmap displaying responsive kinases; Responsive can be defined by a 2-fold change 
in protein expression in at least one mutant cell line vs. parental SW48 cell line. Responsive 
kinases are clustered by cell line and relative changes in protein expression. B) A simplified 
outline showing the responses within the immediate Ras network. Responsive kinases are 
highlighted in orange, unresponsive kinases are highlighted in blue and any kinases that 
were not detected by MIB/MS are left unshaded. C) The scatter plots show the ratios log2 
fold change (mutant/parental) of two kinases, DCLK1 and MET, used as positive controls. 
The graphs display ratios for each kinase taken from three biological replicates. 
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MIB/MS responsive subset cluster based on type of amino acid mutation rather 
than clustering in an isoform specific manner. All three isoforms harbouring a 
G12V mutation cluster together away from the two KRAS mutants harbouring 
an aspartic acid (D) mutation. Once more, there are very few pan-RAS 
responses across the mutant cell lines and very few responsive kinases that 
lie within the immediate RAS network (Figure 4.5B). As with the transcriptome 
responsive subset, only 1/10th of the responsive MIB/MS kinase subset lay 
within the immediate RAS network. Although there is a similar proportion of 
responsive kinases within the network in both datasets, only one kinase that 
was defined as responsive at the transcript level was detected by MIB/MS, so 
we are unable to correlate the pattern of responses across the two datasets.  
 
MET was the only kinase within the RAS network that showed the same 
pattern of response at the transcript level and the protein level. The same 
codon 12 specific upregulation was observed in the KRAS mutant cell lines 
using MIB/MS (Figure 4.5C). In SW48 cells, MET expression is significantly 
upregulated in the K12D mutant vs. parental cells when they are serum 
starved, and downstream activity is induced by HGF stimulation (Figure 4.6). 
This suggests that MET upregulation is due to MET receptor overexpression 
rather than elevated levels of its ligand, HGF. Upregulation of DCLK1 was also 
observed in the K12D mutant cell line, although the kinase was only detected 
in one out of three biological replicates (Figure 4.5C). 
4.2.3. Integrating transcript and protein kinase datasets reveals 
differential expression vs. activity profiles in Ras mutant cells  
Using MIB/MS, we were able to profile 49% of the expressed SW48 kinome 
(Figure 4.7A). A larger proportion of the expressed kinome was defined as 
responsive at the protein level compared to the transcript level (Figure 4.7B). 
Moreover, there were very few common kinase responses across the two 
datasets (Figure 4.7B). The lack of commonalities between the two datasets 
is unsurprising considering it was previously shown that transcript abundance 
only partially predicts protein abundance; It is estimated that only ~40% of 
protein concentrations correlate with mRNA concentrations and that the  
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Figure 4.6. MET signalling in SW48 wild-type and KRAS G12D mutant 
SW48 parental and K12D mutant cells were serum starved for 16hrs before treatment with 
HGF for 0, 5, 10, 20 mins. Cells were lysed with RIPA buffer. Lysates were separated by SDS-





Figure 4.7. Correlation analysis between the NanoString and MIB/MS SW48 kinome 
datasets 
A) The Venn diagram shows the number of expressed kinases defined by NanoString analysis 
vs. the number of kinases captured and identified by MIB/MS. B) The Venn diagram shows 
the overlap between kinases that were defined as responsive at the transcript level and at the 
protein level. C) A correlation analysis was carried between the responsive NanoString and 
MIB/MS datasets. Kinases were included if they were detected by MIB/MS and were defined 
as responsive. The heatmap displays all data included in the analysis. The heatmap is ranked 
based on correlation coefficient and the scale bar indicates the degree of correlation between 
the two datasets. Graphs show examples of kinases with high correlation coefficients; 
transcript (blue) and protein (pink) level responses are mapped across each cell line. Western 
blots were used for validation of the observed responses.  
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remaining 60% can be attributed to post transcriptional regulation (de Sousa 
Abreu et al., 2009). It is now appreciated that protein abundance depends not 
only on mRNA concentration, but almost equally on regulatory mechanisms 
occurring after mRNA production. These include post translational 
modifications, translation efficiency and protein degradation of the existing 
protein (Vogel and Marcotte, 2012).  
 
Going forward, I decided to consider what was significantly changing between 
the datasets, but more importantly, consider the pattern of mRNA expression 
vs. protein expression in order to build more a comprehensive kinase 
signature.  
 
A correlation analysis was conducted between the NanoString and MIB/MS 
datasets to gain a clearer understanding of the differentially expressed kinome 
and how it may potentially be regulated (Figure 4.7C). Using the CORREL 
function in Microsoft excel, a correlation coefficient value was generated that 
indicates how closely related expression of a kinase was at the transcript vs. 
protein level. Kinases were included in the correlation analysis if they were 
detected by MIB/MS and were defined as responsive. There also needed to 
be a sufficient number of related pairs across the two datasets to generate a 
correlation coefficient. The heatmap in figure 4.7C displays the MIB/MS 
responsive data that met these criteria and was therefore included in the 
analysis. Kinases are ranked by correlation coefficient and the scale bar 
indicates the degree of correlation between the two datasets. A correlation 
coefficient of +1 indicates perfect correlation between the expression of a 
kinase at the transcript level and -1 indicates inverse expression. 
 
Two examples of kinases with a high correlation coefficient were RSK2 and 
MET (R2=0.99 and 0.93 respectively). The graphs in Figure 4.7C display the 
(log2) ratios of mutant vs. wild-type expression, at the transcript level (NS) and 
at the protein level (MIB). For both kinases, there is a high degree of correlation 
between the ratios generated from the NanoString and MIB/MS assays across 
all cell lines. Here, it is likely that transcript abundance is the main determinant 
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for protein abundance, and therefore provides an example of how the MIB 
column can report differential kinase expression across the mutant cell lines.  
 
In each case, western blotting was used to confirm protein responses. It is 
important to note that changes in protein abundance can also correspond with 
changes in the amount of phosphorylated protein; If there is a larger pool of 
protein, a higher proportion may be available for phosphorylation. For 
example, elevated expression of RSK2 was observed in the K13D cell line at 
both the transcript level and at the protein level. Western blotting confirmed an 
increase in total RSK2 expression in the K13D cell line however the same 
elevation of p-RSK2 expression was also observed. The phospho-specific 
antibody detects RSK2 when it is phosphorylated at Serine 227, a site 
indicative of RSK2 activation. Thus, in this instance the MIB/MS assay is 
concomitantly reporting differential kinase expression and activity.  
 
Western blotting also confirmed the codon 12 specific upregulation of MET in 
the KRAS mutant cell lines reported by NanoString and MIB/MS. Once more, 
western blotting revealed that changes in MET abundance also correlated with 
changes in the likely total active pool as inferred by the increased abundance 
of phosphor-MET.  
 
Two examples of kinases with a low correlation coefficient were EPHA2 and 
MEK3 (MAP2K3) (both R2<0.29). The graphs in Figure 4.8 display the ratios 
of mutant vs. wild-type expression at the transcript level (NS) and at the protein 
level (MIB). For EPHA2, there is little correlation between the transcript and 
protein concentrations recorded by NanoString or MIB/MS. A decrease in 
mRNA abundance was observed in the K12D mutant cell line versus the 
parental, whereas protein abundance increased. On the other hand, a 
decrease in mRNA abundance was also observed in the N12V mutant cell line 
versus the parental, but in this case protein abundance decreased almost 8-
fold. This suggests that there is some post transcriptional regulation at play. 
Further work would be needed to elucidate such regulatory mechanisms. 
Protein responses were confirmed by western blot. Again, total EPHA2 and 
phospho-EPHA2 followed the same pattern of expression. Here, it is likely that  
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Figure 4.8. Correlation analysis between the NanoString and MIB/MS SW48 kinome 
datasets (2) 
A correlation analysis was carried between the responsive NanoString and MIB/MS datasets. 
Kinases were included if they were detected by MIB/MS and were defined as responsive. The 
heatmap displays all data included in the analysis. The heatmap is ranked based on correlation 
coefficient and the scale bar indicates the degree of correlation between the two datasets. 
Graphs show examples of kinases with low correlation coefficients; transcript (blue) and 
protein (pink) level responses are mapped across each cell line. Western blots were used for 






the MIB/MS assay is reporting changes in expression, and as a result changes 
in kinase activity.  
 
For MEK3, there was little, if any, differential MEK3 transcript expression in 
any of the mutant cell lines vs. parental. In contrast, the MIB/MS assay 
reported differential MEK3 protein responses in some of the mutant cell lines 
vs. parental; a significant decrease in MEK3 response was observed in the 
K12V cell line and to a lesser extent in the K13D cell line. A slight increase in 
MEK3 response was also recorded in the H12V mutant cell line.  
 
Interestingly, there was also disparity between MEK3 responses reported by 
MIB/MS and levels of total MEK3 expression analysed by western blotting. 
Western blotting revealed that the levels of total MEK3 expression in all of the 
mutant cell lines remained similar to parental levels. The MEK3 protein 
expression data obtained by western blotting is comparable to the NanoString 
transcript data and therefore it is likely that MEK3 transcript abundance is the 
main determinant of MEK3 protein abundance. Considering the lack of 
correlation between the MIB/MS data and the transcript and protein expression 
data, it seems unlikely that the MIB column is reporting changes in kinase 
expression.  
 
In fact, further western blotting analysis revealed that in this instance, MIB/MS 
is reporting changes in MEK3 phosphorylation. Blots were probed with a MEK3 
phospho-antibody that detects phosphorylated MEK3/6 at serine residues 189 
and 207, sites indicative of MEK3 activation. pMEK3/6 expression corresponds 
closely to the MEK3 responses reported by MIB/MS analysis indicating that in 
this case, MIB/MS is reporting changes in MEK3 activation status.  
 
It is important to note that there was an inconsistency between the western 
blot and MIB/MS data for MEK3 activity in the K12D cell. One possible reason 
is that the MIB/MS assay only detected MEK3 in the K12D mutant in 1 out of 
the 3 biological replicates and therefore the ratio generated for the K12D 
mutant may not have been truly representative of MEK3 kinase activity. Taking 
this into consideration, it appears that there is a clear KRAS mutant specific 
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downregulation of MEK3 activity. Furthermore, evidence of upregulation of 
MEK3 activity in the HRAS mutant cell line is observed in MIB/MS and western 
blotting datasets.  
4.3. Summary of results 
• The expressed SW48 kinome has been defined using NanoString 
analysis. 
• The NanoString and MIB/MS assays have been applied in order to 
identify RAS isoform and mutation specific kinome responses. 
• I have demonstrated how integrating data from the NanoString and 
MIB/MS analyses can help infer differential kinome expression vs. 
activity in cells. 
• The analyses reveal a subset of Ras responsive kinases for further 
analysis.  
4.4. Discussion 
Using a multi-omic approach, we have successfully performed large-scale 
kinome analysis of a panel of isogenic Ras mutant cells. Deep proteome 
analysis of 23 mammalian cell lines indicate that cell lines typically express 
300-400 kinases (Wilson et al., 2018). NanoString analysis revealed that 
SW48 cells express 362 kinases, thus falling within the expected range. Using 
MIB/MS, we achieved good coverage of the kinome. The method allowed the 
isolation and analysis of 50% of the SW48 expressed kinome, which is 
comparable to the coverage achieved in previous MIB/MS publications 
(Duncan et al., 2012a). In the first pioneering MIB/MS study, Duncan et al., 
were able to profile 50%-60% of the kinome in two TNBC cell lines, over 
several MS runs.  
 
Our studies demonstrate that the ability of MIB/MS to enrich for active vs. 
inactive kinases is context dependent and that kinase binding is a function of 
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kinase expression and in some cases kinase activity. By integrating 
transcriptomic and proteomic datasets, we were able to infer likely kinase 
expression and/or activity changes. High correlation between the 
transcriptomic and proteomic datasets indicated that transcript abundance 
likely determined protein abundance and that the MIB/MS column in this 
instance was reporting differential kinase expression across the mutant cell 
lines. Moreover, analysis revealed that low correlation between the two 
datasets could be due to post translational modification and that the MIB/MS 
column, in some cases, was able to report differential kinase activities. 
Western blotting analysis validated kinase responses reported by the MIB/MS 
column and also highlighted that changes in protein abundance can lead to a 
proportional increase in phosphorylation. 
 
The combination of methodologies was applied to obtain an insight into cellular 
kinase adaptations to different oncogenic RAS mutations. Previous work in the 
laboratory, had focused on quantitative analysis of the proteome and 
phosphoproteome of a panel of isogenic SW48 cells harbouring different 
KRAS mutations (Hammond et al., 2015). Our novel SW48 panel included a 
HRAS and NRAS mutant cell line to complement the existing KRAS mutant 
panel. Thus, the data generated from these studies provides the first kinome-
wide analysis revealing nodes sensitive to endogenous RAS isoform and 
mutation specific signalling in an isogenic background.  
 
On the whole there, there was very little evidence of pan-RAS responses. 
Seemingly, Tribbles 3 (TRIB3) was the only kinase to display the same pattern 
of response over the five mutant cell lines vs. the parental wild-type cell line; 
Significant downregulation of TRIB3 mRNA expression was observed in all five 
mutant cell lines. Previously, it has been shown that TRIB3 loss promotes 
tumorigenesis via dysregulation of AKT S473 phosphorylation (Salazar et al., 
2015). TRIB3 interacts with AKT and has a tumour inhibitory role by limiting 
the capacity of AKT to become activated. Loss of the TRIB3-AKT interaction 
enables hyper phosphorylation of AKT via the mTORC complex. This leads to 
the enhanced phosphorylation and inactivation of the transcription factor 
FOXO3, thought to be responsible for the more aggressive phenotype (Salazar 
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et al., 2015). TRIB3 is a pseudokinase and therefore it was not enriched by the 
ATP competitive inhibitor beads used in the MIB/MS assay. Western blot 
analysis would be needed to establish whether TRIB3 protein expression is 
also downregulated in the mutant cell lines vs. parental wild-type cells. 
Furthermore, RAS knockdown studies would corroborate whether the mutation 
in RAS is responsible for the genetic loss of TRIB3.  
 
Phosphoproteomic analysis of the KRAS mutant SW48 panel revealed that 
very few proteins or phosphosites showed significant pan-KRAS mutation 
responses (Hammond et al., 2015). Consistent with these findings, we 
observed very few KRAS isoform specific responses, with the exception of 
MEK3 whose activity was downregulated in all three KRAS mutant cell lines 
vs. the wild-type cell line. MEK3 (MAP2K3) belongs to the RAS related MAP 
kinase family. It has been previously shown that RAS regulates the activity of 
MEK3 and in turn, the downstream p38 pathway (Shin et al., 2005). In the next 
chapter, I aim to elucidate the mechanism behind the potential isoform specific 
regulation of this kinase that may expose a therapeutic vulnerability in KRAS 
mutant cancers.  
 
Although very few pan-KRAS responses were observed, Hammond et al. 
reported differential responses between the codon 12 and codon 13 KRAS 
mutant cell lines. Authors identified a cluster of proteins that were significantly 
upregulated in the codon 12 mutants only (Hammond et al., 2015). Our 
transcriptome data also indicates that there is a divergence between codon 12 
and codon 13 mutations. Clustering analysis revealed that at the transcript 
level, the KRAS codon 12 mutants share a similar pattern of responses across 
all expressed kinases that are distinct from the codon 13 mutant responses.  
On the contrary, at the protein level, KRAS mutant cell lines cluster based on 
the type of mutation rather than codon positioning. All three isoforms 
harbouring a G12V mutation cluster together away from the two KRAS mutants 
harbouring an aspartic acid (D) substitution. On the whole, it seems that both 
the type of amino acid substitution and the codon positioning of the mutation 
may influence the output of oncogenic RAS, however it is hard to distinguish 
which has the greatest effect.  
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Another layer of complexity is added by the fact that a number of responses 
were unique to each mutant cell line. Furthermore, the number of differential 
responses observed for each mutant cell line varied significantly. Across both 
datasets, there seems to be a significant bias for one particular variant; The 
KRAS G12D mutant cell line harboured the most differential kinase responses 
compared to the wild type cell line. Considering the fact that in colorectal 
cancer, the most prevalent mutation is KRAS G12D, I speculate whether the 
degree of responsiveness downstream of the RAS mutation mirrors the 
mutational frequencies observed in colorectal cancer?  
 
A recent study concludes that oncogenic potency is the major determinant for 
tissue specific RAS mutational profiles (Poulin et al., 2019). Authors show that 
context-dependent variations in signalling downstream of different RAS 
mutants may drive the RAS mutational pattern seen in cancer. Analysis 
reveals that different mutant forms of KRAS have different biochemical 
mechanisms of activation that can lead to profound differences in downstream 
signalling and that signalling is distinct to each tissue. One aspect of the study 
compared the proteomes of colons, pancreas, and spleens from mice 
expressing KRAS WT, KRAS G12D, or KRAS A146. Interestingly, they found 
that KRAS A146 which less potently drives tumorigenesis in the colon, has a 
more similar proteomic signature to WT than KRAS G12D (Poulin et al., 2019). 
This may explain why we see more differential kinome responses in our K12D 
cell line vs. wild type cells and less in the N12V cell line for example and 
emphasises that RAS mutations should not be treated equally (Hobbs and Der, 
2019). 
 
Although many mutation specific responses were observed, I would have 
expected some common responses directly downstream of RAS. As 
previously stated, we had confidence that the NanoString assay was able to 
map the transcript kinome adaptations of the entire expressed SW48 kinome. 
Whilst the MIB/MS assay only enriched 50% of the expressed kinome, there 
was good coverage of the majority of kinase families, including many of the 
Tyrosine Kinases that lie upstream and downstream of RAS. Taking into 
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account the dogma derived from ectopic studies, it seems surprising that there 
were very few responses within the immediate RAS network. Furthermore, we 
did not observe preferential coupling of each RAS isoform to a particular 
pathway, as previously described (Yan et al., 1998; Voice et al., 1999). In 
concordance with our data, many studies investigating endogenous RAS 
signalling did not observe high levels of MAPK and PI3K pathway activity, 
suggesting that oncogenic RAS may cause a subtler, network response 
(Tuveson et al., 2004; Omerovic et al., 2008) (Hood et al., 2019). For many 
years, research has focused on the kinase nodes within the MAPK and PI3K 
pathways. The 12 principle MAPK/PI3K nodes account for 20% of all kinome 
publications, whilst over 300 kinases account for only 5% of research 
publications (Wilson et al., 2018). As a result, much of the kinome is 
understudied and therefore untargeted. Our global, unbiased approaches to 
study the kinome have enabled us to study RAS isoform specific signalling in 
the wider context. Our results suggest there needs to be greater attention and 
appreciation of the effects of RAS isoform and mutation specific signalling in 
the wider signalling network and highlights the unmet need within the kinome.  
 
The panel of isogenic SW48 cell lines have been well characterised previously 
within the lab (Hood et al., 2019). The abundance of mutant RAS has been 
quantified in each cell line and it has been shown that the lack of downstream 
effector activation is not due to a lack of active RAS (Mageean et al., 2015; 
Hood et al., 2019). Another potential explanation for low effector stimulation is 
that SW48 cells harbour an EGFRG719S mutation. This promotes ligand 
independent activation of MAPK signalling which could result in pre-existing 
negative feedback mechanisms. However, it was shown that the engagement 
of negative feedback mechanisms only occurs when the cells are stimulated 
with EGF. Moreover, the observation of low effector activation was also 
extended to a broader panel of colorectal cancer cell lines harbouring mutated 
RAS suggesting that this observation is not specific to SW48 cells(Hood et al., 
2019).  
 
Another possible criticism of the SW48 cell line is that they are not dependent 
on RAS to be viable and therefore are not a true representation of RAS driven 
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oncogenesis. I aim to address this in the next chapter by conducting RAS 
knockdown studies. I will evaluate the RAS dependency of the differentially 
expressed kinases highlighted in this chapter. This will provide a further layer 





























Chapter 5 : Evaluating the RAS 
dependency of RAS responsive kinases 
In Chapter four, we performed the first kinome-wide analysis of endogenous 
isoform and mutation specific RAS signalling. Using an isogenic panel of 
SW48 cell lines, we were able to study the effects of different oncogenic 
mutations in RAS without the confounding effects of variations in the genetic 
background. Using NanoString and MIB/MS, we conducted a comparative 
analysis of five RAS mutant cell lines versus the RAS wild-type cell line. The 
combination of transcriptomic and proteomic approaches generated a list of 
differentially expressed genes and proteins for each mutant cell line. Although 
the SW48 cell panel is isogenic, it is important to confirm there is a direct 
connectivity between differentially expressed kinases and oncogenic RAS, and 
that regulation of kinase expression and/or activity does not result from an 
irreversible adaption or selection pressure.  
 
In this chapter, I will conduct knockdown experiments to evaluate the RAS 
dependency of the responsive kinase list. The KRAS G12D mutant (K12D) 
differentially regulated more kinases at both, the transcript and protein level, 
compared to the other mutant cell lines and therefore was classed as our most 
‘responsive’ RAS mutant cell line. For this reason, I have decided to initially 
focus on evaluating the RAS dependency of kinases that were differentially 
regulated by the K12D SW48 cell line. To achieve KRAS knockdown, I will use 
isogenic SW48 cell lines with stably expressing shRNAs targeting KRAS. One 
advantage of using shRNA versus siRNA is that we are able to control shRNA 
expression using inducible promoters. Furthermore, shRNA is delivered 
directly into the nucleus and uses the endogenous processing machinery 
allowing a more sustained knockdown with fewer off target effects (Rao et al., 
2009).  
 
I will use the NanoString and MIB/MS assays to study kinome adaptations to 
KRAS knockdown at the transcript level and protein level, respectively. To 
confirm RAS dependency, upon knockdown we must observe a reversal of the 
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regulation of gene/protein expression of a responsive kinase back towards 
wild-type levels. In other words, after RAS knockdown the kinase should no 
longer be differentially expressed in the mutant cell line versus the parental 
cell line and therefore no longer defined as responsive.  
 
DCLK1 was the most significantly upregulated kinase in the K12D mutant cells. 
DCLK1 is frequently upregulated in colorectal cancer and is associated with 
poor prognosis (Gagliardi et al., 2012) (Gao et al., 2016). It has been shown 
that DCLK1 expression promotes tumour proliferation and also increases 
chemoresistance in colorectal cancer cells (Li, Jones and Mei, 2019). 
Moreover, depletion of the related kinase DCLK2 has been shown to reduce 
the viability of RAS mutant DLD-1 cells (Luo et al., 2009). Furthermore, a direct 
link between the overexpression of DCLK1 and RAS activation has been 
revealed in PDAC (Qu et al., 2019). It was previously shown in the lab, that 
KRAS codon 12 specific upregulation of DCLK1 was reversed upon KRAS 
knockdown, thus providing further evidence of the biological relevance of this 
kinase in oncogenic RAS signalling (Hammond et al., 2015). As I am using the 
same cell system, I will use DCLK1 as a positive control for KRAS knockdown.  
 
A similar pattern of KRAS codon 12 specific upregulation was observed for the 
receptor tyrosine kinase, MET. Although MET sits upstream of RAS, potential 
negative feedback from downstream kinases may regulate the expression of 
the receptor. Unlike DCLK1, the RAS dependency of MET upregulation was 
not previously evaluated in SW48 cell lines (Hammond et al., 2015). In this 
chapter, I will investigate whether the upregulation of MET in K12D cells is 
directly KRAS-dependent.  
 
Additionally, I will explore the potential interplay between RAS and MEK3 
(MAP2K3) activation. Significant downregulation of MEK3 phosphorylation 
was observed in all three KRAS mutant cell lines. In contrast, an increase in 
MEK3 activation was observed in the HRAS mutant cell line. Therefore, it will 
be interesting to validate these findings and see if MEK3 has opposing isoform-
specific effects.  MEK3 activation is observed in human cancers although it 
remains unclear if it is an oncogene or a tumour suppressor gene. In lung 
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cancer, MEK3 is tumour promoting (Galan-Moya et al., 2011), whereas in 
breast cancer it is tumour suppressive (Jia et al., 2010; MacNeil et al., 2014).  
 
It was previously reported that HRAS, but not NRAS, induces MEK3/p38 
pathway activation, leading to an invasive and migrative phenotype in human 
breast cancer cells (Shin et al., 2005). Since Rac1 had been shown to induce 
p38 activation previously, a Rac1 activity assay was conducted to see whether 
HRAS and NRAS differentially regulated levels of Rac1-GTP (Zhang et al., 
1995). Activation of Rac1 was induced by HRAS and not NRAS, in line with 
HRAS stimulating MCF10A cell motility. Moreover, MEK3/6 and p38 activation 
was shown to be dependent on Rac1 activity (Shin et al., 2005). In this chapter, 
I aim to establish whether HRAS specific upregulation of MEK3 activity occurs 
via Rac1 and whether subsequent p38 activation leads to an invasive and 
migrative phenotype in SW48 HRAS G12V cells.  
 
Paradoxically, it has been reported that oncogenic RAS can induce cellular 
senescence via MEK3 and p38 activation (Wang et al., 2002). The study 
showed that the activation of MEK3/6, and subsequent activation of p38 
induces premature senescence in primary human fibroblasts. Furthermore, 
inhibition of p38 activity rescued cells from cell cycle arrest indicating that p38 
is essential for RAS induced senescence. Moreover, MEK3 and p38 is 
stimulated by RAS following MEK and ERK activation; Premature senescence 
induced by MEK3/p38 pathway activation is dependent on MEK1 activity 
revealing an interaction between the two linear pathways (Wang et al., 2002; 
Deng et al., 2004). Signalling between the two pathways is thought to be 
indirect since MEK3 activation occurs several days after MAPK activation 
however the intermediate steps linking ERK and MEK3 are unclear (Iwasa, 
Han and Ishikawa, 2003).  
 
It is well documented that RAS induced senescence acts a homeostatic 
mechanism in response to prolonged RAS signalling and that tumour cells may 
evade this anti-proliferative mechanism for transformation (Serrano et al., 
1997; Ferbeyre et al., 2002). SW48 KRAS mutant cells may evade cellular 
senescence by downregulating MEK3 pathway activation. In this chapter, I aim 
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to establish the mechanism by which KRAS may be potentially regulating 
MEK3 activity. Furthermore, I will look to dissect the mechanism linking the 




Figure 5.1. Potential mechanisms for RAS induced MEK3/6 activation 
MEK3 activation can result in a 1) tumourgenic or 2) tumour suppressive phenotype in RAS 
mutant cells. 1) HRAS specific up regulation of MEK3/6 occurs via Rac1 activation leading 
to tumourigenesis in human breast cancer cells. 2) RAS induced senescence via MEK3/p38 
pathway. MAPK activation indirectly increases in MEK3/p38 pathway activation, causing 
premature senescence. Mutant RAS cells may evade this homeostatic protective 
mechanism by down regulating the MEK3/p38 pathway activation. 
5.1. Objective 
The objective of this chapter is to evaluate the RAS dependency of kinases 
that are differentially regulated in RAS mutant versus wild-type cells. I aim to 
achieve this by knocking down KRAS in the K12D mutant cell line and 
analysing KRAS-dependent regulation of kinase expression and/or activity. 
Moving on from this, I will follow up any potential RAS isoform and mutation 
specific responsive kinases identified in Chapter Four.  
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5.2. Results  
5.2.1. Stable knockdown of KRAS by shRNA in SW48 KRAS G12D mutant 
cells 
To examine the effects of the knockdown of oncogenic KRAS, we used a panel 
of four isogenic cell lines: The Parental and K12D cell lines as controls, and 
two independent K12D cell lines stably expressing doxycycline-inducible 
KRAS-specific shRNAs. As expected, the induced expression of both shRNAs 
resulted in significant decreases in KRAS expression (Figure 5.2). 
Approximately, a 73% and 63% loss of KRAS protein expression can be 
observed in response to the induced expression of shRNA2 and shRNA3 
respectively. Moreover, consistent with previous observations, KRAS loss was 
accompanied by a significant loss of DCLK1 protein expression, thus giving 
further affirmation of KRAS knockdown (Hammond et al., 2015). It is important 
to note, we were able to achieve similar levels of KRAS knockdown over 
several biological replicates with the shRNA2 construct consistently producing 
a higher level of protein knockdown.  
5.2.2. NanoString analysis after KRAS knockdown reveals KRAS 
dependent transcript responses 
NanoString analysis was conducted to measure transcript level changes in the 
kinome after KRAS knockdown. Both shRNAs were used in the analysis, thus 
providing two technical replicates for each biological replicate (n=4, t=8). 
KRAS knockdown was confirmed by western blotting before the lysates were 
processed by the NanoString nCounter platform (Figure 5.3).   
 
Differential expression (DE) analysis was conducted using the NanoString 
advanced analysis software, providing an insight into which kinases were 
significantly changing: A) in the K12D mutant vs. Parental cell line and B) after 
knockdown of oncogenic KRAS in the mutant K12D cell lines. The software 
used statistical t testing to calculate a p-value for each kinase and the 
Benjamini-Hochberg method was applied to reduce the False Discovery Rate 
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Figure 5.2. Stable knockdown of KRAS by shRNA in SW48 KRAS G12D mutant cells 
reduces DCLK1 expression 
SW48 K12D cells with inducible expression of 2 different shRNAs targeting KRAS (sh2 and 
sh3) were treated with 100ng/mL doxycycline for 1 week to induce shRNA expression where 
indicated. Cells were lysed using RIPA buffer and separated using SDS-PAGE. Western blots 
were probed with the indicated antibodies. The pan-RAS antibody recognizes all 3 isoforms 
and detects a doublet band; the top band represents KRAS expression and the bottom band 
both HRAS and NRAS expression. Approximately, a 73% and 63% loss of KRAS protein 
expression can be observed in response to the induced expression of shRNA2 and shRNA3 




Figure 5.3. KRAS knockdown in SW48 KRAS G12D mutant cells reduces expression of 
DCLK1.  
Western blot analysis displays KRAS knockdown over four biological replicates (NS1-NS4). 
SW48 K12D cells with inducible expression of 2 different shRNAs targeting KRAS (sh2 and 
sh3) were treated with 100ng/mL doxycycline for 1 week to induce shRNA expression where 
indicated. Cells were lysed in RIPA buffer and saved for NanoString analysis. A small 
proportion of the lysates were taken for western blotting analysis. Lysates were separated by 




(FDR) (see section 2.3.7). The volcano plots in figure 5.4 display the results of 
the differential expression analysis. The fold change (log2 ratio) and p-value is 
displayed for each kinase. Highly statistically significant kinases fall above the 
p-value threshold (p<0.0001) and differentially expressed kinases fall either 
side of the plot. Some of the most statistically significant kinases are labelled 
for each condition. Any kinases that fell below the threshold, highlighted in 
grey, were removed from further analyses. 
 
The aim was to identify kinase adaptations that show dependency to mutant 
KRAS.  To confirm KRAS dependency, upon KRAS knockdown we needed to 
observe a reversal of mRNA expression levels in the mutant K12D cell line 
back towards parental levels. For example, as expected DCLK1 mRNA 
expression was significantly upregulated in the K12D mutant cell line vs. 
parental cell line (Figure 5.4). Upon KRAS knockdown, DCLK1 mRNA 
expression levels decreased by over 2-fold, back towards parental wild-type 
levels (Figure 5.4).  
 
Figure 5.5 displays a shortlist of kinases extracted from the differential 
expression analysis, that like DCLK1, show some dependence on oncogenic 
KRAS. To be shortlisted, the differential expression of each kinase had to be 
significant in both DE analyses (MUT/WT and KD/MUT p>0.0001). The 
kinases are grouped based on the degree of RAS dependence characterised 
by fold-changes before and after knockdown.  
 
Group One represents kinases that show the highest degree of KRAS 
dependency; Kinases included in this group were differentially regulated >1.5-
fold in the mutant K12D cell line vs. parental wild-type cell line, and upon KRAS 
knockdown mRNA expression shifted >1.5-fold back towards parental levels. 
Alongside DCLK1, examples of kinases in Group One included EPHA1 and 
MET. EPHA1 mRNA expression was downregulated by over 2-fold in the 
K12D mutant vs. parental cell line. After KRAS knockdown, EPHA1 mRNA 
levels were restored back to near parental levels. MET mRNA expression was 




Figure 5.4. NanoString analysis after KRAS knockdown reveals KRAS dependent 
transcript responses 
SW48 K12D cells with inducible expression of 2 different shRNAs targeting KRAS (sh2 and 
sh3) were treated with 100ng/mL doxycycline for 1 week to induce shRNA expression and 
lysates analysed using the NanoString platform. Volcano plots displaying the differential 
expression of kinases in A) SW48 K12D mutant cells vs. SW48 parental (WT) cells and B) 
SW48 K12D mutant cells after KRAS knockdown. Only kinases that show a 1.5-fold-change 
in transcript expression and p-values in the significant range are coloured or annotated (n=4). 
 143 
 
Figure 5.5. Shortlisting KRAS dependent transcript responses reveals MET up 
regulation is KRAS dependent 
Only kinases with significant p-values in both differential expression analyses were 
shortlisted (MUT/WT and KD/MUT p>0.0001). Kinases were grouped based on fold-
change. Group 1 represents kinases that showed >1.5-fold change in MUT vs. WT, and 
upon knockdown mRNA expression shifted >1.5-fold back towards parental levels. Group 
2 represents kinases that were differentially regulated >1.5 fold in MUT vs. WT however, 
upon knockdown expression shifted <1.5-fold back towards parental levels. Group 3 
represents kinases that significantly changed in opposing directions however not to a 
significant level. 
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KRAS knockdown, mRNA expression decreased by almost 2-fold, suggesting 
MET upregulation is in fact dependent on mutant KRAS.  
 
Group Two represents kinases that were differentially regulated >1.5-fold in 
the mutant K12D cell line vs. parental cell line; however, upon KRAS 
knockdown, expression shifted <1.5-fold back towards parental levels. 
Considering, we don’t achieve full KRAS knockdown in SW48 cells, we may 
only see a partial reversal in mRNA expression back towards parental levels 
after knockdown. In some cases, KRAS gene knockout would be required in 
order to observe a complete reversal of mRNA expression back to parental 
levels. Thus, (Group Two) kinase mRNA regulation may still prove to be 
dependent on KRAS.  
 
Group Three kinases are not significantly regulated by oncogenic KRAS; 
however, upon KRAS knockdown, any subtle changes in mRNA expression 
that were observed, are reversed back toward parental levels. These data may 
prove useful when looking at the information flow of a particular pathway. 
Although they are not significantly changing kinases, they could still represent 
nodes within a KRAS dependent pathway, where the regulation of a 
combination of kinases may produce an effect. 
5.2.3. MIB/MS analysis after KRAS knockdown reveals KRAS dependent 
protein responses 
MIB/MS analysis was conducted to measure protein level adaptations in the 
kinome after KRAS knockdown. Figure 5.6A. describes the experimental set 
up for the MIB/MS knockdown experiments. Individual MIB columns were run 
for each shRNA cell line, making a total of two technical replicates for each 
biological replicate (n=3, t=6). Stable Isotopic Labelling (SILAC) provides the 
opportunity to compare three cell conditions in a single run, these were: the 
parental wild-type cell line vs. the K12D mutant cell line, with and without, 
doxycycline induced KRAS shRNA expression. The light labelled parental cell 
lysates were mixed in a 1:1:1 ratio with medium labelled K12D mutant cells (no 
knockdown) and heavy labelled K12D mutant cells (with knockdown). 
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Figure 5.6. MIB/MS analysis after KRAS knockdown reveals KRAS dependent protein 
responses 
SW48 K12D cells with inducible expression of 2 different shRNAs targeting KRAS (sh2 and 
sh3) were treated with 100ng/mL doxycycline for 1 week to induce shRNA expression. A) 
Experimental set up of MIB/MS knockdown experiments. SILAC labelled lysates: SW48 
parental (light), K12D no knockdown (medium) and K12D with knockdown (heavy) were mixed 
in a 1:1:1 ratio and loaded onto a column containing MIB beads. B) Western blotting analysis 
validates that KRAS knockdown was successfully achieved in all cell lysates loaded onto the 
MIB columns, over 3 biological and 6 technical replicates. Cells were lysed using RIPA buffer 
and separated with SDS-PAGE. Western blots probed with the indicated antibodies (n=3). C) 
MIB/MS analysis. The average intensities taken across three biological replicates were used 
to determine the fold change in expression (log2 ratio) 1) SW48 K12D mutant cells vs. parental 
cells and 2) SW48 K12D mutant cells +/- knockdown (n=3).  
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It is important to note, that KRAS knockdown was confirmed by western 
blotting before the lysates were mixed and loaded onto the MIB columns 
(Figure 5.6B). Consistent with previous analyses, DCLK1 upregulation in the 
K12D mutant seems to be dependent on KRAS expression. Unlike DCLK1, 
the KRAS dependency of MET upregulation was not previously evaluated in 
SW48 cell lines (Hammond et al., 2015). Figure 5.6B, displays MET protein 
expression before and after KRAS knockdown. Two bands are visualised 
using the MET antibody. One represents the precursor Pro-MET (170kDa) that 
matures through proteolytic cleavage by Furin. The cleavage leads to the 
formation of a disulphide linked heterodimer, comprised of an alpha subunit 
(45kDa) and a beta subunit (145kDa) (Fernandes, Duplaquet and Tulasne, 
2019). The second band visualised in the blot in figure 5.6B represents the 
beta subunit of the mature MET protein.    
 
MET follows a similar pattern of expression to DCLK1 in the parental and K12D 
mutant cells, however only marginal decreases in protein expression is 
observed after KRAS knockdown. NanoString analysis revealed that MET 
mRNA regulation was directly dependent on KRAS expression however, we 
do not observe the same compelling evidence for MET protein expression 
dependency. It is important to note, that there does seem to be more 
convincing evidence of RAS dependency in the K12D shRNA2 cell line vs. 
shRNA3 cell line, consistent with a higher level of KRAS knockdown achieved 
using the shRNA 2 oligo.   
 
The graphs in Figure 5.6C display data collated from the MIB/MS experiments 
using the same lysates. As anticipated, a 4-fold increase in DCLK1 protein 
expression was observed in the K12D mutant cell line vs. parental cell line. 
Moreover, DCLK1 expression reduced by over 3-fold, back towards parental 
levels after knockdown, giving confidence the MIB/MS column could report 
KRAS dependency. The MIB/MS assay reported a 3-fold upregulation in MET 
protein expression in the K12D mutant vs. parental cell line however, in 
concordance with the western blot analyses, no reduction of MET protein 
expression was observed post knockdown. The final graph shows data for the 
Ephrin receptor, EPHA1; EPHA1 protein expression is downregulated by over 
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1.5-fold in the mutant vs. parental cell line and is restored back to parental 
levels after KRAS knockdown. This is similar to what we observed at the 
transcript level and therefore EPHA1 seems like an interesting KRAS 
dependent hit to take forward. 
5.2.4. Regulation of Ephrin Receptor Tyrosine Kinases by oncogenic 
KRAS 
EphA1 belongs to the largest family of receptor tyrosine kinases (RTKs) 
comprising of 16 Ephrin receptors (Ephs) and 9 ephrin ligands (Lisabeth, 
Falivelli and Pasquale, 2013). There are two subgroups of Eph receptors: 
EphA receptors (A1-A10) and EphB receptors (B1-B6). Ephs are present in 
the majority of cancer cells however both upregulation and downregulation of 
Eph expression has been reported (Kou and Kandpal, 2018). Furthermore, it 
has been well documented that different Eph family members can either 
promote or inhibit tumour progression in different cancer types (Herath and 
Boyd, 2010).  
 
Considering many members of the Eph receptor family are paradoxically 
regulated in a variety of different cancers, I decided to investigate the family 
as a whole. Figure 5.7 displays data taken from A) NanoString analyses and 
B) MIB/MS analyses following KRAS knockdown. As previously stated, EphA1 
showed a high degree of KRAS dependency at both the transcript and protein 
level. In both cases, EphA1 was downregulated in the mutant vs. parental cell 
line. Upon knockdown, EphA1 mRNA and protein expression increased by 
over two-fold and was restored back to near parental levels. NanoString 
analysis also revealed that SW48 cells express a further 6 EPH receptors 
making a total of: 3 EphA and 4 EphB receptors (Figure 5.7A) Moreover, 
EphA2, A4, B2, and B3 showed some degree of RAS dependence at the 
transcript level. There was less coverage of the Eph family using MIB/MS 
however, once more, some degree of RAS dependency was observed for 
EphB2 at the protein level (Figure 5.7B). Notably, despite the fact that EphA2 
seems to be differentially regulated at the transcript level and protein level, 
both mRNA and protein expression appear to be RAS dependent.  
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Figure 5.7.NanoString and MIB/MS analyses reveal KRAS dependent group of Ephrin 
Receptor Tyrosine Kinases in SW48 K12D cells 
SW48 KRAS G12D cells with inducible expression of shRNA targeting KRAS were treated 
with 100 ng/mL doxycycline for 1 week to induce knockdown of KRAS and analysed using 
A) NanoString analysis (n=4) and B) MIB/MS analysis (n=3). The average counts taken 
across all biological replicates were used to determine the fold change (log2 ratio) in 
expression of the 1) K12D mutant cell line vs. the parental SW48 cell line and 2) the K12D 
cell +/- KRAS knockdown. Ephrin RTKs that are not expressed/detected in SW48 cells are 
coloured in grey. 
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Since the majority of expressed Ephs show some degree of RAS dependence, 
I decided to review Eph expression across all mutant SW48 cell lines to 
determine whether RAS mutations generally regulate this group of kinases. 
Figure 5.8 displays the expression data for Eph receptors across all five mutant 
cell lines, in relation to parental expression levels (data is derived from the (A) 
NanoString and (B) MIB/MS experiments conducted in Chapter four). With the 
exception of the K12V cell line at the protein level, EphA1 expression is 
downregulated in all KRAS mutant cell lines at both the transcript level and 
protein level. This suggests that EphA1 downregulation may be KRAS specific, 
however western blotting would be needed to confirm protein responses. Once 
again, we observe differential regulation of the EphA2 kinase at the protein 
level vs. transcript level. Furthermore, whilst we don’t see any significant 
changes to EphA4 mRNA expression, the MIB column reports significant 
upregulation of EphA4 expression/activity in the KRAS and HRAS mutant cell 
lines. A diverse range of responses were observed for the EphB group of 
receptors at the transcript level, and protein expression was only measured for 
2/4 EphB receptors.   
 
Western blotting was conducted to confirm EphA protein responses and gain 
a greater insight into EphB protein regulation (Figure 5.9). Unfortunately, we 
observed a lack of antibody sensitivity and specificity for EphA1. EphA1 was 
one of the most highly abundant proteins measured by MIB/MS in SW48 cells, 
so we would expect to see protein expression by western blotting. Despite 
several stages of antibody optimisation, I was unable to detect a band for total 
EphA1 and phosphorylated EphA1. Although the NanoString and MIB/MS 
assay provide us with a level of confidence that EphA1 expression is RAS 
regulated, a suitable antibody would need to be sourced for further validation.  
 
Western blotting analysis confirmed EphA2 protein responses reported by 
MIB/MS across all cell lines (Figure 5.9). Changes in EphA2 protein 
abundance correlated with the amount of active protein; The phospho-antibody 
detects EphA2 when its phosphorylated at Tyrosine 772 (Y772), a site 
indicative of activation. Across all cell lines, there appears to be a similar 
pattern of expression/activation to another RTK, MET (Figure 4.7).  
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Figure 5.8. NanoString and MIB/MS analyses reveal transcript-level and protein level 
expression of Ephrin Receptor Tyrosine Kinases in isogenic SW48 cells harbouring 
different RAS codon mutations 
A) NanoString analysis (n=4) and B) MIB/MS analysis (n=3) of isogenic SW48 cells reveals 
differential expression of Ephrin receptors at the transcript-level and protein-level. The 
square data points represent the panel of KRAS mutant SW48 cells, the HRAS mutant cell 
line is represented by the circular data point and the NRAS mutant by the diamond data 
point. For each mutant, the average counts/intensities taken from all biological replicates 
were used to determine the fold change (log2 ratio MUT/PAR) in expression in comparison 
to parental SW48 cells. Each point is coloured based on the magnitude of change in 
expression compared to the parental SW48 cell line. Ephrin RTKs that are not 
expressed/detected in SW48 cells are coloured in grey. 
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Figure 5.9. Western blotting analysis confirms protein responses of Ephrin Receptor 
Tyrosine Kinases in isogenic SW48 cells harbouring different RAS codon mutations 
SW48 cells were grown in 10%FBS and subsequently lysed in RIPA buffer. Lysates were 






Experiments to establish any potential relationship between EphA2 and MET 
may provide an insight into why EphA2 is differentially regulated at the 
transcript level and protein level. Moreover, western blotting would be required 
to confirm the RAS dependency of EphA2. 
 
For EphA4, protein responses measured by western blotting and MIB/MS do 
not correlate; a significant upregulation in EphA4 was reported by MIB/MS 
however it is important to note, that the assay may have been reporting 
changes in activation state rather than protein abundance, and therefore it 
would be important to blot for active protein.  
 
Western blotting analysis for EphB4 closely mapped the protein responses 
reported by MIB/MS (Figure 5.9). Although there was weak coverage of the 
other EphB receptors using MIB/MS, we were able to measure protein 
responses by western blot. Interestingly, the three EphB receptors follow a 
similar pattern of expression across all SW48 cell lines suggesting that there 
may be reciprocal activity between this subgroup of Eph receptors.  
5.2.5. Regulation of MEK3 activation by oncogenic RAS  
Figure 5.10A displays the potential mechanisms regulating MEK3/6 activity in 
SW48 RAS mutant cells. There seems to be a dichotomy between whether 
MEK3/6 pathway activation leads to tumour promoting or tumour inhibitory 
properties. Whilst levels of MEK3 mRNA remained constant, MIB/MS reported 
differential MEK3 activity across the mutant cell lines (Figure 5.10B). An ~0.5-
fold upregulation of MEK3 activity was observed in the HRAS mutant cell line 
vs. parental cell line, mapping to increased retention of p38 to the MIB column. 
On the other hand, MIB/MS reported downregulation of MEK3 in 2/3 KRAS 
mutant cell lines; however, subsequent western blotting revealed MEK3 
activity was in fact significantly downregulated in all three KRAS mutant cell 
lines.  
 
The HRAS- and KRAS-dependent MEK3 responses suggested different 
mechanisms of regulation and effect that I investigated further. 
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Figure 5.10. MEK3/p38 pathway regulation by oncogenic RAS 
A) A simplified outline of potential mechanisms for RAS induced MEK3/6 pathway activation. 
B) NanoString (blue) and MIB/MS (pink) analyses reveal differential expression of MEK3 and 
p38 across the mutant SW48 panel vs. parental SW48 cell line. Data is derived from the 
NanoString (n=4) and MIB/MS experiments (n=3) conducted in Chapter Four. The average 
counts/intensities taken across all biological replicates were used to determine the fold change 
in expression of the mutant panel vs. parental cell line (log2 ratio MUT/PAR). C) Western 
blotting analysis of nodes within the MEK3/p38 pathway. SW48 cells were grown in 10%FBS 
and subsequently lysed in RIPA buffer. Lysates were separated by SDS-PAGE and western 











































































































































































5.2.5.1. HRAS  
The HRAS-specific upregulation of MEK3 required further investigation to 
identify the signalling route from Ras to MEK3. Two pathways depicted in 
Figure 5.10A link via the MAPK pathway or via Rac1. Focussing on the Rac1 
link, I measured Rac1 protein abundance.  The first western blot in Figure 
5.10C shows an increase in Rac1 expression in the HRAS mutant cell line, 
corresponding with an increase in downstream MEK3 activity inferred by 
phosphorylation of S189/S207 of MEK3. Furthermore, Rac1 expression 
remains fairly constant across all other cell lines indicating that MEK3 
regulation via Rac1 may be HRAS specific, as previously described (Shin et 
al., 2005). An increase in phosphorylated p38 is observed in the HRAS mutant, 
providing further evidence of HRAS-specific activation of the MEK3 pathway. 
Shin et al. had previously linked HRAS-specific upregulation of MEK3/6 with 
an invasive and migrative phenotype. However, further downstream an 
upregulation of total and phosphorylated levels of p53 is observed; SW48 cells 
have wild type p53 status, so one would expect an increase in p53 would have 
a tumour suppressive effect on the H12V mutant cell line. Furthermore, levels 
of p21 are also upregulated in the HRAS mutant vs. parental cell line. Further 
analyses would be needed to reveal the effect of MEK3 activity on SW48 
HRAS mutant cell phenotype.  
5.2.5.2. KRAS  
MIB/MS also reported KRAS-specific downregulation of p38, a kinase 
downstream of MEK3. Western blotting analysis was performed in order to 
confirm p38 protein responses, and also probe the effects on downstream 
readouts depicted in Figure 5.10A. Firstly, I wanted to investigate whether 
SW48 KRAS mutant cells were downregulating MEK3 pathway activation in 
order to evade cellular senescence. Western blotting revealed that MEK3 
activation status has no effect on total p38 levels (Figure 5.10C). Instead, loss 
of MEK3 phosphorylation correlates with a loss of p38 activation in the KRAS 
mutant cell lines; The phospho-antibody detects p38 when its phosphorylated 
at threonine 180 and tyrosine 182 (T180/Y182), sites indicative of activation 
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by MEK3 and MEK6 respectively (ref needed). Further downstream, whilst 
total levels of p53 remain fairly consistent across the KRAS mutant panel, 
phosphorylated levels of p53 appear also to be marginally downregulated. 
Expression of p21 is variable across the KRAS mutant panel and we were 
unable to probe p16 expression due to reagent availability. On the whole, 
western blotting analyses has provided some evidence that the KRAS mutant 
cell panel may be downregulating nodes of the MEK3 pathway in order to 
evade cellular senescence via p53, however further studies measuring 
senescence markers would be required to confirm this hypothesis.  
 
It was previously shown that MEK3 pathway activation is dependent on MAPK 
activity (Wang et al., 2002). Considering the intermediate steps linking MAPK 
and MEK3 pathway activation are still unclear, I wanted to examine the 
potential upstream regulators of MEK3; The expression/activity of a potential 
regulator of MEK3 may be downregulated in the KRAS mutant cell lines at 
either the transcript or protein level, which could in turn downregulate MEK3 
activity. Figure 5.11 displays the A) transcript and B) protein level expression 
of 16 MAP3Ks that could potentially regulate MEK3 (MAP2K3) activity. At the 
transcript level, two kinases: TPL2 and MINK1 are downregulated in 2/3 KRAS 
mutant cell lines. At the protein level, MINK1 is significantly downregulated in 
2/3 KRAS mutant cell lines whilst, TPL2 wasn’t retained on the MIB column.  
To prove a direct link between MAPK and MEK3 pathway activation, a potential 
regulator of MEK3 should show RAS dependency upon KRAS knockdown. 
Figure 5.12 displays the expression of the same 16 potential regulators, before 
and after KRAS knockdown in the K12D cell line. NanoString analysis revealed 
that both TPL2 and MINK1 display dependency on KRAS; Both kinases are 
downregulated in the K12D mutant, and upon knockdown, mRNA expression 
is restored back towards parental levels. Western blotting would be required 
to prove TPL2 and MINK1 upregulation is dependent on KRAS at the protein 
level. Moreover, measuring the effect of MEK3 activity after knockdown of 
either kinase could prove direct dependency.  
 
Thus far, we had obtained evidence of reduced MEK3 activity in three 
independent KRAS mutant cell lines vs. the wild type cell line. Furthermore,  
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Figure 5.11. NanoString and MIB/MS analyses reveals potential upstream regulators of 
MKK3/6 in isogenic SW48 cells 
NanoString (n=4) and MIB/MS (n=3) analyses were used to measure transcript and protein 
responses of potential MEK3 upstream regulators. The square data points represent the panel 
of KRAS mutant SW48 cells and the HRAS mutant cell line is represented by the circular data 
point. For each mutant, the average counts taken across all biological replicates were used to 
determine the fold change in expression in comparison to the parental SW48 cells (log2 ratio 
MUT/PAR). Each point is coloured based on the magnitude of change in expression compared 
to the parental SW48 cell line. Kinases that were not expressed/detected in SW48 cells are 
coloured in grey. 
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Figure 5.12. NanoString analysis after KRAS knockdown reveals the KRAS 
dependent upstream regulators of MEK3/6 in SW48 K12D cells 
SW48 KRAS G12D cells with inducible expression of shRNA targeting KRAS were treated 
with 100 ng/mL doxycycline for 1 week to induce knockdown of KRAS and then analysed 
using NanoString analysis (n=4). The average counts taken from four biological replicates 
were used to determine the fold change (log2 ratio) in expression of the 1) K12D mutant cell 
line vs. the parental SW48 cells and 2) K12D mutant +/- knockdown. The expression of a 
potential Ras dependent regulator of pMKK3/6 would be downregulated in the K12D mutant 
cell line compared to the parental levels and then restored back towards parental levels 
upon KRAS knockdown. 
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we observed some reduction in the phosphorylation and activation of 
downstream nodes. We also identified potential upstream regulators of MEK3 
and evaluated their dependency on KRAS.  
 
For MEK3 itself, we were unable to confirm KRAS dependency by NanoString 
and MIB/MS analysis. Differential MEK3 regulation was observed at the 
protein level, making NanoString analysis after KRAS knockdown redundant. 
Plus, we were unable to detect MEK3 by MIB/MS in any of the knockdown 
experiments (figure 5.6). Using western blotting analysis, we were unable to 
confirm KRAS dependency for MEK3 (Figure 5.13). As expected, levels of 
phosphorylated MEK3 were significantly downregulated in the K12D mutant 
vs. parental cell line, however no change was observed upon KRAS 
knockdown; after KRAS knockdown, one would expect pMEK3 levels to 
increase back toward parental levels.  
 
Figure 5.14 displays data from preliminary DNA transfection experiments. 
Plasmid DNA encoding the different RAS G12V isoforms, N-terminally tagged 
with EGFP, were transfected into parental SW48 cells. There was no reduction 
in pMEK3 levels when the KRAS plasmid was transfected into parental SW48 
cells. However, an increase in pMEK3 was observed upon HRAS plasmid 
transfection, when total MEK3 levels remained constant across all cell lines. It 
is important to note that this is preliminary data and experimental conditions 




Figure 5.13. KRAS knockdown in SW48 KRAS G12D mutant cells has no effect on 
pMKK3/6 expression 
SW48 K12D cells with inducible expression of 2 different shRNAs targeting KRAS (sh1 and 
sh2) were treated with 100ng/mL doxycycline for 1 week to induce shRNA expression. Cells 
were lysed using RIPA buffer and separated with SDS-PAGE. Western blots probed with the 


























Figure 5.14. Transient expression of mutant RAS isoforms in Parental SW48 cells 
Plasmid DNA encoding the different RAS G12V isoforms, n-terminally tagged with EGFP, were 
transfected into parental SW48 cells using the Lipofectamine 2000 transfection system. The 
DNA-lipid complex was incubated for 20 minutes at room temperature before being added 
dropwise to the cells. After 24hrs transfection efficiency was evaluated by visualising GFP 
expressing cells under a NIKON TiE microscope. A separate dish of cells were grown in 
parallel and harvested for western blotting analysis (see above). Cells were lysed using RIPA 
buffer and separated using SDS-PAGE. Western blots were probed with the indicated 




















































5.3. Summary of results 
• The induced expression of two independent shRNAs specific for KRAS 
resulted in significant loss of KRAS expression in SW48 K12D cells. 
• NanoString, MIB/MS and Western blotting analyses were used to study 
kinome adaptations after KRAS knockdown. The methods were applied 
to determine whether there is a direct link between oncogenic KRAS 
G12D and differentially regulated kinases.  
• A significant loss of DCLK1 expression was observed in response to 
either of the two independent shRNAs for KRAS.  
• NanoString analysis revealed a direct link between oncogenic KRAS 
and MET mRNA upregulation.  
• Oncogenic KRAS differentially regulates the group of Ephrin receptor 
tyrosine kinases (Eph RTKs). 
• Whilst the link between oncogenic RAS and MEK3 activity is not clear, 
nodes within the pathway were probed by western blotting and their 
RAS dependence evaluated using NanoString and MIB/MS assays. 
5.4. Discussion 
In this chapter, I successfully evaluated the RAS dependency of kinases that 
are differentially regulated in the K12D vs. Parental SW48 cell line. The 
induced expression of two independent shRNAs specific for KRAS resulted in 
significant loss of KRAS expression. Using this cell system and a combination 
of NanoString, MIB/MS and western blotting analyses, we were able to identify 
KRAS dependent regulation of kinase expression and/or activity. Furthermore, 
I have been able to investigate some of the KRAS isoform and allele specific 
responses identified in chapter four.  
 
Our studies provide corroborating evidence of a link between DCLK1 
upregulation and oncogenic KRAS. DCLK1 was the most significantly 
upregulated kinase in the KRAS codon 12 mutant cell lines. NanoString, 
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MIB/MS and western blotting analysis all confirmed that DCLK1 upregulation 
is dependent on oncogenic KRAS. Indeed, a direct connectivity between 
DCLK1 overexpression and RAS activation has been described in these cells 
previously, but also in another recent study in PDAC (Hammond et al., 2015; 
Qu et al., 2019). In fact, DCLK1 is upregulated in several cancers, including 
colorectal cancer, and therefore is a promising drug target (Li, Jones and Mei, 
2019). However, it is a relatively understudied kinase and its biology remains 
poorly understood. Drug Discovery efforts tend to focus on kinases with well-
established roles in cancer cell signalling, therefore it is not surprising that up 
until April 2020, no selective inhibitor for DCLK1 had been described 
(Ferguson et al., 2020). The recent study describes the first potent chemical 
inhibitor of DCLK1, DCLK1-IN1. Using multi-omic approaches, authors reveal 
that DCLK1 inhibition in PDAC organoids regulates proteins and pathways 
involved in cell motility, although studies thus far are limited to in vitro 
(Ferguson et al., 2020). DCLK1 is one of 300 members of the kinome that still 
don’t have any inhibitors that have entered a clinical trial (Wilson et al., 2018). 
This highlights an area of unmet need within the kinome; understudied kinases 
lack selective inhibitors however, counterintuitively a lack of inhibitor 
availability stifles our understanding of kinase biology.  
 
The receptor tyrosine kinase, MET was also upregulated in the KRAS codon 
12 mutant cells. MET overexpression has previously been reported in several 
different epithelial cancers including thyroid (Di Renzo et al., 1992), ovarian (Di 
Renzo et al., 1994), pancreatic (Di Renzo et al., 1995b), colorectal and gastric 
cancers (Di Renzo et al., 1991) (Liu, Park and Tsao, 1992). A study of 
colorectal carcinomas concluded that MET is overexpressed without gene 
amplification in the large majority of cases (Di Renzo et al., 1995a). Moreover, 
activated oncogenes such as RAS can induce MET overexpression in cancer 
by enhancing cMET transcription (Gambarotta et al., 1996) (Ivan et al., 1997). 
 
In SW48 cells, MET expression is significantly upregulated in the K12D mutant 
vs. parental cells when they are serum starved, and downstream activity is 
induced by HGF stimulation (Figure 4.6). This suggests that MET upregulation 
is due to MET receptor overexpression rather than elevated levels of its ligand, 
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HGF. Our studies reveal that MET overexpression is dependent on oncogenic 
KRAS. Knockdown of KRAS in SW48 K12D mutant cells resulted in a 
significant reduction of MET mRNA suggesting that, like previously described, 
MET overexpression occurs from oncogene induced enhanced transcription 
(Gambarotta et al., 1996) (Ivan et al., 1997).  
 
It is important to note that although NanoString analysis revealed that MET 
mRNA deregulation was directly dependent on KRAS, we did not see a 
reduction in MET protein expression after KRAS knockdown. The half-life of 
MET protein has been shown to be approximately 5h, therefore a reduction in 
protein expression should have been observed after a week of doxycycline 
treatment (Giordano et al., 1989). Marginal decreases in MET protein 
expression were seen in the K12D cell line with induced sh2 oligo expression. 
Considering that a higher level of KRAS knockdown was achieved using this 
shRNA, one could speculate that higher levels of KRAS knockdown or 
complete knockout would be needed to see an effect on MET protein 
expression by western blotting. One other possible reason may be due to 
antibody specificity; the MET antibody recognises the beta subunit (145kDa) 
of MET whereas, KRAS may regulate the expression of the alpha subunit 
(45kDa). Impaired degradation may also cause an accumulation of MET 
protein even when there is less mRNA available for translation. It has been 
revealed that activated MET variants display resistance to degradation 
suggesting impaired degradation may contribute to tumorigenesis (Mak et al., 
2007; Joffre et al., 2011). Along with enhanced cMET transcription, defective 
degradation of the receptor may also contribute to MET overexpression in 
SW48 K12D cells; after KRAS knockdown, MET mRNA levels reduce however 
if the cells have become resistant to degradation, we may not necessarily see 
a reduction in receptor expression.  
 
Forced degradation through targeting one of the many mechanisms of MET 
degradation, has now become a promising therapeutic strategy. Proteolysis 
targeting chimera (PROTACs), a technology for post-translational protein 
degradation, has been developed against MET and other RTKs (Burslem et 
al., 2018). The group employed a selective inhibitor of MET, foretinib as a 
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recruiting element, tethered to an E3 ligase, to target Met for proteasomal 
degradation. When compared to conventional TKIs, PROTACs provided a 
more potent and sustained effect on MET signalling inhibition that was also 
less susceptible to kinome rewiring (Burslem et al., 2018). There has also been 
some success with monoclonal antibodies that primarily target the interaction 
between HGF and MET, but unexpectedly induce its internalisation and 
degradation. One example, DN30, inhibits MET signalling by inducing the 
cleavage of MET on the cell surface by metalloproteases such as ADAM10. 
The fragments can then be internalised and degraded by the lysosome (Petrelli 
et al., 2006).  
 
Other efforts to target MET directly using monoclonal antibodies or TKIs, have 
been confounded by drug resistance. There is increasing evidence that RAS 
mutations confer resistance to MET inhibition, and that targeting MET  in 
combination with nodes of the MAPK pathway, may circumvent kinome 
rewiring (Leiser et al., 2015; Suzawa et al., 2019; Rotow et al., 2020). Taking 
this into consideration, I would like to extend our findings to a panel of KRAS 
mutant cell lines. If KRAS codon 12 specific upregulation of MET occurs 
generally in colorectal cancer, targeting the MAPK pathway and MET in 
combination could be beneficial in this setting and may inform treatment 
choices in the clinic.  
 
Another kinase that displayed strong evidence of KRAS dependency was 
EPHA1. Downregulation of EPHA1 expression has been associated with an 
invasive and migrative phenotype in breast cancer (Fox and Kandpal, 2004) 
and colorectal cancer cells (Dong et al., 2009). Epigenetic silencing of EPHA1 
in colorectal cancer is correlated with poorer survival (Herath et al., 2009). 
Furthermore, knockdown of EPHA1 promotes adhesion and motility in HRT18 
colorectal cancer cells (Wu et al., 2016). NanoString and MIB/MS analysis 
revealed EPHA1 expression is downregulated in the panel of SW48 cells 
harbouring KRAS mutations. Moreover, we found evidence at the transcript 
and protein level that EPHA1 downregulation was directly dependent on 
oncogenic KRAS. One unique property of this receptor compared with other 
RTKs is its ability to inhibit RAS and MAPK signalling (Miao et al., 2001); SW48 
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KRAS mutant cells may downregulate EPHA1 expression in order to bypass 
the effects of EPHA1 on MAPK inhibition. Unfortunately, due to poor antibody 
specificity we were unable to confirm protein responses by western blotting, a 
common obstacle often encountered in kinase studies.  
 
Whilst EPHA1 is generally thought of as a tumour suppressor, its most closely 
related family member EPHA2 has been described as tumour promoting in a 
variety of different cancers (Kou and Kandpal, 2018). EPHA2 is overexpressed 
in several cancer types, including breast (Zelinski et al., 2001), melanoma 
(Udayakumar et al., 2011) and prostate cancer (Walker-Daniels et al., 1999). 
Moreover, it has been shown that EPHA2 promotes invasion and migration in 
colorectal cancer and is associated with poor survival (Dunne et al., 2016). In 
SW48 K12D cells, we observed KRAS dependent upregulation of EPHA2 
protein expression. Notably, at the transcript level, EPHA2 was differentially 
regulated whilst also being KRAS dependent; EPHA2 mRNA was 
downregulated and upon knockdown its expression increased.  
 
A RAS-EPHA2 feedback loop has been described which may provide an 
explanation of why EPHA2 mRNA and protein levels are differentially 
regulated in SW48 cells (Macrae et al., 2005). It has been shown that whilst 
RAS/MAPK signalling induces EPHA2 expression, ligand stimulated EPHA2 
downregulates MAPK signalling. In cancer cells, the EPHA2 ligand, ephrin-A1 
is downregulated in order to bypass negative regulation of MAPK signalling; 
the expression of EPHA2 and ephrin-A1 was inversely proportional in a panel 
of breast cancer cell lines and this was shown to contribute to hyperactive RAS 
signalling (Macrae et al., 2005). Indeed, MIB/MS analysis revealed that 
oncogenic KRAS upregulates EPHA2 expression in SW48 K12D cells 
however, I would be interested to probe ephrin-A1 expression to see if EPHA2 
and ephrin-A1 expression is inversely proportional. One could expect that 
SW48 KRAS mutant cells downregulate ephrin-A1 expression in order to 
circumvent the ligand dependent negative feedback loop. If this mechanism is 
typically adopted in KRAS mutant colorectal cancer cells, targeting EPHA2 
with a molecule that mimics ephrin-A1 thus downregulating MAPK signalling, 
may be a promising therapeutic strategy in RAS mutant cells.  
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Interestingly, EPHA2 and MET expression and activation status correlated 
across the SW48 cell panel. An RNA sequencing study of 675 human cancer 
cells revealed that EPHA2 expression is strongly correlated with other RTKs, 
such as MET and EGFR (Klijn et al., 2015). Moreover, it was shown that the 
expression of these co-expressed genes is regulated by MAPK or PI3K 
signalling. A recent study has identified EPHA2 as a biomarker of resistance 
to anti-EGFR therapy (Martini et al., 2019). Enhanced EPHA2 levels is a 
mechanism of resistance to cetuximab therapy and inhibition of EPHA2 could 
overcome resistance in RAS mutant colorectal cancer cells. Considering RAS 
mutations also confer resistance to MET inhibition, targeting MET in 
combination with EPHA2, may circumvent kinome rewiring. Therefore, I would 
be interested in targeting MET and EPHA2 in the SW48 KRAS codon 12 
mutant panel to see whether this may be a promising combinational therapy.  
 
In this chapter, we also investigated the potential interplay between oncogenic 
RAS and MEK3 regulation. MIB/MS and western blotting analyses revealed 
RAS isoform specific activation of MEK3; MEK3 activation was upregulated in 
the HRAS mutant cell line, whilst MEK3 activity was downregulated in the 
KRAS mutant panel.  
 
HRAS specific upregulation of MEK3 has previously been described in breast 
cancer cells (Shin et al., 2005). Authors showed that HRAS, but not NRAS, 
upregulates MEK3 activity via Rac1, leading to an invasive and migrative 
phenotype. Western blotting analysis revealed that Rac1 expression is 
upregulated in the SW48 HRAS mutant vs. parental cell line, corresponding 
with elevated levels of pMEK3 and p38. However, we would need to 
knockdown Rac1 to confirm direct connectivity between Rac1 and MEK3/p38 
activity. Surprisingly, further downstream, there was evidence of p53 and p21 
upregulation in the HRAS mutant vs. parental cell line. Considering p53 and 
p21 are markers of cellular senescence, further analyses would be needed to 
reveal the effect of MEK3 activation in this context. HRAS specific upregulation 
of the MEK3/p38 pathway may result in cellular senescence and may 
potentially act as a protective mechanism to prolonged RAS signalling 
(Serrano et al., 1997). Notably, SW48 HRAS mutant cell morphology is larger 
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and flatter than the other SW48 cell lines. Going forward, I would like to 
measure B-galactosidase levels across the cell lines to determine whether the 
cells are in fact senescent.  
 
Indeed, oncogenic RAS can induce cellular senescence via MEK3 and p38 
activation (Wang et al., 2002). SW48 KRAS mutant cells may evade cellular 
senescence by downregulating MEK3 pathway activation. Western blotting 
analyses reported downregulation of the downstream nodes, p38 and p53 in 
SW48 KRAS mutant cells; whilst total expression of p38 and p53 remained 
constant across the SW48 panel, marginal decreases in p38 and p53 
activation were observed in the KRAS mutant panel. However, I would suggest 
caution as to whether the level of downregulation downstream of MEK3 is 
significant enough to produce a phenotypic effect.  
 
Although there is evidence of reduced MEK3 activity in three independent 
KRAS mutant cell lines, it was notable that MEK3 levels did not change in 
either the KRAS knockdown (Figure 5.12) or KRAS over-expression 
experiments (Figure 5.13). This may indicate stable rewiring of the signalling 
network regulating MEK3 expression so that it is now independent of KRAS. 
There are a variety of links between Ras and MEK3 that may be responsible, 
one is via MINK1. A study in ovarian epithelial cells, revealed that the kinase, 
MINK1, may be involved in RAS induced cellular senescence (Nicke et al., 
2005). Authors showed that RAS activates MINK1, which in turn activates 
MEK3 and p38, resulting in cellular senescence through elevated levels of p21. 
Furthermore, it was shown that oxidative stress is necessary for the activation 
of MINK1 downstream of RAS. RAS activates MINK1 with delayed kinetics 
involving reactive oxygen species (ROS), and this may provide the missing link 
between RAS and MEK3 pathway induction. They identified MINK1 as a 
potential tumour suppressor that could limit the oncogenic potential of cancer 
cells (Nicke et al., 2005).  
 
In SW48 cells we found evidence of reduced MINK1 expression. NanoString 
and MIB/MS analyses revealed that like MEK3, MINK1 was downregulated in 
the KRAS mutant panel. Moreover, we were also able to confirm that MINK1 
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mRNA downregulation is directly dependent on KRAS. Further work would be 
needed to elucidate whether KRAS mutant cells are potentially downregulating 
MINK1 and MEK3 activation in order to evade cellular senescence. Going 
forward, I would like to confirm direct dependency between MINK1 and MEK3 
and also measure levels of ROS in the mutant vs. parental cell lines.  
 
In this chapter, I have successfully identified kinases that are regulated by 
oncogenic RAS isoforms and I have suggested follow-up work that would be 
necessary to identify potential mechanisms. We were hampered by a lack of 
specific inhibitors and antibodies; however, our data highlight the utility of the 






Chapter 6 : Final discussion 
In the initial stages of my PhD, I successfully established and optimised the 
MIB/MS assay in our lab. During this time, the viewpoint on how the MIB/MS 
assay can be used to study the kinome shifted. Whilst it was originally claimed 
to be sensitive to kinase activation state, data emerged suggesting that the 
ability to differentially enrich for active vs. inactive kinases is likely to be highly 
context dependent (Ruprecht et al., 2015). Evaluating the findings from 
Chapter three led me to similar conclusions. I established that the assay mainly 
reports changes in kinase abundance, and in limited cases, changes in kinase 
activity. Concurrent with the data presented by the Kuster lab, the data 
generated in this thesis contributed to understanding within the field as to how 
the method can be used to profile the kinome. It is now widely accepted that 
the capability of the MIB/MS assay to report dynamic changes in kinase 
activation depends on three main factors: 
 
• The level of expression of a kinase in a cell 
• Kinase affinity to MIBs  
• Kinase conformation or activation status 
 
Nevertheless, due to low cellular abundance, kinases are often 
underrepresented in proteomic and phosphoproteomic datasets and therefore 
the assay is still a good tool for enrichment (Daub et al., 2008). The method 
allowed the isolation and analysis of 50% of the SW48 expressed kinome, 
which is comparable to the coverage achieved in previous MIB/MS 
publications (Duncan et al., 2012a). In Chapter four, I demonstrated how 
integrating data from MIB/MS analyses with transcriptomic analyses can help 
infer differential kinome expression vs. activity in cells. However, it is important 
to note that further validation is required to discriminate between each 
possibility. 
 
The combination of methodologies was applied to obtain an insight into cellular 
kinase adaptations to different oncogenic RAS mutations. Most of our 
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understanding of RAS isoform specific signalling has been inferred from 
studies of mouse development (Koera et al., 1997; Esteban et al., 2001). 
Furthermore, cancer mutational studies have helped us to understand that 
there is distinct tissue specific RAS mutational profiles for each RAS isoform 
(Prior, Lewis and Mattos, 2012; Prior, Hood and Hartley, 2020). However, why 
RAS isoforms differentially and preferentially couple to specific cancers, 
codons and amino acid substitutions remains unclear. Classical studies of 
ectopically expressed activated RAS describe preferential coupling of the RAS 
isoforms to key kinase effectors, RAF and PI3K (Yan et al., 1998; Voice et al., 
1999). However, studies of endogenous RAS expression have helped us to 
appreciate that this perception was likely to be over-simplistic and RAS 
signalling is in fact more context dependent (Tuveson et al., 2004; Omerovic 
et al., 2008; Hood et al., 2019). Moreover, ectopically expressed RAS proteins 
are often produced at supraphysiological levels and can alter cell signalling 
and even induce cellular senescence (Serrano et al., 1997).  
 
For these reasons, we used an isogenic panel of SW48 colorectal cancer cell 
lines to study endogenous RAS signalling. Isogenic cell models provide the 
opportunity to study the cellular consequences of RAS mutations, without the 
additional effects of differences in the genetic background. Furthermore, a 
matched parental cell line can be used as a reference and therefore 
comparisons can be made across the whole panel of mutations. To date, most 
studies have focused on comparative analysis of KRAS mutant vs. wild type 
cells (Hammond et al., 2015; Winters et al., 2017). However, our cell line panel 
included a G12V mutant in all three isoforms, alongside a KRAS panel 
harbouring different codon mutations. This novel cell line panel has enabled 
us to carry out the first kinome wide analysis of endogenous isoform and 
mutation specific Ras signalling.  
 
One of the possible criticisms of the SW48 cell line is that they are not 
dependent on RAS to be viable and therefore are not a true representation of 
RAS driven oncogenesis. To address this, we conducted RAS knockdown 
studies to determine whether there was a direct link between oncogenic RAS 
and differentially regulated kinases.  
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NanoString and MIB/MS analyses revealed a subset of Ras responsive 
kinases for further analysis. A notable observation was the lack of responses 
within the immediate RAS network; in concordance with many studies 
investigating endogenous RAS isoform signalling, effector activation was 
minimal downstream of mutant RAS (Tuveson et al., 2004; Omerovic et al., 
2008; Hood et al., 2019). It seems likely that RAS induces oncogenesis 
through a complex network of signalling nodes rather than just the classical 
linear pathways we have come to know. Our global, unbiased approaches to 
study the kinome have enabled us to study RAS isoform specific signalling in 
the wider context. Our data suggests there needs to be greater attention and 
appreciation of the effects of RAS isoform and mutation specific signalling in 
the wider signalling network and highlights the unmet need within the kinome. 
 
Another key observation was that there were very few common responses 
across the RAS mutant panel. Furthermore, there was evidence of divergence 
between codon 12 and codon 13 mutations in the KRAS mutant panel; in 
concordance with previous data generated in the lab, we identified a cluster of 
proteins that were significantly upregulated in the KRAS codon 12 mutants 
only (Hammond et al., 2015). A final layer of complexity was added by the fact 
that each RAS mutant cell line activated distinct kinase networks. Altogether, 
this emphasises the point that RAS mutations should not be treated equally. 
In the clinic, patients with RAS mutant tumours are often treated as one 
homologous group. Our data suggests that differential signalling occurs 
downstream of different RAS mutations and therefore RAS mutations need to 
be assessed on a case-by-case basis. Moreover, RAS isoform specific 
signalling needs to be investigated in the context of different tissues.  
 
Going forward, I would have liked to extend my findings to a wider panel of 
colorectal cancer cell lines in order to identify common isoform/mutation 
specific kinase responses to oncogenic RAS. Moreover, these global kinase 
profiling approaches could be applied to other cancer types to help 
characterise the context dependence of endogenous isoform-specific Ras-
signalling responses in different tissues. Interestingly, there was a significant 
bias towards the KRAS G12D variant; the mutant cell line harboured the most 
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differential kinase responses compared to the wild type cell line. A recent study 
provided the first indication that variations in signalling downstream of different 
RAS mutations may drive the RAS mutational pattern seen in human cancers 
(Poulin et al., 2019). Considering KRAS G12D is the most prevalent mutation 
in colorectal cancer, it may be likely that we see more responses downstream 
of this variant due to its oncogenic potency in this tissue type. It would be 
interesting to investigate whether, there would be similar observations for 
NRAS in melanoma, for example.  
 
Using the discovery based NanoString/MIB approach, I was able to 
successfully identify kinases that are regulated by oncogenic RAS variants. 
Unfortunately, we were hampered by a lack of specific antibodies and 
inhibitors, an often-common challenge in kinome studies, and therefore follow 
up work would need to be done to validate any potential mechanisms. 
Nevertheless, our data highlight the utility of these global kinase approaches 
in identifying new areas of RAS relevant biology. These approaches could be 
used to identify novel targets downstream of RAS or inform the rationale 
selection of existing treatments for different RAS mutant tumours. Moreover, 
the combination of methodologies could be used to understand what kinome 
rewiring occurs in response to RAS pathway inhibition. Several studies have 
used the MIB/MS approach to inform the rationale selection of new 
combinational therapies that may overcome resistance in patients (Duncan et 
al., 2012a; Johnson et al., 2014; Stuhlmiller et al., 2015; Kurimchak et al., 
2019). Furthermore, considering that resistance is likely to arise in response 
to direct RAS inhibition, understanding the specific requirements of each RAS 
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